<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000025" GROUP_ID="PREG" ID="700499072309501357" MERGED_FROM="" MODIFIED="2010-09-30 11:38:40 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Short title (no longer in use): Anticonvulsants for pre-eclampsia&lt;/p&gt;&lt;p&gt;subgroups by severity...but long term outcome in none?placebo&lt;/p&gt;" NOTES_MODIFIED="2010-09-21 13:39:52 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0125" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2010-09-30 11:38:40 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Magnesium sulphate and other anticonvulsants for women with pre-eclampsia</TITLE>
<CONTACT MODIFIED="2010-09-30 11:38:40 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Professor of Obstetric Epidemiology</POSITION><EMAIL_1>l.duley@leeds.ac.uk</EMAIL_1><MOBILE_PHONE>07979744934</MOBILE_PHONE><ADDRESS><DEPARTMENT>Centre for Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Bradford Institute for Health Research</ADDRESS_1><ADDRESS_2>Bradford Royal Infirmary, Duckworth Lane</ADDRESS_2><CITY>Bradford</CITY><ZIP>BD9 6RJ</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1274 383410</PHONE_1><FAX_1>+44 1274 382767</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-30 11:38:40 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="7397" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lelia</FIRST_NAME><LAST_NAME>Duley</LAST_NAME><POSITION>Professor of Obstetric Epidemiology</POSITION><EMAIL_1>l.duley@leeds.ac.uk</EMAIL_1><MOBILE_PHONE>07979744934</MOBILE_PHONE><ADDRESS><DEPARTMENT>Centre for Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Bradford Institute for Health Research</ADDRESS_1><ADDRESS_2>Bradford Royal Infirmary, Duckworth Lane</ADDRESS_2><CITY>Bradford</CITY><ZIP>BD9 6RJ</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1274 383410</PHONE_1><FAX_1>+44 1274 382767</FAX_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="4691" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Henderson-Smart</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>dhs@mail.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>NSW Centre for Perinatal Health Services Research</DEPARTMENT><ORGANISATION>Queen Elizabeth II Research Institute</ORGANISATION><ADDRESS_1>Building DO2</ADDRESS_1><ADDRESS_2>University of Sydney</ADDRESS_2><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 93517318</PHONE_1><PHONE_2>+61 2 93517728</PHONE_2><FAX_1>+61 2 93517742</FAX_1></ADDRESS></PERSON><PERSON ID="2995FCBF82E26AA200636A7EB8EEB4B0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Doris</FIRST_NAME><LAST_NAME>Chou</LAST_NAME><POSITION>Medical Officer</POSITION><EMAIL_1>choud@who.int</EMAIL_1><EMAIL_2>choud13@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-09-02 16:20:22 +0200" MODIFIED_BY="Sonja L  Henderson">
<UP_TO_DATE>
<DATE DAY="2" MONTH="9" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="6" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="9" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-02 16:44:00 +0200" MODIFIED_BY="Sonja L  Henderson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-02 16:44:00 +0200" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="24" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>Updated search: two new studies included (<LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>; <LINK REF="STD-Mexico-1998" TYPE="STUDY">Mexico 1998</LINK>), 27 new studies excluded and a new ongoing trial identified. Longer term follow-up is now included.</P>
<P>Methods updated according to the new <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-09-02 16:26:01 +0200" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="24" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>New author (D Chou) joined the review team.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-07-07 13:00:48 +0200" MODIFIED_BY="Denise Atherton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-07 13:00:27 +0200" MODIFIED_BY="Denise Atherton">
<DATE DAY="11" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Review converted to new format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-07-07 13:00:48 +0200" MODIFIED_BY="Denise Atherton">
<DATE DAY="25" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
<P>The search strategy has been updated. Subgroup analyses are now included in the comparisons tables. New included trials identified: <LINK REF="STD-Denmark-2000" TYPE="STUDY">Denmark 2000</LINK>; <LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>. Also new excluded trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>HRP-UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-09-21 13:39:52 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-09-02 16:44:36 +0200" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2008-09-11 12:53:12 +0200" MODIFIED_BY="[Empty name]">Magnesium sulphate and other anticonvulsants for women with pre-eclampsia</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-02 16:44:36 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Magnesium sulphate helps prevent eclamptic fits in pregnant women with pre-eclampsia ('toxaemia').</P>
<P>Some women have high blood pressure with protein in their urine during pregnancy (pre-eclampsia, or 'toxaemia'). Most women with pre-eclampsia give birth without problems. However, severe pre-eclampsia can cause problems such as stroke, kidney failure, liver failure, and blood clotting. A few women have seizures (eclampsia). These problems can lead to the baby being born too small or too soon. If the woman has eclampsia, both she and her baby are at high risk of death. Eclampsia is most common in low- and middle-income countries.</P>
<P>This review of 15 studies showed magnesium sulphate reduced the number of women having eclampsia, but did not improve the babies' health. Magnesium sulphate had side effects for the mother, mostly flushing. Follow-up of women and children is reassuring that there are no adverse effects later on.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-09-21 13:38:17 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-06-29 14:09:33 +0200" MODIFIED_BY="Lelia Duley">
<P>Eclampsia, the occurrence of a seizure (fit) in association with pre-eclampsia, is rare but potentially life-threatening. Magnesium sulphate is the drug of choice for treating eclampsia. This review assesses its use for preventing eclampsia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-07-08 13:26:20 +0200" MODIFIED_BY="Denise Atherton">
<P>To assess the effects of magnesium sulphate, and other anticonvulsants, for prevention of eclampsia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-08-04 13:29:45 +0200" MODIFIED_BY="Denise Atherton">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (4 June 2010), and the Cochrane Central Register of Controlled Trials Register (<I>The Cochrane Library </I>2010, Issue 3).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-06-28 11:19:01 +0200" MODIFIED_BY="Lelia Duley">
<P>Randomised trials comparing anticonvulsants with placebo or no anticonvulsant, or comparisons of different drugs, for pre-eclampsia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-06-04 13:17:51 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Two authors assessed trial quality and extracted data independently.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-21 13:38:17 +0200" MODIFIED_BY="[Empty name]">
<P>We included 15 trials. Six (11,444 women) compared magnesium sulphate with placebo or no anticonvulsant: magnesium sulphate more than a halved the risk of eclampsia (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.29 to 0.58; number needed to treat for an additional beneficial outcome (NNTB) 100, 95% CI 50 to 100), with a non-significant reduction in maternal death (RR 0.54, 95% CI 0.26 to 1.10) but no clear difference in serious maternal morbidity (RR 1.08, 95% CI 0.89 to 1.32). It reduced the risk of placental abruption (RR 0.64, 95% CI 0.50 to 0.83; NNTB 100, 95% CI 50 to 1000), and increased caesarean section (RR 1.05, 95% CI 1.01 to 1.10). There was no clear difference in stillbirth or neonatal death (RR 1.04, 95% CI 0.93 to 1.15). Side effects, primarily flushing, were more common with magnesium sulphate (24% versus 5%; RR 5.26, 95% CI 4.59 to 6.03; number need to treat for an additional harmful outcome (NNTH) 6, 95% CI 5 to 6).</P>
<P>Follow-up was reported by one trial comparing magnesium sulphate with placebo: for 3375 women there was no clear difference in death (RR 1.79, 95% CI 0.71 to 4.53) or morbidity potentially related to pre-eclampsia (RR 0.84, 95% CI 0.55 to 1.26) (median follow-up 26 months); for 3283 children exposed <I>in utero</I> there was no clear difference in death (RR 1.02, 95% CI 0.57 to 1.84) or neurosensory disability (RR 0.77, 95% CI 0.38 to 1.58) at age 18 months.</P>
<P>Magnesium sulphate reduced eclampsia compared to phenytoin (three trials, 2291 women; RR 0.08, 95% CI 0.01 to 0.60) and nimodipine (one trial, 1650 women; RR 0.33, 95% CI 0.14 to 0.77).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-09-01 18:15:33 +0200" MODIFIED_BY="[Empty name]">
<P>Magnesium sulphate more than halves the risk of eclampsia, and probably reduces maternal death. There is no clear effect on outcome after discharge from hospital. A quarter of women report side effects with magnesium sulphate.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-09-21 13:39:52 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-01 18:19:32 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-06-04 13:13:10 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Pre-eclampsia is a multisystem disorder that is usually associated with raised blood pressure and proteinuria, but can also involve the woman's liver, kidneys, clotting system, or brain. If the placenta is involved this may led to growth restriction or premature birth. Pre-eclampsia is a relatively common complication of pregnancy, and can occur at any time during the second half of pregnancy or in the first few weeks after delivery. Pre-eclampsia is described in more detail in the generic protocol on interventions for treatment of pre-eclampsia and its consequences (<LINK REF="REF-Duley-2009" TYPE="REFERENCE">Duley 2009</LINK>).</P>
<P>For many women who have pre-eclampsia the outcome is good, but severe disease can lead to death or serious problems for the woman and/or her baby.</P>
<P>Eclampsia, defined as the occurrence of one or more seizures (fits) in association with the syndrome of pre-eclampsia, is a rare but serious complication. In the UK it is associated with one in 2000 deliveries (<LINK REF="REF-Douglas-1994" TYPE="REFERENCE">Douglas 1994</LINK>), while in low- and middle-income countries it complicates between one in 100 and one in 1700 deliveries (<LINK REF="REF-WHO-1988" TYPE="REFERENCE">WHO 1988</LINK>). Eclampsia probably accounts for 50,000 deaths a year worldwide, which is about 10% of direct maternal deaths (<LINK REF="REF-Duley-1992" TYPE="REFERENCE">Duley 1992</LINK>). One aim of antenatal care is to detect pre-eclampsia in the hope that the onset of serious complications (including eclampsia) can be delayed or prevented.</P>
<P>Magnesium sulphate is the anticonvulsant of choice for treatment of women with eclampsia, as it is better than diazepam (<LINK REF="REF-Duley-2003b" TYPE="REFERENCE">Duley 2003b</LINK>), phenytoin (<LINK REF="REF-Duley-2003a" TYPE="REFERENCE">Duley 2003a</LINK>) or lytic cocktail (<LINK REF="REF-Duley-2000" TYPE="REFERENCE">Duley 2000</LINK>).</P>
<P>Anticonvulsants were introduced for women with pre-eclampsia in the belief that they would prevent the first seizure, and so improve outcome. Predicting who is at risk of an eclamptic seizure is difficult, as only around 1% to 2% of those with even severe pre-eclampsia will have a seizure. This has contributed to the wide variation in policies for prophylactic anticonvulsants (<LINK REF="REF-Duley-1994" TYPE="REFERENCE">Duley 1994</LINK>). In the USA, for example, an estimated 5% of pregnant women receive magnesium sulphate before delivery (<LINK REF="STD-USA-_x002d_-Texas-1995" TYPE="STUDY">USA - Texas 1995</LINK>), whilst in the UK a quarter of obstetricians do not use any prophylactic anticonvulsant and only 40% report using magnesium sulphate (<LINK REF="REF-G_x00fc_lmezoglu-1998" TYPE="REFERENCE">Gülmezoglu 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-09-01 18:18:23 +0200" MODIFIED_BY="[Empty name]">
<P>The formulation used for clinical care is magnesium sulphate heptahydrate, usually provided as a 50% solution which is approximately 2 mmol magnesium/mL. Traditionally this is given as a loading dose followed by a maintenance regimen, which can be either intramuscular (<LINK REF="REF-Pritchard-1955" TYPE="REFERENCE">Pritchard 1955</LINK>; <LINK REF="REF-Pritchard-1984" TYPE="REFERENCE">Pritchard 1984</LINK>) or intravenous (<LINK REF="REF-Zuspan-1978" TYPE="REFERENCE">Zuspan 1978</LINK>).</P>
<P>The loading dose is usually 4 g given over a few minutes, either by intravenous injection or a short infusion. However, 6 g has been advocated (<LINK REF="REF-Sibai-1990" TYPE="REFERENCE">Sibai 1990</LINK>) whilst others omit an intravenous loading dose when using the intramuscular maintenance regimen (<LINK REF="REF-Begum-2001" TYPE="REFERENCE">Begum 2001</LINK>). The traditional intramuscular regimen starts with 10 g by intramuscular injection (given as 5 g into each buttock) combined with the 4 g intravenous loading dose, and the maintenance regimen is then 5 g by intramuscular infection every four hours (<LINK REF="REF-Pritchard-1955" TYPE="REFERENCE">Pritchard 1955</LINK>; <LINK REF="REF-Pritchard-1984" TYPE="REFERENCE">Pritchard 1984</LINK>). For the intravenous regimen, the magnesium sulphate maintenance regimen is usually an infusion of 1 g/hour (<LINK REF="REF-Zuspan-1978" TYPE="REFERENCE">Zuspan 1978</LINK>, although 2 g/hour has been advocated (<LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>). Duration of therapy is usually 24 hours in total. Alternatives are to continue until 24 hours after delivery, or to stop treatment after 12 hours unless there is a specific indication to continue. Alternative regimens for magnesium sulphate are covered by a separate Cochrane review (<LINK REF="REF-Duley-2008" TYPE="REFERENCE">Duley 2008</LINK>).</P>
<P>There are potential hazards associated with the use of magnesium sulphate. Side effects include flushing, muscle weakness and nausea. Serious adverse effects such as respiratory and cardiac arrest are rare, but if they do occur are potentially life threatening. As magnesium sulphate is a smooth muscle relaxant it is used in some countries, such as the USA, as a tocolytic drug to prevent preterm birth for women in threatened preterm labour. Although this practice is not supported by evidence from randomised trials (<LINK REF="REF-Crowther-2003" TYPE="REFERENCE">Crowther 2003</LINK>), if magnesium sulphate does have a tocolytic effect on uterine muscle this would be a potential adverse effect when used for women with pre-eclampsia, as it might lead to an increase in caesarean section, postpartum haemorrhage or retained placenta.</P>
<P>Case-controlled studies first suggested that exposure to magnesium sulphate whilst in utero was associated with a reduction in cerebral palsy or low birthweight children (<LINK REF="REF-Nelson-1995" TYPE="REFERENCE">Nelson 1995</LINK>), and other studies suggested there may be an increase in the risk of paediatric death (<LINK REF="REF-Mittendorf-1998" TYPE="REFERENCE">Mittendorf 1998</LINK>; <LINK REF="REF-Scudiero-2000" TYPE="REFERENCE">Scudiero 2000</LINK>). This hypothesis that in utero exposure to magnesium sulphate might be neuro protective for preterm infants has now been tested in randomised trials (<LINK REF="REF-Doyle-2009" TYPE="REFERENCE">Doyle 2009</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-09-01 18:19:32 +0200" MODIFIED_BY="[Empty name]">
<P>The aetiology of pre-eclampsia and eclampsia remains unclear. It is therefore unsurprising that the mode of action for magnesium sulphate in prevention and treatment of eclamptic seizures is also not clearly understood. Although magnesium sulphate is not usually considered to be an 'anticonvulsant', it is better than traditional anticonvulsant drugs for control of eclamptic seizures. This anticonvulsant activity may be mediated by magnesium&#8217;s role as an N-methyl-D-aspartate (NMDA) antagonist (<LINK REF="REF-Euser-2009" TYPE="REFERENCE">Euser 2009</LINK>). Stimulation of NMDA receptors by neurotransmitters such as glutamate may lead to seizures when neuronal networks are over-activated. Magnesium may prevent and control eclamptic seizures by inhibiting NMDA receptors. The action of magnesium as an NMDA inhibitor may also block the neuronal damage associated with ischaemia (<LINK REF="REF-Goldman-1988" TYPE="REFERENCE">Goldman 1988</LINK>; <LINK REF="REF-Sadeh-1989" TYPE="REFERENCE">Sadeh 1989</LINK>). Another possible mechanism is that magnesium sulphate may lead to cerebral vasodilatation, with subsequent reduction of cerebral ischaemia (<LINK REF="REF-Belfort-1992" TYPE="REFERENCE">Belfort 1992</LINK>).</P>
<P>Magnesium is also a calcium antagonist, and a smooth muscle relaxant. It may therefore affect the cerebral endothelium which forms the blood brain barrier. Lowering intracellular calcium may limit paracellular transport of vascular contents, such as ions and proteins, effectively decreasing the factors which promote cerebral oedema and seizure activity (<LINK REF="REF-Euser-2009" TYPE="REFERENCE">Euser 2009</LINK>).</P>
<P>The calcium antagonist activity of magnesium sulphate has led to the belief that it also lowers systemic blood pressure, but this has not been supported by evidence from randomised trials (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>). Magnesium sulphate does not appear to be an effective antihypertensive drug (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>).</P>
<P>The serious adverse effects of magnesium sulphate, such as respiratory depression and respiratory or cardiac arrest, are due to its action as a smooth muscle relaxant. However, the effect on smooth muscle follows a dose response: deep tendon reflexes are lost at a serum magnesium level of 10 mEq/L; respiratory depression begins at 15 mEq/L; and cardiac arrest is a risk at greater than15 mEq/L. This very specific dose response relationship means that careful clinical monitoring, with prompt action to stop or reduce the magnesium sulphate, will minimise serious adverse effects. As magnesium is excreted by the kidneys, women with impaired renal function may accumulate magnesium, and so be at risk of serious adverse effects if the dose is not reduced or stopped when tendon reflexes disappear. Clinical monitoring of tendon reflexes, respiration rate and urine output is therefore recommended during administration of magnesium sulphate (<LINK REF="REF-Duley-1996" TYPE="REFERENCE">Duley 1996</LINK>). Monitoring of serum magnesium levels is costly and unnecessary.</P>
<P>If toxicity does develop, calcium gluconate is an effective antidote.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-07-07 13:12:37 +0200" MODIFIED_BY="Denise Atherton">
<P>The principal question is whether a policy of using an anticonvulsant drug for women with pre-eclampsia does more good than harm, to both her and her baby, than a policy of not using an anticonvulsant. In the past a variety of anticonvulsant drugs have been suggested for the care of women with pre-eclampsia. Magnesium sulphate is now the drug of choice for treatment of women with eclampsia (<LINK REF="REF-Collab-Trial-1995" TYPE="REFERENCE">Collab Trial 1995</LINK>; <LINK REF="REF-Duley-2000" TYPE="REFERENCE">Duley 2000</LINK>; <LINK REF="REF-Duley-2003a" TYPE="REFERENCE">Duley 2003a</LINK>; <LINK REF="REF-Duley-2003b" TYPE="REFERENCE">Duley 2003b</LINK>), however, and so it is also the drug of choice to evaluate for women with pre-eclampsia.</P>
<P>As we do not have any reliable way of predicting who will develop eclampsia, the number of women potentially eligible for anticonvulsant therapy is large. As for any prophylactic therapy, for magnesium sulphate to be worthwhile for women with pre-eclampsia, it must be safe for both the woman and the baby, as well as effective in preventing eclampsia.</P>
<P>Other aspects of the care of women with very high blood pressure or severe pre-eclampsia are covered by other Cochrane reviews. These include drugs for very high blood pressure (<LINK REF="REF-Duley-2006" TYPE="REFERENCE">Duley 2006</LINK>), plasma volume expansion (<LINK REF="REF-Duley-1999" TYPE="REFERENCE">Duley 1999</LINK>) and timing of delivery (<LINK REF="REF-Churchill-2002" TYPE="REFERENCE">Churchill 2002</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-06-24 10:56:33 +0200" MODIFIED_BY="[Empty name]">
<P>The primary aim was to assess the benefits and hazards for women and their babies of magnesium sulphate, or other anticonvulsant drug, when used for women with pre-eclampsia. If magnesium sulphate or other anticonvulsant therapy is beneficial, secondary aims were to compare the differential effects of alternative agents, and to assess whether the effects differed with different levels of severity of pre-eclampsia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-02 16:44:44 +0200" MODIFIED_BY="Sonja L  Henderson">
<SELECTION_CRITERIA MODIFIED="2010-09-02 16:44:44 +0200" MODIFIED_BY="Sonja L  Henderson">
<CRIT_STUDIES MODIFIED="2010-06-04 12:26:48 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>All randomised trials of the administration of an anticonvulsant drug to women with pre-eclampsia, including trials that compared an anticonvulsant with none or with placebo, and trials that compared one anticonvulsant drug with another. We excluded quasi-randomised trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-09-01 18:22:24 +0200" MODIFIED_BY="[Empty name]">
<P>Any women with pre-eclampsia, regardless of whether before or after delivery, whether a singleton or multiple pregnancy, or whether an anticonvulsant had been given before trial entry. If women with eclampsia had also been entered into the trial, we included only data for women with pre-eclampsia in this review.</P>
<P>As sufficient data are now available, we have included the planned subgroup analysis by severity of pre-eclampsia in the updated review. Severe pre-eclampsia was defined wherever possible as women with two or more signs or symptoms of imminent eclampsia, or blood pressure of at least 170/110 mmHg and 3+ proteinuria or, if on antihypertensive agents, 150/100 mmHg and 2+ proteinuria If the definition of severe pre-eclampsia was not specified, we still included women in this category if the authors described them as having severe pre-eclampsia. We classified women who did not have any of these criteria as 'not severe pre-eclampsia'.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-03-12 15:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised comparisons of an anticonvulsant drug, or other agents used specifically to prevent eclampsia, with placebo (or no anticonvulsant). Also, comparisons of one anticonvulsant drug with another.</P>
<P>Anticonvulsant drugs which have been used for pre-eclampsia include magnesium sulphate, diazepam (Valium), phenytoin, nimodipine, and chlormethiazole.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-02 16:44:44 +0200" MODIFIED_BY="Sonja L  Henderson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-07-07 13:13:56 +0200" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="5">For women</HEADING>
<OL>
<LI>Death;</LI>
<LI>eclampsia;</LI>
<LI>measures of serious maternal morbidity related to either pre-eclampsia or anticonvulsant use (such as renal failure, cardiac arrest, liver failure, stroke, coagulopathy and respiratory depression).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For the baby</HEADING>
<OL>
<LI>Death: stillbirths (death in utero at or after 20 weeks' gestation), perinatal deaths (stillbirths plus deaths in the first week of life), death before discharge from hospital, neonatal deaths (death in the first 28 days after birth), deaths after the first 28 days;</LI>
<LI>preterm birth, defined as birth before 37 completed weeks' gestation;</LI>
<LI>in a special care nursery for more than seven days.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-09-02 16:44:44 +0200" MODIFIED_BY="Sonja L  Henderson">
<SUBSECTION>
<HEADING LEVEL="5">For women</HEADING>
<OL>
<LI>Pulmonary edema;</LI>
<LI>pneumonia;</LI>
<LI>antihypertensive therapy;</LI>
<LI>progression from mild to severe pre-eclampsia;</LI>
<LI>toxicity;</LI>
<LI>side effects;</LI>
<LI>dialysis;</LI>
<LI>ventilation;</LI>
<LI>admission to intensive care;</LI>
<LI>length of stay;</LI>
<LI>induction of labour;</LI>
<LI>length of labour;</LI>
<LI>placental abruption;</LI>
<LI>caesarean section;</LI>
<LI>retained placenta;</LI>
<LI>postpartum haemorrhage;</LI>
<LI>long-term follow-up (death after discharge from hospital, serious morbidity potentially related to pre-eclampsia, stroke, renal failure, hypertension, depression).</LI>
</OL>
<P>
<B>For the baby</B>
</P>
<OL>
<LI>Severity of preterm birth: very preterm birth (before 32 to 34 completed weeks) and extremely preterm birth (before 26 to 28 completed weeks);</LI>
<LI>death before discharge from hospital or in a special care nursery for more than seven days;</LI>
<LI>respiratory distress syndrome;</LI>
<LI>infection;</LI>
<LI>necrotising enterocolitis;</LI>
<LI>retinopathy of prematurity;</LI>
<LI>intraventricular haemorrhage;</LI>
<LI>small-for-gestational age: defined as growth below the 3rd centile, or lowest centile reported;</LI>
<LI>Apgar score at five minutes: low (less than seven) and very low (less than four) or lowest reported;</LI>
<LI>use of hospital resources: admission to special care nursery, length of stay, endotracheal intubation, use of mechanical ventilation;</LI>
<LI>long-term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay and cerebral palsy;</LI>
<LI>side effects associated with the intervention.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-02 15:48:16 +0200" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-02 15:48:16 +0200" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (4 June 2010).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. </P>
<P>In addition, we searched CENTRAL (<I>The Cochrane Library </I>2010, Issue 3) using the search strategy detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-01 19:13:05 +0200" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review, <I>see </I>
<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. For this update we used the following methods when assessing the reports identified by the updated search.</P>
<STUDY_SELECTION MODIFIED="2010-07-07 13:18:29 +0200" MODIFIED_BY="Denise Atherton">
<P>Two review authors independently assessed studies for eligibility (for this update D Chou (DC) and L Duley (LD)). We resolved differences and discrepancies by discussion with a third review author (for this update M Gulmezoglu (MG)). As LD had been involved in one trial potentially eligible for this review (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>), DC and MG assessed and extracted data for this study.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-01 19:07:19 +0200" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data from newly included papers. DC entered the data into Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) and LD or MG checked them for accuracy. We resolved discrepancies by discussion. If the two review authors could not agree, we consulted a third review author.</P>
<P>There was no blinding of authorship or results. Whenever possible, we sought unpublished data from investigators.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-01 19:08:52 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We describe for each included study whether the method used to generate the allocation sequence was described in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>adequate (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We describe for each included study whether the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered studies to be at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate, inadequate or unclear for participants;</LI>
<LI>adequate, inadequate or unclear for personnel;</LI>
<LI>adequate, inadequate or unclear for outcome assessors</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information was reported, or was supplied by the trial authors, we re-included missing data in the analyses which we undertook. We assessed methods as:</P>
<UL>
<LI>adequate;</LI>
<LI>inadequate;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>adequate (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>inadequate (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We describe for each included study any important concerns we had about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-09-01 19:09:03 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as risk ratio with 95% confidence intervals. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we present the results as mean difference with 95% confidence intervals. When pooling data across studies, we estimated the mean difference if the outcomes are measured in the same way between trials. We used the standardised mean difference to combine trials that measure the same outcome, but use different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-09-01 19:09:26 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We did not anticipate any cluster-randomised trials on this topic. However, if we did find any, we would have included them using the guidance in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Crossover trials</HEADING>
<P>We excluded crossover trials, as for pre-eclampsia they can only assess surrogate outcomes and markers. The important clinical outcomes are at birth, and beyond.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-09-01 19:10:01 +0200" MODIFIED_BY="[Empty name]">
<P>We noted the levels of attrition for included studies. We explored, using sensitivity analysis, the impact of including studies with high levels of missing data in the overall assessment of treatment effect.</P>
<P>For all outcomes, we analysed the data, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing ('available case' analysis).</P>
<P>We analysed data on all participants with available data in the group to which they were allocated, regardless of whether or not they received the allocated intervention. If in the original reports participants were not analysed in the group to which they were randomised, and there was sufficient information in the trial report, we would have attempted to restore them to the correct group. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-01 19:10:23 +0200" MODIFIED_BY="[Empty name]">
<P>We applied tests of heterogeneity between trials, if appropriate, using the I² statistic. If we identified heterogeneity among the trials (I² greater than 50%), we would have explored it by prespecified subgroup analysis and performing sensitivity analyses. We would have used a random-effects meta-analysis as an overall summary if this was considered appropriate<I>.</I> <B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-09-01 19:10:45 +0200" MODIFIED_BY="[Empty name]">
<P>Where we suspected reporting bias (<I>see</I> 'Selective reporting bias' above), we attempted to contact study authors asking them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we have explored the impact of including such studies in the overall assessment of results by sensitivity analysis. </P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-01 19:11:31 +0200" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We used fixed-effect inverse variance meta-analysis for combining data where trials examined the same intervention, and the trials' populations and methods were judged sufficiently similar. Where we suspected clinical or methodological heterogeneity between studies sufficient to suggest that treatment effects may differ among trials, we used random effects meta-analysis.</P>
<P>If we identified substantial heterogeneity in a fixed-effect meta-analysis we noted this and repeated the analysis using a random-effects method, when appropriate.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-09-01 19:12:57 +0200" MODIFIED_BY="[Empty name]">
<P>We performed statistical analyses using the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), with results presented as risk ratios (RR)and risk difference (RD). From 1/RD, we calculated the number needed to treat for benefits or harm. For each measure we have provided the 95% confidence intervals. We used the fixed-effect model for calculating the RR. If there was clear heterogeneity among the studies in any one outcome, we used a random-effects model. We also explored possible factors in the heterogeneity, including study quality, clinical factors as determined by the pre-specified subgroup analyses, and the play of chance.</P>
<P>We planned subgroup analyses for the main outcomes by:</P>
<OL>
<LI>severity of pre-eclampsia at trial entry: severe pre-eclampsia; not-severe pre-eclampsia; severity unclear, unspecified or mixed (see above for definitions);</LI>
<LI>whether delivered or not at trial entry: not delivered at trial entry; delivered; unclear, unspecified or mixed;</LI>
<LI>gestation at trial entry: 34 weeks' gestation or more at trial entry; below 34 weeks, unclear, unspecified, or mixed;</LI>
<LI>whether anticonvulsants had been given before trial entry: no anticonvulsant before trial entry; anticonvulsant before trial entry; unclear, unspecified, or mixed.</LI>
</OL>
<P>We used primary outcomes only for the subgroup analyses. We planned subgroups by dose and route of administration for magnesium sulphate for maternal death, eclampsia, baby deaths and side effects.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-09-01 19:13:05 +0200" MODIFIED_BY="[Empty name]">
<P>We carried out sensitivity analyses to explore the effect of trial quality for important outcomes in the review. Where there is risk of bias associated with a particular aspect of study quality (e.g. inadequate allocation concealment), we explored this by sensitivity analyses using the primary outcomes.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-21 13:39:52 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-21 12:22:11 +0200" MODIFIED_BY="[Empty name]">
<P>For a full description of the characteristics of included studies, <I>see</I> table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. <BR/>
</P>
<SEARCH_RESULTS MODIFIED="2010-09-01 19:13:34 +0200" MODIFIED_BY="[Empty name]">
<P>We have included 15 studies, and excluded 34.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-02 16:45:07 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>One international trial (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>) was considerably larger than any others, with 10,141 women recruited. Two other studies had more than 1000 women (<LINK REF="STD-Nimodipine-SG-2003" TYPE="STUDY">Nimodipine SG 2003</LINK>; <LINK REF="STD-USA-_x002d_-Texas-1995" TYPE="STUDY">USA - Texas 1995</LINK>); five had 100 to 1000 women (<LINK REF="STD-South-Africa-1994" TYPE="STUDY">South Africa 1994</LINK>; <LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998</LINK>; <LINK REF="STD-USA-_x002d_-Maryland-1993" TYPE="STUDY">USA - Maryland 1993</LINK>; <LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>); and the remaining seven studies had fewer than 100 women (<LINK REF="STD-Denmark-2000" TYPE="STUDY">Denmark 2000</LINK>; <LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>; <LINK REF="STD-Malaysia-1994" TYPE="STUDY">Malaysia 1994</LINK>; <LINK REF="STD-Mexico-1992" TYPE="STUDY">Mexico 1992</LINK>; <LINK REF="STD-Mexico-1998" TYPE="STUDY">Mexico 1998</LINK>; <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>; <LINK REF="STD-USA-_x002d_-Alabama-1995" TYPE="STUDY">USA - Alabama 1995</LINK>).</P>
<P>The trials were conducted in a mix of high-income, middle-income and low-income countries. They were all conducted in hospitals. The small trials were largely in tertiary referral hospitals. However, the largest trial, with 175 centres in 33 countries, included a wide range of secondary level hospitals as well as tertiary level (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Most trials in the review recruited women with severe, or relatively severe, pre-eclampsia. Two small USA trials (<LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>) included women with mild pre-eclampsia. Thirteen trials included only women who had not yet given birth. Two trials included women recruited postpartum: in one large trial 13% of women were randomised in the 24 hours after delivery (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>); in the other small trial postpartum women were included, but the numbers of women randomised before and after delivery are not reported (<LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Six trials (11,444 women) compared magnesium sulphate with placebo or no anticonvulsant (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>; <LINK REF="STD-South-Africa-1994" TYPE="STUDY">South Africa 1994</LINK>; <LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998</LINK>; <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>; <LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>). In the largest of these studies (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>, 10,141 women) around half the women recruited had magnesium sulphate maintenance therapy by the intravenous route (1 g/hour), and half by the intramuscular route. In one study maintenance therapy was by the intramuscular route (<LINK REF="STD-South-Africa-1994" TYPE="STUDY">South Africa 1994</LINK>). In the other four studies maintenance was by the intravenous route (<LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998;</LINK> <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>; <LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>); in two of these the dose was 1 g/hour (<LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998</LINK>; <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>) and in the other two it was 2 g/hour (<LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>).</P>
<P>For most of the women in these six trials, the magnesium sulphate regimen was administered by local hospital staff within their normal clinical practice. Clinical monitoring of respiration, tendon reflexes and urine output was reported to have been used for most trials. None of the six studies reported using serum monitoring for magnesium sulphate.</P>
<P>Magnesium sulphate was also compared with phenytoin (four trials, 2345 women) (<LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>; <LINK REF="STD-USA-_x002d_-Alabama-1995" TYPE="STUDY">USA - Alabama 1995</LINK>; <LINK REF="STD-USA-_x002d_-Maryland-1993" TYPE="STUDY">USA - Maryland 1993</LINK>; <LINK REF="STD-USA-_x002d_-Texas-1995" TYPE="STUDY">USA - Texas 1995</LINK>); diazepam (two trials, 66 women) (<LINK REF="STD-Malaysia-1994" TYPE="STUDY">Malaysia 1994</LINK>; <LINK REF="STD-Mexico-1992" TYPE="STUDY">Mexico 1992</LINK>); nimodipine (one trial, 1750 women) (<LINK REF="STD-Nimodipine-SG-2003" TYPE="STUDY">Nimodipine SG 2003</LINK>); and isosorbide (one trial, 36 women) (<LINK REF="STD-Mexico-1998" TYPE="STUDY">Mexico 1998</LINK>). For three of these studies, maintenance magnesium sulphate therapy was by the intramuscular route (<LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>; <LINK REF="STD-Malaysia-1994" TYPE="STUDY">Malaysia 1994</LINK>; <LINK REF="STD-USA-_x002d_-Texas-1995" TYPE="STUDY">USA - Texas 1995</LINK>). The other studies used the intravenous route; in one the dose was 1 g/hour (<LINK REF="STD-Mexico-1992" TYPE="STUDY">Mexico 1992</LINK>), in the remainder it was 2 g/hour. One small trial (33 women) compared magnesium chloride with methyl dopa (<LINK REF="STD-Denmark-2000" TYPE="STUDY">Denmark 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term follow-up</HEADING>
<P>Only one trial has reported long-term follow-up for the women and children (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>). This study recruited 10,141 women in 175 centres in 33 countries. As follow-up was not possible in all centres, 125 centres in 19 countries participated in the follow-up study. At these 125 centres, 4782 women were selected for follow-up, of whom 3375 (71%) were traced; and 4483 children were selected for follow-up, of whom 3283 (73%) were traced.</P>
<P>The median time from delivery to follow up for women was 26 months (range from within 12 months to greater than 48 months from delivery, interquartile range 19 to 36 months). Outcome for children was assessed when they were 18 months old (corrected for gestational age at birth).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-21 12:22:11 +0200" MODIFIED_BY="[Empty name]">
<P>We have excluded 35 studies. For details, <I>see </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-02 16:45:54 +0200" MODIFIED_BY="Sonja L  Henderson">
<ALLOCATION MODIFIED="2010-09-02 16:45:13 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>For the six trials comparing magnesium sulphate with placebo/no anticonvulsant, in the largest study concealment of allocation was secure and completeness of follow-up was 99% (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>). Adequate concealment of allocation was described for three trials (<LINK REF="STD-South-Africa-1994" TYPE="STUDY">South Africa 1994</LINK>; <LINK REF="STD-USA-_x002d_-Memphis-1997" TYPE="STUDY">USA - Memphis 1997</LINK>; <LINK REF="STD-USA-_x002d_-Tennessee-2001" TYPE="STUDY">USA - Tennessee 2001</LINK>), in one another concealment of allocation was not adequate (<LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998</LINK>), and for two studies concealment of allocation was unclear (<LINK REF="STD-India-2008" TYPE="STUDY">India 2008</LINK>; <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>).</P>
<P>For the trials comparing magnesium sulphate with another anticonvulsant, in the two large trials the procedure used to conceal allocation was not described in one (<LINK REF="STD-USA-_x002d_-Texas-1995" TYPE="STUDY">USA - Texas 1995</LINK>) and for the other it is unclear whether concealment of allocation was secure (<LINK REF="STD-Nimodipine-SG-2003" TYPE="STUDY">Nimodipine SG 2003</LINK>). Of the remaining trials, one described adequate concealment of allocation (<LINK REF="STD-Denmark-2000" TYPE="STUDY">Denmark 2000</LINK>), but for the remainder concealment of allocation was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-09-01 19:17:40 +0200" MODIFIED_BY="[Empty name]">
<P>Of the six trials comparing magnesium sulphate with placebo or no anticonvulsant, three used a placebo (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>; <LINK REF="STD-South-Africa-1994" TYPE="STUDY">South Africa 1994</LINK>; <LINK REF="STD-Taiwan-1995" TYPE="STUDY">Taiwan 1995</LINK>). For the comparisons of one drug with another, blinding of the intervention was not possible.</P>
<P>If blinding in the assessment of outcome was not mentioned, it was assumed not to have been done, and this was the case for all the trials that were not placebo controlled. Data coding and review of follow-up data for women and babies in the Magpie Trial follow-up study was blinded to treatment allocation (<LINK REF="REF-Magpie-2004" TYPE="REFERENCE">Magpie 2004</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-09-02 16:45:54 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>In one trial, 17% of women were lost to follow-up (<LINK REF="STD-South-Africa-1998" TYPE="STUDY">South Africa 1998</LINK>). This study also recruited over a long time period, 13+ years.</P>
<P>For the long-term follow-up of women and children in the Magpie Trial, data were available for 71% and 73% respectively. Losses to follow-up were higher in countries with high perinatal mortality. Data were available for 49% women in high perinatal mortality countries, 74% in middle perinatal mortality countries, and 95% in low perinatal mortality countries. For the children, 92 centres reported 100% follow-up, and 106 centres reported at least 90% follow-up of the children born to women randomised prior to delivery. We excluded centres with less than 20% follow-up.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-09-21 13:39:52 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Magnesium sulphate versus placebo or no anticonvulsant</HEADING>
<P>Six trials (11,444 women) compared magnesium sulphate with placebo or no anticonvulsant.</P>
<SUBSECTION>
<HEADING LEVEL="4">For the woman</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Maternal death</HEADING>
<P>Two trials (10,795 women) reported maternal deaths. The risk of dying was reduced by 46% for women allocated magnesium sulphate rather than placebo or no anticonvulsant, although this did not achieve statistical significance (risk ratio (RR) 0.54, 95% confidence interval (CI) 0.26 to 1.10). This effect was consistent regardless of severity of pre-eclampsia, whether antepartum at trial entry, gestation at trial entry or whether an anticonvulsant had been given before trial entry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Eclampsia</HEADING>
<P>Eclampsia was reported in six trials (11,444 women). There was more than a halving in the risk of eclampsia associated with the use of magnesium sulphate (RR 0.41, 95% confidence interval (CI) 0.29 to 0.58; risk difference (RD) -0.01, 95% CI -0.02 to -0.01; number needed to treat (NNTB) 100, 95% CI 50 to 100) rather than placebo or no anticonvulsant.</P>
<P>This effect is consistent regardless of whether or not women had severe pre-eclampsia at trial entry: for women with severe pre-eclampsia (RR 0.37, 95% CI 0.22 to 0.64; RD -0.02, 95% CI -0.03 to -0.01; NNTB 50, 95% CI 34 to 100); for women with not severe pre-eclampsia (RR 0.44, 95% CI 0.28 to 0.69; RD -0.01, 95% CI -0.01 to -0.00; NNTB 100, 95% CI 100 to 500). It is also consistent regardless of whether the women were antepartum at trial entry, and irrespective of gestation at trial entry. The only exception is the small subgroup of women who had another anticonvulsant before trial entry, and this result probably reflects the play of chance as the numbers were small.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serious maternal morbidity</HEADING>
<P>For the two trials (10,332 women) reporting a composite outcome of serious maternal morbidity, there was no clear difference between the two groups (RR 1.08, 95% CI 0.89 to 1.32). This result was consistent across the subgroups. For the individual measures of serious morbidity, such as pneumonia, renal failure and liver failure, there was also no clear evidence of an overall difference in effect between the two groups.</P>
<P>Two trials (10,795 women) reported use of antihypertensive therapy after trial entry. There was a small (3%) reduction in the need for antihypertensive therapy associated with the use of magnesium sulphate rather than placebo or no anticonvulsant (RR 0.97, 95% CI 0.95 to 0.99).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects and toxicity</HEADING>
<P>Side effects were reported by women in both treatment groups (24% versus 5%), although the risk of any side effect was much higher for those allocated magnesium sulphate (RR 5.26, 95% CI 4.59 to 6.03; RD 0.19, 95% CI 0.18 to 0.21; NNTH 6, 95% CI 5 to 6) rather than placebo or no anticonvulsant. By far the most common side effect was flushing (20% versus 2%). Although other side effects were reported less frequently, all were increased for women allocated magnesium sulphate. These included nausea and/or vomiting, slurred speech, muscle weakness, hypotension (low blood pressure), dizziness, drowsiness or confusion, and headache.</P>
<P>Problems at the injection site were also more common for women allocated magnesium sulphate rather than placebo. Intramuscular administration of both magnesium sulphate and placebo was associated with more problems at the injection site (12% versus 8%) than intravenous use (5% versus 2%). For intramuscular use the risk of problems was increased for women allocated magnesium sulphate (RR 1.49, 95% CI 1.25 to 1.79; RD 0.04, 95% CI 0.02 to 0.06; NNTH 25, 95% CI 17 to 50) rather than placebo. Similarly it was also increased for intravenous use (RR 3.05, 95% CI 2.15 to 4.32; RD 0.03, 95% CI 0.02 to 0.04; NNTH 34, 95% CI 25 to 50).</P>
<P>Toxicity (absent or reduced tendon reflexes and/or respiratory depression) was uncommon, occurring in around 1% of women allocated magnesium sulphate and 0.5% of those allocated placebo. There was no clear evidence of an overall difference in the risk of absent or reduced tendon reflexes (RR 1.00, 95% CI 0.70 to 1.42). Although respiratory depression, or other respiratory problems, were rare, there was an increased risk for women allocated magnesium sulphate (RR 1.98, 95% CI 1.24 to 3.15; RD 0.0049, 95% CI 0.000 to 0.01; NNTH 206, 95% CI 100 to 1000) rather than placebo. There was no clear difference between the groups in whether the women received calcium gluconate (RR 1.35, 95% CI 0.63 to 2.88).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Complications of pregnancy, labour and delivery</HEADING>
<P>The risk of placental abruption was reduced for women allocated magnesium sulphate (RR 0.64, 95% CI 0.50 to 0.83; RD -0.01, 95% CI -0.02 to 0.00; NNTB 100, 95% CI 50 to 1000) rather than placebo or no anticonvulsant. The risk of caesarean section was high in both groups (50% versus 47%). Women allocated magnesium sulphate had a small (5%) increased risk of caesarean section (six trials, 10,096 women) (RR 1.05, 95% CI 1.01 to 1.10; RD 0.03, 95% CI 0.01 to 0.04; NNTH 34, 95% CI 25 to 100) compared to those allocated placebo or no anticonvulsant.</P>
<P>There was no clear difference between the groups in the risk of induction of labour (one trial, 8771 women; RR 0.99, 95% CI 0.94 to 1.04), postpartum haemorrhage (RR 0.96, 95% CI 0.88 to 1.05), or manual removal of placenta (RR 0.90, 95% CI 0.72 to 1.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up for women after discharge from hospital</HEADING>
<P>At a median follow-up time of two years, for the women there was no clear difference between the groups in the risk of death (RR 1.79, 95% CI 0.71 to 4.53) or of serious morbidity: serious renal problems (RR 0.65, 95% CI 0.21 to 1.99), persistent hypertension (RR 0.78, 95% CI 0.51 to 1.20) or depression (RR 0.90, 95% CI 0.66 to 1.22).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For the child</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Stillbirth and neonatal death</HEADING>
<P>There was no overall difference in the risk of stillbirth or neonatal death (three trials, 9961 babies; RR 1.04, 95% CI 0.93 to 1.15). This result is consistent regardless of whether or not the woman had severe pre-eclampsia, and irrespective of gestation at trial entry.</P>
<P>For the composite outcome of death or in special care baby unit, there is no clear evidence of a clinically important difference (RR 1.02, 95% CI 0.95 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neonatal morbidity</HEADING>
<P>There was no clear difference in neonatal morbidity between the two groups: admission to special care baby unit (RR 1.01, 95% CI 0.96 to 1.06); admission to special care baby unit for more than seven days (RR 1.02, 95% CI 0.93 to 1.11); intubation at the place of delivery (RR 1.01, 95% CI 0.82 to 1.24).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up for the children after discharge from hospital</HEADING>
<P>Follow-up at 18 months of age (corrected for gestation at birth) was reported by one trial (3283 children). There was no clear difference between the groups in the risk of death (RR 1.02, 95% CI 0.57 to 1.84), neurosensory disability (RR 0.77, 95% CI 0.38 to 1.58), cerebral palsy (RR 0.34, 95% CI 0.09 to 1.26), or the composite outcome of death or neurosensory disability (RR 1.06, 95% CI 0.90 to 1.25).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Magnesium sulphate versus phenytoin</HEADING>
<P>Four trials (2343 women) compared magnesium sulphate with phenytoin. Magnesium sulphate reduced the risk of eclampsia compared with phenytoin (three trials, 2291 women RR 0.08, 95% CI 0.01 to 0.60; NNTB 97, 95% CI 62 to 221), although the number of events is small (0 versus 12).</P>
<P>Magnesium sulphate also increased the risk of caesarean section (two trials, 2192 women; RR 1.21, 95% CI 1.04 to 1.40; RD 0.048, 95% CI 0.012 to 0.084; NNTH 21 95% CI 12 to 83) compared with phenytoin. There is no information on other important measures of maternal morbidity. One trial (2165 babies) reported stillbirths (RR 0.62, 95% CI 0.27 to 1.41) and neonatal deaths (RR 0.26, 95% CI 0.03 to 2.31), with no clear difference between the two groups. There are no clear differences between the groups in the other reported measures of neonatal morbidity: Apgar at five minutes (RR 0.58, 95% CI 0.26 to 1.30) and admission to neonatal care (RR 1.00, 95% CI 0.63 to 1.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Magnesium sulphate versus diazepam</HEADING>
<P>The two trials (66 women) comparing magnesium sulphate with diazepam are too small for any reliable conclusions about their differential effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Magnesium sulphate versus nimodipine</HEADING>
<P>One trial compared magnesium sulphate with nimodipine (1650 women). The risk of eclampsia was lower for women allocated magnesium sulphate rather than nimodipine (0.8% versus 2.6%; RR 0.33, 95% CI 0.14 to 0.77; RD -0.02, 95% CI -0.03 to -0.00; NNTB 50, 95% CI 34 to 1000). The only other clear differences were an increase in respiratory problems associated with magnesium sulphate compared to nimodipine (1.3% versus 0.4%; RR 3.61, 95% CI 1.01 to 12.91), and a greater need for additional antihypertensive drugs associated with magnesium sulphate rather than nimodipine (54% versus 46%, RR 1.19, 95% CI 1.08 to 1.31).</P>
<P>Mortality for the baby is not reported. The only measures of neonatal morbidity reported were respiratory distress, hypotonia, intubation and hypotension; there were no clear differences between the groups for any of these four outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Magnesium chloride versus methyl dopa</HEADING>
<P>One trial compared magnesium chloride with methyl dopa (31 women) and it was too small for any reliable conclusions about potential differential effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Magnesium sulphate versus nitrates</HEADING>
<P>One trial (36 women) compared magnesium sulphate with isosorbide, a nitrate. Eclampsia was the only clinical outcome reported, and the study was too small for any reliable conclusions.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-01 19:47:33 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-09-01 19:43:31 +0200" MODIFIED_BY="[Empty name]">
<P>More than 11,000 women have been randomised into trials comparing magnesium sulphate with placebo or no anticonvulsant. Most other trials have compared magnesium sulphate with an alternative drug. The use of magnesium sulphate, rather than placebo or no anticonvulsant, for women with pre-eclampsia is associated with a halving in the risk of eclampsia, and it seems likely that there is also a clinically important reduction in the risk of maternal death. There is no clear evidence that these benefits are reflected in any reduction in other measures of serious maternal morbidity. The only other effects are that there appears to be a reduction in the risk of placental abruption associated with magnesium sulphate, and a small increase (5%) in the risk of caesarean section. This review provides reasonable reassurance that there is no substantive effect on stillbirth or neonatal mortality associated with the use of magnesium sulphate. Nevertheless, a small increase or decrease in mortality for the baby has not been excluded. Additional reassurance about the safety of magnesium sulphate when used for women with pre-eclampsia is that there is also no substantive effect on the composite outcome of death or in special care nursery for more than seven days.</P>
<P>The reduction in placental abruption is not reflected in any overall effect on mortality or morbidity for the baby. This is not surprising, as the number of women who had a placental abruption in these trials was small. The difference between the groups in the number with a placental abruption was 49 women. Even a moderate impact, for example a 15% reduction in mortality, would therefore only represent seven deaths and so be unlikely to influence the overall risk.</P>
<P>About a quarter of women report side effects associated with magnesium sulphate, the vast majority being flushing. Almost all the data on side effects and safety come from studies that used either the intramuscular regimen for maintenance therapy, or the intravenous route with 1 g per hour, and for around 24 hours. The use of higher doses and longer duration cannot be supported by these data. In particular, the reassurance about safety and lack of serious side effects cannot be extrapolated to higher doses or longer duration of therapy.</P>
<P>Follow-up data from one large trial are now available. These data show that the reduction in risk of eclampsia following prophylaxis with magnesium sulphate is not associated with an excess of death or disability for the women after two to three years, and that exposure to magnesium sulphate whilst <I>in utero</I> is not associated with any clear difference in the risk of death or neurosensory disability for the children at 18 months of age. This provides reassurance about the longer term safety of magnesium sulphate when used for women with pre-eclampsia.</P>
<P>In the comparisons of magnesium sulphate with other anticonvulsant drugs, magnesium sulphate was better than either phenytoin or nimodipine for prevention of eclampsia. There were insufficient data for reliable conclusions about the differential effects in the other comparisons.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-09-01 19:46:23 +0200" MODIFIED_BY="[Empty name]">
<P>The halving in risk of eclampsia is consistent across the subgroups. In particular the reduction in risk ratio is similar regardless of severity of pre-eclampsia. As eclampsia is more common amongst women with severe pre-eclampsia than amongst those with moderate or mild pre-eclampsia, the number of women who would need to be treated to prevent one case of eclampsia is greater for non-severe pre-eclampsia. Few women in this review had mild pre-eclampsia, as the non-severe category primarily includes women with moderate disease.</P>
<P>Although few women in this review had mild pre-eclampsia, it would seem plausible that magnesium sulphate would also reduce the risk of eclampsia for these women. As the risk of eclampsia is low for these women, however, the number needed to treat would be high. The cost-effectiveness of magnesium sulphate is best when its use is restricted to women with severe pre-eclampsia (<LINK REF="REF-Simon-2006" TYPE="REFERENCE">Simon 2006</LINK>).</P>
<P>Women in these trials have been recruited in a wide range of countries and settings. The trials were all conducted in hospitals, at either secondary or tertiary level, in high-, middle- and low-income countries. All trials comparing magnesium sulphate with placebo or no anticonvulsant used clinical monitoring. Serum monitoring is not required. These results are therefore widely applicable to hospital settings throughout the world.</P>
<P>In high-income countries, the intravenous maintenance regimen is usually used for magnesium sulphate. In low- and middle-income countries, if hospitals do not have the resources to administer and monitor an intravenous infusion, intramuscular administration is preferable despite the higher incidence of problems at the injection site.</P>
<P>The benefits from use of magnesium sulphate for women with pre-eclampsia must also be balanced against the costs associated with treatment. Using data from the Magpie Trial, the overall financial healthcare cost, adjusted for 2001 US dollars, to prevent a single case of eclampsia is $21,202 in high-, $2473 in middle-, and $456 in low-income countries (<LINK REF="REF-Simon-2006" TYPE="REFERENCE">Simon 2006</LINK>). The cost effectiveness of magnesium sulphate is improved if it is used only for women with severe pre-eclampsia, and in low-income countries if the cost of purchasing the drug is reduced.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-06-29 13:33:13 +0200" MODIFIED_BY="Lelia Duley">
<P>The quality of the studies included in this review ranged from excellent to poor. However, most of the poor quality studies were small. The large study comparing magnesium sulphate with placebo was of high quality (<LINK REF="STD-Magpie-Trial-2002" TYPE="STUDY">Magpie Trial 2002</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-09-01 19:47:23 +0200" MODIFIED_BY="[Empty name]">
<P>The evidence for this review is derived from studies identified in a detailed search process. It is possible (but unlikely) that additional trials comparing the use of magnesium sulphate versus other medications in the treatment of pre-eclampsia have been published but not identified. It is also possible that other studies have been conducted but are not yet published. Should any such studies be identified, we will include them in future updates of this review.</P>
<P>As one of the review authors was principal investigator for the Magpie Trial, two other review authors (M Gulmezoglu and D Chou) performed data extraction.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-09-01 19:47:33 +0200" MODIFIED_BY="[Empty name]">
<P>This review presents strong evidence that magnesium sulphate is the drug of choice for prevention eclampsia, and that this benefit in the short term is not associated with any clear evidence of an effect on long-term outcome for either the women or children.</P>
<P>Other Cochrane reviews confirm that magnesium sulphate is also the treatment of choice for women with eclampsia (<LINK REF="REF-Duley-2000" TYPE="REFERENCE">Duley 2000</LINK>; <LINK REF="REF-Duley-2003a" TYPE="REFERENCE">Duley 2003a</LINK>; <LINK REF="REF-Duley-2003b" TYPE="REFERENCE">Duley 2003b</LINK>). Magnesium sulphate is therefore widely recommended for both prevention and treatment of eclampsia (<LINK REF="REF-Langer-2008" TYPE="REFERENCE">Langer 2008</LINK>; <LINK REF="REF-RCOG-2006" TYPE="REFERENCE">RCOG 2006</LINK>; <LINK REF="REF-Sheth-2002" TYPE="REFERENCE">Sheth 2002</LINK>). Alternative regimens for administration of magnesium sulphate for women with eclampsia and pre-eclampsia are compared elsewhere (<LINK REF="REF-Duley-2008" TYPE="REFERENCE">Duley 2008</LINK>).</P>
<P>For women at risk of preterm birth, the use of magnesium sulphate also reduces the risk of their child having cerebral palsy (<LINK REF="REF-Doyle-2009" TYPE="REFERENCE">Doyle 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-09-02 16:46:18 +0200" MODIFIED_BY="Sonja L  Henderson">
<IMPLICATIONS_PRACTICE MODIFIED="2010-07-07 13:38:34 +0200" MODIFIED_BY="Denise Atherton">
<P>Magnesium sulphate should be available in all hospitals providing care for women with eclampsia and pre-eclampsia. Its use should be considered for women with pre-eclampsia for whom there is concern about the risk of eclampsia. Cost effectiveness is improved if its use is restricted to women with severe pre-eclampsia. As magnesium sulphate is an inexpensive drug, it is appropriate for low-income countries. For low-income countries, cost effectiveness is also improved if the purchase price for magnesium sulphate is low.</P>
<P>Intravenous administration for maintenance therapy is preferable, where there are appropriate resources, as this is associated with fewer side effects and injection site problems than intramuscular use. Duration of treatment should not normally exceed 24 hours, and if the intravenous route is used for maintenance therapy the dose should not exceed 1 g/hour. Data on side effects, serious adverse effects and long-term outcome presented in this review may not apply to use of higher doses. Administration and clinical monitoring of magnesium sulphate can be done by medical, midwifery or nursing staff, provided they are appropriately trained. Serum monitoring is not necessary.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-02 16:46:18 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>The trials in this review included women only after admission to hospital. Whether a loading dose of magnesium sulphate should be used for women at primary care level before they are transferred to hospital is unclear. Other factors in this decision are likely to include how long it will take to get the woman to hospital, the support that is available during transfer, and severity of her pre-eclampsia.</P>
<P>Other questions that require further research are what is the minimum effective dose of magnesium sulphate; what is the optimal duration of therapy; and when is the optimal time to give it.</P>
<P>Any new agents for eclampsia prophylaxis should be compared with magnesium sulphate in large randomised trials. These studies should include long-term follow-up of women and children, and assessment of cost effectiveness.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-02 16:35:36 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>We thank Rebecca Gainey for translating <LINK REF="REF-Vargas-1998" TYPE="REFERENCE">Vargas 1998</LINK>; Xiaojing Lai for translating <LINK REF="STD-Li-1998" TYPE="STUDY">Li 1998</LINK>; Maria Kalousi for translating <LINK REF="STD-Neto-2000" TYPE="STUDY">Neto 2000</LINK>; Ussanee Sangkomkamhang for translating <LINK REF="STD-Tongsong-1992" TYPE="STUDY">Tongsong 1992</LINK>; Maria Tenorio for translating <LINK REF="STD-Rodriquez-1990" TYPE="STUDY">Rodriquez 1990</LINK>; and Laura Woodhouse for translating <LINK REF="REF-Walss-1992" TYPE="REFERENCE">Walss 1992</LINK>.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-06-04 13:12:17 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Lelia Duley is a principal investigator for the Magpie Trial, which compared magnesium sulphate with placebo and was, therefore, not involved in the assessment or data extraction of this trial.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-06-04 13:12:55 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>All review authors contributed to developing the methods. The initial review was written by L Duley (LD), D Henderson-Smart (DHS), and M Gülmezoglu (MG). For this updated review, MG and D Chou (DC) extracted and double checked the newly included data. The text of the updated review was drafted by DC with the assistance of LD and contributions from MG and DHS.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-02 05:03:24 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-02 05:03:24 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-02 05:03:24 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Denmark-2000" MODIFIED="2010-05-26 11:49:57 +0200" MODIFIED_BY="Jill V Hampson" NAME="Denmark 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-26 11:49:57 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Frolich A, Pilsgaard K, Nyrnberg L, Moller M, Sanchez M et al</AU>
<TI>Comparison of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2000</YR>
<VL>49</VL>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-India-2008" MODIFIED="2010-09-02 05:03:24 +0200" MODIFIED_BY="[Empty name]" NAME="India 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-02 05:03:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma R, Mir S, Rizvi M, Akthar S</AU>
<TI>Efficacy of magnesium sulphate versus phenytoin in seizure control and prophylaxis in patients of eclampsia and severe pre-eclampsia</TI>
<SO>JK Science</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>4</NO>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Magpie-Trial-2002" MODIFIED="2010-05-26 11:53:36 +0200" MODIFIED_BY="Jill V Hampson" NAME="Magpie Trial 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-26 11:50:25 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bricker L, Magpie Trial Collaborative Group</AU>
<TI>The Magpie Trial: magnesium sulphate versus placebo for women with pre-eclampsia</TI>
<SO>XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duley L, Campbell L</AU>
<TI>The Magpie Trial: magnesium sulphate for pre-eclampsia, evaluating the effects on women and their babies</TI>
<SO>MIDIRS Midwifery Digest</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duley L, Magpie Trial Collaborative Group</AU>
<TI>The Magpie Trial: magnesium sulphate versus placebo for women with pre-eclampsia</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duley L, Neilson JP</AU>
<TI>Magnesium sulphate and pre-eclampsia. Trial needed to see whether it's as valuable in pre-eclampsia as in eclampsia</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duley L, Watkins K</AU>
<TI>Magnesium sulphate for treatment of pre-eclampsia: a trial to evaluate the effects on women and their babies</TI>
<SO>Contemporary Reviews in Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>4</NO>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:15:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duley L</AU>
<TI>The Magpie follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Magpie Trial Collaborative Group</AU>
<TI>Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>1877-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:15:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magpie Trial Follow-Up Study Collaborative Group</AU>
<TI>The Magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>3</NO>
<PG>289-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:15:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magpie Trial Follow-Up Study Collaborative Group</AU>
<TI>The Magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>3</NO>
<PG>300-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:51:01 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moodley J, Magpie Trial Collaborative Group</AU>
<TI>The Magpie Trial: magnesium sulphate versus placebo for women with pre-eclampsia</TI>
<SO>Women's Health - into the new millennium. Proceedings of the 4th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1999 October 3-6; Cape Town, South Africa</SO>
<YR>1999</YR>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:45:42 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon J, Gray A, Duley L, on behalf of the Magpie Trial Collaborative Group</AU>
<TI>Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial</TI>
<SO>BJOG: An International Journal of Obstetrics and Gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:53:36 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smyth RM, Spark P, Armstrong N, Duley L</AU>
<TI>Magpie Trial in the UK: methods and additional data for women and children at 2 years following pregnancy complicated by pre-eclampsia</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19366459"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:16:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan K</AU>
<TI>The use of magnesium sulphate in pre-eclampsia [abstract]</TI>
<SO>Singapore Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Malaysia-1994" MODIFIED="2010-05-26 11:51:42 +0200" MODIFIED_BY="Jill V Hampson" NAME="Malaysia 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-26 11:51:26 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Adeeb N, Hatta AZ, Shariff J</AU>
<TI>Comparing magnesium sulphate to diazepam in managing severe pre-eclampsia and eclampsia</TI>
<SO>10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4-8; Seattle, Washington, USA</SO>
<YR>1996</YR>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:51:42 +0200" MODIFIED_BY="Jill V Hampson" NOTES="&lt;p&gt;[7240]&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 11:51:42 +0200" NOTES_MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Adeeb N, Ho CM</AU>
<TI>Comparing magnesium sulphate versus diazepam in the management of severe pre-eclampsia and eclampsia</TI>
<SO>9th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1994 March 15-18; Sydney, Australia</SO>
<YR>1994</YR>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mexico-1992" NAME="Mexico 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[7788]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walss Rodriguez RJ, Levario AR</AU>
<TI>Anticonvulsant treatment of severe pre-eclampsia: comparison of diazepam and magnesium sulfate</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1992</YR>
<VL>60</VL>
<PG>331-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mexico-1998" MODIFIED="2010-05-26 11:52:51 +0200" MODIFIED_BY="Jill V Hampson" NAME="Mexico 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-26 11:52:51 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vargas AG, Salmeron PI, Sanchez GAR, Jiminez AL, Rubio GAF</AU>
<TI>Efficancy of isosorbide in aerosol in the management of hypertensive crisis of severe preeclampsia</TI>
<TO>Eficacia del isosorbide en aerosol en el manejo de la crisis hipertensiva de la preeclampsia</TO>
<SO>Ginecologia y Obstetricia De Mexico</SO>
<YR>1998</YR>
<VL>66</VL>
<PG>316-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimodipine-SG-2003" MODIFIED="2009-06-29 12:16:23 +0200" MODIFIED_BY="[Empty name]" NAME="Nimodipine SG 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belfort M, Anthony J, Saade G, Nimodipine Study Group</AU>
<TI>Interim report of the nimodipine vs. magnesium sulfate for seizure prophylaxis in severe preeclampsia study: an international randomized controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belfort M, Saade G, Yared M, Abedejos P, Dorman K</AU>
<TI>Change in estimated cerebral perfusion pressure following nimodipine or magnesium sulfate in patients with severe preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<PG>S114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belfort MA, Anthony J, Saade GR, Allen JC, for the Nimodipine Study Group</AU>
<TI>A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>304-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belfort MA, Saade GR, Yared M, Grunewald C, Herd A, Varner MA et al</AU>
<TI>Change in estimated cerebral perfusion pressure after treatment with nimodipine or magnesium sulfate in patients with pre-eclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>181</VL>
<PG>402-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:16:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollenberg NK</AU>
<TI>A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia</TI>
<SO>Current Hypertension Reports</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>4</NO>
<PG>288-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1994" NAME="South Africa 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[8999]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moodley J, Moodley J</AU>
<TI>Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large randomized trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>245-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1998" MODIFIED="2010-09-02 03:22:19 +0200" MODIFIED_BY="[Empty name]" NAME="South Africa 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anthony J, Rush R</AU>
<TI>A randomised controlled trial of intravenous magnesium sulphate versus placebo</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>809-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[9665] &lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coetzee E, Dommisse J, Anthony J</AU>
<TI>A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>300-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:53:10 +0200" MODIFIED_BY="Jill V Hampson" NOTES="&lt;p&gt;[8952]&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 11:53:10 +0200" NOTES_MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coetzee E, Dommisse J, Anthony J</AU>
<TI>Are anticonvulsants necessary in the management of severe gestational proteinuric hypertension</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>121</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-02 03:22:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Coetzee E, Dommisse J, Anthony J</AU>
<TI>The prediction and prevention of seizures in 571 patients with severe pre-eclampsia</TI>
<SO>10th World Congress of the International Society for the Study of Hypertension in Pregnancy; 1996 August 4-8; Seattle, Washington, USA, 1996:124</SO>
<YR>1996</YR>
<PG>124</PG>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coetzee EJ, Anthony J, Dommisse AJ</AU>
<TI>Does magnesium sulphate prevent eclampsia in severe gestational proteinuria hypertension</TI>
<SO>Prenatal and Neonatal Medicine</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-02 03:22:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Coetzee EJ, Dommisse AJ</AU>
<TI>Eclampsia: not a preventable disease in the South African context</TI>
<SO>Proceedings of the 13th conference on Prioirities in Perinatal Care; 1994; South Africa, 1994:3-5</SO>
<YR>1994</YR>
<PG>3-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moodley J, Pattinson RC, Hofmeyr GJ</AU>
<TI>A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia [letter; comment]</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>3</NO>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:54:16 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Woods D, Anthony J, Dommisse J, Coetzee E</AU>
<TI>Can magnesium sulphate before delivery reduce the risk of hypoxic-ischaemic encephalopathy</TI>
<SO>Proceedings of the 15th Conference on Priorities in Perinatal Care in South Africa; March 5-8; Goudini Spa, South Africa</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taiwan-1995" NAME="Taiwan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[8682]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen FP, Chang SD, Chu KK</AU>
<TI>Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1995</YR>
<VL>74</VL>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Alabama-1995" NAME="USA - Alabama 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;[8944]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson MW, Guinn D, Owen J, Hauth JC</AU>
<TI>Does magnesium sulfate affect the length of labor induction in women with pregnancy-associated hypertension?</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>1219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[8748]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson MW, Guinn D, Owen J, Hauth JC</AU>
<TI>Does magnesium sulfate prolong labor induction in women with gestational hypertension?</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>384</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Maryland-1993" MODIFIED="2010-05-26 11:55:27 +0200" MODIFIED_BY="Jill V Hampson" NAME="USA - Maryland 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[8010]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedman SA, Lim KH, Baker C, Repke JT</AU>
<TI>Phenytoin vs magnesium sulfate in preeclampsia: a pilot study</TI>
<SO>American Journal of Perinatology</SO>
<YR>1993</YR>
<VL>10</VL>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:55:05 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Friedman SA, Lim KH, Baker CA, Repke JT</AU>
<TI>A comparison of phenytoin infusion versus magnesium sulphate infusion in preeclampsia</TI>
<SO>Proceedings of the 10th Annual Meeting of the Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:55:27 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Repke JT, Friedman SA, Lim KH, Baker CA</AU>
<TI>Magnesium sulfate vs phenytoin in preeclampsia: preliminary results from a randomized clinical trial</TI>
<SO>Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1-4; New Orleans, Louisiana, USA</SO>
<YR>1989</YR>
<PG>123</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Memphis-1997" NAME="USA - Memphis 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witlin A, Friedman S, Sibai B</AU>
<TI>The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized double-blind, placebo-controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[9664]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Witlin AG, Friedman SA, Sibai BM</AU>
<TI>The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>623-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Tennessee-2001" NAME="USA - Tennessee 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livingston J, Livingston L, Mabie B, Sibai B</AU>
<TI>The efficacy of magnesium sulfate in women with mild preeclampsia: a double blinded placebo controlled trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livingston J, Livingston L, Ramsey R, Kao L, Mabie B, Sibai B</AU>
<TI>Magnesium sulfate in women with mild preeclampsia: a double blind placebo controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>185</VL>
<NO>Suppl 6</NO>
<PG>S75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM</AU>
<TI>Magnesium sulfate in women with mild preeclampsia: a randomised controlled trial</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>2</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Texas-1995" NAME="USA - Texas 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leveno KJ, Alexander JM, McIntire DD, Lucas MJ</AU>
<TI>Does magnesium sulfate given for the prevention of eclampsia affect the outcome of labor?</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<PG>707-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[8881]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lucas MJ, Leveno KJ, Cunningham MD</AU>
<TI>A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-06-21 18:48:48 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbade-2006" MODIFIED="2010-05-26 11:55:44 +0200" MODIFIED_BY="Jill V Hampson" NAME="Abbade 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-26 11:55:44 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbade JF, Costa RAA, Martins AMVC, Rudge MVC, Peracoli JC</AU>
<TI>Zuspan's scheme versus alternative scheme of magnesium sulphate to prevent or to treat eclampsia: comparison of magnesium serum concentrations</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antartani-2006" MODIFIED="2010-05-26 11:55:54 +0200" MODIFIED_BY="Jill V Hampson" NAME="Antartani 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-26 11:55:54 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Antartani RC, Kiran A</AU>
<TI>A comparative study of magnesium sulfate vs phenytoin for prevention of recurrence of seizures in eclampsia</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 Jan 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Begum-2002" MODIFIED="2010-05-26 11:56:12 +0200" MODIFIED_BY="Jill V Hampson" NAME="Begum 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-26 11:56:12 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Begum A</AU>
<TI>Loading dose vs standard regime of magnesium sulphate in the management of eclampsia - a randomized trial</TI>
<SO>XVI FIGO World Congress of Obstetrics &amp; Gynecology (Book 2); 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:26:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Begum MR, Begum A, Quadir E</AU>
<TI>Loading dose versus standard regime of magnesium sulfate in the management of eclampsia: a randomized trial</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Begum-2009" MODIFIED="2010-06-21 18:48:27 +0200" MODIFIED_BY="[Empty name]" NAME="Begum 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-21 18:48:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Begum K</AU>
<TI>A lower dose of magnesium sulphate for control of convulsion in eclamptic women of Bangladesh</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>Suppl 2</NO>
<PG>S124</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-China-2000" MODIFIED="2010-05-26 11:56:21 +0200" MODIFIED_BY="Jill V Hampson" NAME="China 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-26 11:56:21 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dianrong S, Lirong Y, Yinglin L</AU>
<TI>A comparison of phentolamine and magnesium sulphate in pre-eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2000</YR>
<VL>68</VL>
<PG>259-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chissell-1994" MODIFIED="2009-06-29 12:07:02 +0200" MODIFIED_BY="[Empty name]" NAME="Chissell 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-06-29 12:07:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chissell S, Botha JH, Moodley J, McFadyen L</AU>
<TI>Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia</TI>
<SO>South African Medical Journal</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>607-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chowdhury-2009" MODIFIED="2010-06-21 18:48:30 +0200" MODIFIED_BY="[Empty name]" NAME="Chowdhury 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-21 18:48:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury JR, Chaudhuri S, Bhattacharyya N, Biswas PK, Panpalia M</AU>
<TI>Comparison of intramuscular magnesium sulfate with low dose intravenous magnesium sulfate regimen for treatment of eclampsia</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>1</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehrenberg-2006" MODIFIED="2010-05-26 11:56:29 +0200" MODIFIED_BY="Jill V Hampson" NAME="Ehrenberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-26 11:56:29 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehrenberg H, Mercer B</AU>
<TI>Abbreviated post-partum magnesium sulfate therapy for women with mild preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<NO>6 Suppl 1</NO>
<PG>S73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 12:07:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehrenberg HM, Mercer BM</AU>
<TI>Abbreviated postpartum magnesium sulfate therapy for women with mild preeclampsia: a randomized controlled trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>4</NO>
<PG>833-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontenot-2005" MODIFIED="2009-06-29 12:07:40 +0200" MODIFIED_BY="[Empty name]" NAME="Fontenot 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-29 12:07:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fontenot MT, Lewis DF, Frederick JB, Wang Y, DeFranco EA, Groome LJ et al</AU>
<TI>A prospective randomized trial of magnesium sulfate in severe preeclampsia: use of diuresis as a clinical parameter to determine the duration of postpartum therapy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<PG>1788-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghahiri-2005" MODIFIED="2009-06-29 12:07:45 +0200" MODIFIED_BY="[Empty name]" NAME="Ghahiri 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-29 12:07:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghahiri A, Berjis K</AU>
<TI>A comparison between intravenous magnesium sulfate and oral magnesium chloride in mild preeclampsia</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>6-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hangarga-2001" MODIFIED="2009-06-29 12:07:51 +0200" MODIFIED_BY="[Empty name]" NAME="Hangarga 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-06-29 12:07:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hangarga US, Pragya S</AU>
<TI>A comparative study of phenytoin sodium with magnesium sulphate and Menon's regime in the treatment of eclampsia</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>3</NO>
<PG>68-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laiteerapong-1999" MODIFIED="2009-06-29 12:08:16 +0200" MODIFIED_BY="[Empty name]" NAME="Laiteerapong 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-06-29 12:08:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laiteerapong U, Leelahakorn S</AU>
<TI>Comparative study of serum magnesium levels attained from magnesium sulfate therapy for severe pre-eclamptic patients between 1 gm/hr and 2 gm/hr regimen</TI>
<SO>Thai Journal of Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>4</NO>
<PG>281</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1998" MODIFIED="2009-06-29 12:08:22 +0200" MODIFIED_BY="[Empty name]" NAME="Li 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-06-29 12:08:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li M, Yang M, Qiu X</AU>
<TI>The effect of nimodipine on retinal blood flow in pregnancy induced hypertension</TI>
<SO>Zhonghua Fu Chan Ke Za Zh</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>7</NO>
<PG>397-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maheshwari-1989" MODIFIED="2010-06-21 18:48:34 +0200" MODIFIED_BY="[Empty name]" NAME="Maheshwari 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-21 18:48:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maheshwari JR, Desai SV, Hansotia MD, Walvekar VR</AU>
<TI>Anti-convulsant therapy in eclampsia</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>2</NO>
<PG>66-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muhammad-2009" MODIFIED="2010-06-21 18:48:37 +0200" MODIFIED_BY="[Empty name]" NAME="Muhammad 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-21 18:48:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muhammad A, Ibrahim U, Nighat K, Muhammad Y, Abdullahi A</AU>
<TI>Low dose magnesium sulfate in the control of eclamptic fits: a randomized control trial</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>Suppl 2</NO>
<PG>S277-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mundle-2009" MODIFIED="2010-06-21 18:48:40 +0200" MODIFIED_BY="[Empty name]" NAME="Mundle 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-21 18:48:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mundle S, Regi A, Biswas B, Bracken H, Easterling T, Winikoff B</AU>
<TI>Preeclampsia in low-resource settings: a randomized trial of IV MgSO4 via flow controlled pump</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>Suppl 2</NO>
<PG>S278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagar-1988" MODIFIED="2009-06-29 12:08:30 +0200" MODIFIED_BY="[Empty name]" NAME="Nagar 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-06-29 12:08:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagar S, Jain S, Kumari S, Ahuja L</AU>
<TI>Reassessment of therapy of eclampsia: comparison of mortality and morbidity of mother and fetus with parenteral magnesium sulphate and lytic cocktail therapy</TI>
<SO>Journal of Obstetrics and Gynaecology of India</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>3</NO>
<PG>250-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neto-2000" MODIFIED="2009-06-29 12:08:37 +0200" MODIFIED_BY="[Empty name]" NAME="Neto 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-06-29 12:08:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neto JDV, Bertini AM, Taborda WC, Parente JV</AU>
<TI>Treatment of eclampsia: comparative study on the use of magnesium sulfate and phenytoin</TI>
<TO>Tratamento da eclampsia:estudio comparativo entre sulfato de magnesio e a fenitoina</TO>
<SO>Revista Brasileira de Ginecologia e Obstetricia</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>9</NO>
<PG>543-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ola-2004" MODIFIED="2009-06-29 12:08:51 +0200" MODIFIED_BY="[Empty name]" NAME="Ola 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-29 12:08:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ola RE, Odeneye OT, Abudu OO</AU>
<TI>Eclampsia: a randomized double blind trial of magnesium sulphate and diazepam in Lagos, Nigeria</TI>
<SO>Tropical Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>2</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriquez-1990" MODIFIED="2010-05-26 11:57:38 +0200" MODIFIED_BY="Jill V Hampson" NAME="Rodriquez 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-26 11:57:38 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriquez Cruz CM, Suero Holguin HJ, Pena Acosta CA, Cots Martinez JM, Garcia CA, Camilo MA</AU>
<TI>Magnesium sulfate versus diazepam in the treatment of severe preeclampsia</TI>
<TO>Sulfato de magnesio versus diazepam en el manejo de la pre-eclampsia severa</TO>
<SO>Acta Medica Dominicana</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>5</NO>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudnicki-1990" MODIFIED="2009-06-29 12:09:41 +0200" MODIFIED_BY="[Empty name]" NAME="Rudnicki 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-06-29 12:09:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Junge J, Frolich A, Ornvold K, Fischer-Rasmussen W</AU>
<TI>Magnesium supplement in pregnancy-induced hypertension. A clinicopathological study</TI>
<SO>APMIS</SO>
<YR>1990</YR>
<VL>98</VL>
<PG>1123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudnicki-1991" MODIFIED="2009-06-29 12:09:46 +0200" MODIFIED_BY="[Empty name]" NAME="Rudnicki 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-06-29 12:09:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Frolich A, Rasmussen WF, McNair P</AU>
<TI>The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>445-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samal-2001" MODIFIED="2010-06-21 18:48:42 +0200" MODIFIED_BY="[Empty name]" NAME="Samal 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-06-21 18:48:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samal S, Gupta U, Agarwal P</AU>
<TI>Management of eclampsia with magnesium sulphate and nifedipine</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>3</NO>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shilva-2007" MODIFIED="2009-06-29 12:14:17 +0200" MODIFIED_BY="[Empty name]" NAME="Shilva 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-29 12:14:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shilva, Saha SC, Kalra J, Prasad R</AU>
<TI>Safety and efficacy of low-dose MgSO4 in the treatment of eclampsia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2007</YR>
<VL>97</VL>
<NO>2</NO>
<PG>150-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2005" MODIFIED="2009-06-29 12:10:13 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-29 12:10:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith D, Warren J, Saade G, Clark S, Belfort M</AU>
<TI>Oral labetalol given to treated non hypertensive patients with preeclampsia is no more likely to cause hypotension than magnesium sulfate [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>193</VL>
<NO>6 Suppl</NO>
<PG>S78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-South-Africa-1996" NAME="South Africa 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payne AJ, Naidu S, Moodley J, Hoffmann M, Gouws F</AU>
<TI>Non-invasive assessment of the maternal cerebral circulation by transcranial doppler ultrasound in the hypertensive crises of pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<PG>320</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suneja-2008" MODIFIED="2010-06-21 18:48:48 +0200" MODIFIED_BY="[Empty name]" NAME="Suneja 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-21 18:48:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suneja A, Sinha S, Vaid N, Ahuja S</AU>
<TI>A prospective randomized controlled trial to individualize the duration of post partum magnesium sulfate therapy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanzania-1994" MODIFIED="2010-05-26 11:58:03 +0200" MODIFIED_BY="Jill V Hampson" NAME="Tanzania 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-26 11:58:03 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ramsay M, Rimoy G, Rubin P</AU>
<TI>Are anticonvulsants necessary to prevent eclampsia?</TI>
<SO>Proceedings of the 9th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1994 March 15-18; Sydney, Australia</SO>
<YR>1994</YR>
<PG>279</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay MM, Rimoy GH, Rubin PC</AU>
<TI>Are anticonvulsants necessary to prevent eclampsia</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>540-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tongsong-1992" MODIFIED="2009-06-29 12:11:06 +0200" MODIFIED_BY="[Empty name]" NAME="Tongsong 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-06-29 12:11:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tongsong T, Dejkijwikrom W, Tansuwannont W, Jantachai U, Siangpura U</AU>
<TI>A comparison of intravenous magnesium sulfate regimens in preeclampsia-eclampsia between rate 1 gram and 2 grams per hour</TI>
<SO>Siriraj Hospital Gazette</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>7</NO>
<PG>509-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK-1989" NAME="UK 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slater RM, Wilcox FL, Smith WD, Maresh M</AU>
<TI>Phenytoin in pre-eclampsia</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>ii</VL>
<PG>1224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Texas-1991" MODIFIED="2010-05-28 11:38:41 +0200" MODIFIED_BY="Lynn Hampson" NAME="USA - Texas 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[6308]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appleton M, Kuehl T, Raebel M, Adams H, Pickens J, Koops B et al</AU>
<TI>Magnesium sulfate vs. phenytoin in pregnancy-induced hypertension</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>273</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-28 11:38:41 +0200" MODIFIED_BY="Lynn Hampson" NOTES="&lt;p&gt;[6899]&lt;/p&gt;" NOTES_MODIFIED="2010-05-28 11:38:41 +0200" NOTES_MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Appleton MP, Kuehl TJ, Raebel MA, Adams HR, Knight AB, Gold WR</AU>
<TI>Magnesium sulfate versus phenytoin for seizure prophylaxis in pregnancy-induced hypertension</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>165</VL>
<PG>907-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Texas-1992" MODIFIED="2010-05-28 11:39:12 +0200" MODIFIED_BY="Lynn Hampson" NAME="USA - Texas 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-26 11:58:48 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Belfort MA, Moise KJ, Saade G</AU>
<TI>The effect of magnesium sulfate on maternal retinal blood flow in pregnancy-induced hypertension: a randomized placebo-controlled study</TI>
<SO>Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18-21; San Antonio, USA</SO>
<YR>1992</YR>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-28 11:39:12 +0200" MODIFIED_BY="Lynn Hampson" NOTES="&lt;p&gt;[7386]&lt;/p&gt;" NOTES_MODIFIED="2010-05-28 11:39:12 +0200" NOTES_MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belfort MA, Moise KJ</AU>
<TI>Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<PG>661-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[7411]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belfort MA, Saade GR, Moise KJ</AU>
<TI>The effect of magnesium sulfate on maternal retinal blood flow in preeclampsia: a randomized placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<PG>1548-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varma-1972" MODIFIED="2009-06-29 12:11:19 +0200" MODIFIED_BY="[Empty name]" NAME="Varma 1972" YEAR="1972">
<REFERENCE MODIFIED="2009-06-29 12:11:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varma T</AU>
<TI>Chlormethiazole in the treatment of pre-eclampsia</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1972</YR>
<VL>79</VL>
<PG>513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2010-05-26 11:59:00 +0200" MODIFIED_BY="Jill V Hampson" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-26 11:59:00 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Philibert L, Zhang Y, Gu Y, Tynes K, Lewis DF</AU>
<TI>Effects of magnesium sulfate on prostacyclin and thromboxane in women with severe preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>6 Suppl 1</NO>
<PG>S92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-29 15:15:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Zhang Y, Canzoneri BJ, Gu Y, Philibert L, Lewis DF</AU>
<TI>Prostacyclin and thromboxane levels in women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>1</NO>
<PG>17-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-29 12:14:17 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-05-28 11:37:41 +0200" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-USA-_x002d_-Utah" MODIFIED="2010-05-28 11:37:41 +0200" MODIFIED_BY="Lynn Hampson" NAME="USA - Utah" NOTES="&lt;p&gt;recheck ct.gov&lt;/p&gt;" NOTES_MODIFIED="2010-05-28 11:37:41 +0200" NOTES_MODIFIED_BY="Lynn Hampson" YEAR="">
<REFERENCE MODIFIED="2009-12-30 15:05:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;accessed 29 december 2009&lt;/p&gt;" NOTES_MODIFIED="2009-12-30 15:05:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Belfort MA</AU>
<TI>Labetalol versus MgSO4 for the prevention of eclampsia trial (ongoing trial)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/)</SO>
<YR>(accessed 21 March 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-26 11:59:17 +0200" MODIFIED_BY="Jill V Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren J, Lacoursiere Y, Varner M, Silver R, Anthony J, Belfort M</AU>
<TI>First interim report on the labetalol versus magnesium sulfate for the prevention of eclampsia trial (LAMPET)</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-05-28 11:37:41 +0200" MODIFIED_BY="Lynn Hampson"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-02 04:08:06 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-02 04:08:06 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abalos-2007" MODIFIED="2010-05-26 12:02:39 +0200" MODIFIED_BY="Jill V Hampson" NAME="Abalos 2007" TYPE="COCHRANE_REVIEW">
<AU>Abalos E, Duley L, Steyn DW, Henderson-Smart DJ</AU>
<TI>Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2010-05-26 11:59:49 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 11:59:49 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD002252.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Begum-2001" MODIFIED="2010-05-26 12:00:19 +0200" MODIFIED_BY="Jill V Hampson" NAME="Begum 2001" NOTES="&lt;p&gt;11703195&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:00:19 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Begum R, Begum A, Johanson R, Ali MN, Akhter S</AU>
<TI>A low dose ("Dhaka") magnesium sulphate regime for eclampsia</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2001</YR>
<VL>80</VL>
<NO>11</NO>
<PG>998-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belfort-1992" MODIFIED="2010-05-26 12:01:01 +0200" MODIFIED_BY="Jill V Hampson" NAME="Belfort 1992" TYPE="JOURNAL_ARTICLE">
<AU>Belfort MA, Moise KJ</AU>
<TI>Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<NO>3</NO>
<PG>661-6</PG>
<IDENTIFIERS MODIFIED="2009-12-30 13:46:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1530019"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Churchill-2002" MODIFIED="2010-05-26 12:02:23 +0200" MODIFIED_BY="Jill V Hampson" NAME="Churchill 2002" TYPE="COCHRANE_REVIEW">
<AU>Churchill D, Duley L</AU>
<TI>Interventionist versus expectant care for severe pre-eclampsia before term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2010-05-26 12:02:23 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:02:23 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD003106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collab-Trial-1995" NAME="Collab Trial 1995" NOTES="&lt;p&gt;[8671]&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>The Eclampsia Trial Collaborative Group</AU>
<TI>Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>1455-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2003" MODIFIED="2010-05-26 12:03:45 +0200" MODIFIED_BY="Jill V Hampson" NAME="Crowther 2003" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Hiller JE, Doyle LW</AU>
<TI>Magnesium sulphate for preventing preterm birth in threatened preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2010-05-26 12:03:45 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:03:45 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD001060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Douglas-1994" NAME="Douglas 1994" TYPE="JOURNAL_ARTICLE">
<AU>Douglas KA, Redman CWG</AU>
<TI>Eclampsia in the United Kingdom</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2009" MODIFIED="2010-05-26 12:04:39 +0200" MODIFIED_BY="Jill V Hampson" NAME="Doyle 2009" TYPE="COCHRANE_REVIEW">
<AU>Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D</AU>
<TI>Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:04:39 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:04:39 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD004661.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-1992" NAME="Duley 1992" TYPE="JOURNAL_ARTICLE">
<AU>Duley L</AU>
<TI>Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-1994" NAME="Duley 1994" TYPE="JOURNAL_ARTICLE">
<AU>Duley L, Johanson R</AU>
<TI>Magnesium sulphate for pre-eclampsia and eclampsia: the evidence so far</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1994</YR>
<VL>101</VL>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-1996" MODIFIED="2010-05-26 12:04:57 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 1996" NOTES="&lt;p&gt;8616123&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:04:57 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Duley L</AU>
<TI>Magnesium sulphate regimens for women with eclampsia: messages from the Collaborative Eclampsia Trial</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>2</NO>
<PG>103-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-1999" MODIFIED="2010-05-26 12:14:45 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 1999" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Williams J, Henderson-Smart DJ</AU>
<TI>Plasma volume expansion for treatment of pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:14:45 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:14:45 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD001805"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2000" MODIFIED="2010-05-26 12:23:50 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2000" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Gülmezoglu AM</AU>
<TI>Magnesium sulphate versus lytic cocktail for eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:23:50 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:23:50 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD002960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2003a" MODIFIED="2010-05-26 12:06:08 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2003a" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart D</AU>
<TI>Magnesium sulphate versus phenytoin for eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:06:08 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:06:08 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD000128"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2003b" MODIFIED="2010-05-26 12:08:21 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2003b" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart D</AU>
<TI>Magnesium sulphate versus diazepam for eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:08:18 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:08:18 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD000127"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2006" MODIFIED="2010-05-26 12:10:32 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2006" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Henderson-Smart DJ, Meher S</AU>
<TI>Drugs for treatment of very high blood pressure during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:10:32 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:10:32 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD001449.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2008" MODIFIED="2010-05-26 12:11:31 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Duley L, Matar HE, Almerie MQ, Hall DR</AU>
<TI>Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:11:31 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:11:31 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD007388"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duley-2009" MODIFIED="2010-05-26 12:12:26 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2009" TYPE="COCHRANE_PROTOCOL">
<AU>Duley L, Henderson-Smart DJ, Walker GJA</AU>
<TI>Interventions for treating pre-eclampsia and its consequences: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:12:24 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:12:24 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD007756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Euser-2009" MODIFIED="2009-12-30 13:31:33 +0100" MODIFIED_BY="[Empty name]" NAME="Euser 2009" TYPE="JOURNAL_ARTICLE">
<AU>Euser AG, Cipolla MJ</AU>
<TI>Magnesium sulfate for the treatment of eclampsia: a brief review</TI>
<SO>Stroke; a journal of cerebral circulation</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>4</NO>
<PG>1169-75</PG>
<IDENTIFIERS MODIFIED="2009-12-30 13:31:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19211496"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1988" MODIFIED="2010-05-26 12:15:25 +0200" MODIFIED_BY="Jill V Hampson" NAME="Goldman 1988" TYPE="OTHER">
<AU>Goldman RS, Finkbeiner SM</AU>
<TI>Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>18</NO>
<PG>1224-5</PG>
<IDENTIFIERS MODIFIED="2009-12-30 13:46:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3173462"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00fc_lmezoglu-1998" MODIFIED="2010-06-04 13:13:10 +0200" MODIFIED_BY="Sonja L  Henderson" NAME="Gülmezoglu 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gülmezoglu M, Duley L</AU>
<TI>Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and the Republic of Ireland</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>975-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-05-26 12:24:04 +0200" MODIFIED_BY="Jill V Hampson" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2002" MODIFIED="2010-05-26 12:16:49 +0200" MODIFIED_BY="Jill V Hampson" NAME="Jones 2002" NOTES="&lt;p&gt;11806874&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:16:49 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Jones HP, Guildea ZE, Stewart JH, Cartlidge PH</AU>
<TI>The Health Status Questionnaire: achieving concordance with published disability criteria</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langer-2008" MODIFIED="2010-02-18 00:12:34 +0100" MODIFIED_BY="Lelia Duley" NAME="Langer 2008" NOTES="&lt;p&gt;18313488&lt;/p&gt;" NOTES_MODIFIED="2010-02-18 00:12:34 +0100" NOTES_MODIFIED_BY="Lelia Duley" TYPE="JOURNAL_ARTICLE">
<AU>Langer A, Villar J, Tell K, Kim T, Kennedy S</AU>
<TI>Reducing eclampsia-related deaths--a call to action</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9614</NO>
<PG>705-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magpie-2004" MODIFIED="2010-05-26 12:18:30 +0200" MODIFIED_BY="Jill V Hampson" NAME="Magpie 2004" NOTES="&lt;p&gt;15113445&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:18:30 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Magpie Trial Follow Up Study Management Group, Magpie Trial Follow Up Study Collaborative Group</AU>
<TI>The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mittendorf-1998" NAME="Mittendorf 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mittendorf R, Covert R, Boman J, Khoshnood B, Kwang-Sun L, Siegler M</AU>
<TI>Is tocolytic magnesium sulphate associated with increased total paediatric mortality?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>1517-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1995" NAME="Nelson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Nelson KB, Grether JK</AU>
<TI>Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>263-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-North-2009" MODIFIED="2010-05-26 12:18:44 +0200" MODIFIED_BY="Jill V Hampson" NAME="North 2009" TYPE="JOURNAL_ARTICLE">
<AU>North RA, Taylor RN</AU>
<TI>Subclinical hypothyroidism after pre-eclampsia</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b5183</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pritchard-1955" MODIFIED="2010-05-26 12:18:56 +0200" MODIFIED_BY="Jill V Hampson" NAME="Pritchard 1955" NOTES="&lt;p&gt;13238166&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:18:56 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard JA</AU>
<TI>The use of the magnesium ion in the management of eclamptogenic toxemias</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1955</YR>
<VL>100</VL>
<NO>2</NO>
<PG>131-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pritchard-1984" MODIFIED="2010-05-26 12:19:12 +0200" MODIFIED_BY="Jill V Hampson" NAME="Pritchard 1984" NOTES="&lt;p&gt;6711634&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:19:12 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard JA, Cunningham FG, Pritchard SA</AU>
<TI>The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1984</YR>
<VL>148</VL>
<NO>7</NO>
<PG>951-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCOG-2006" MODIFIED="2010-05-26 12:29:06 +0200" MODIFIED_BY="Jill V Hampson" NAME="RCOG 2006" TYPE="BOOK">
<AU>Royal College of Obstetricians and Gynaecologists</AU>
<SO>RCOG Green-top Guidelines. The Management of Severe Pre-Eclampsia/Eclampsia</SO>
<YR>2006</YR>
<PB>RCOG</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-09-02 04:08:06 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sadeh-1989" MODIFIED="2009-12-30 13:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Sadeh 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sadeh M</AU>
<TI>Action of magnesium sulfate in the treatment of preeclampsia-eclampsia</TI>
<SO>Stroke; a journal of cerebral circulation</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1273-5</PG>
<IDENTIFIERS MODIFIED="2009-12-30 13:46:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2672428"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scudiero-2000" MODIFIED="2010-05-26 12:19:39 +0200" MODIFIED_BY="Jill V Hampson" NAME="Scudiero 2000" TYPE="JOURNAL_ARTICLE">
<AU>Scudiero R, Khoshnood B, Pryde PG, Lee KS, Wall S</AU>
<TI>Perinatal death and tocolytic magnesium sulfate</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>178-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheth-2002" MODIFIED="2010-02-18 00:12:34 +0100" MODIFIED_BY="Lelia Duley" NAME="Sheth 2002" NOTES="&lt;p&gt;12057545&lt;/p&gt;" NOTES_MODIFIED="2010-02-18 00:12:34 +0100" NOTES_MODIFIED_BY="Lelia Duley" TYPE="JOURNAL_ARTICLE">
<AU>Sheth SS, Chalmers I</AU>
<TI>Magnesium for preventing and treating eclampsia: time for international action</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9321</NO>
<PG>1872-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibai-1990" MODIFIED="2010-05-26 12:19:53 +0200" MODIFIED_BY="Jill V Hampson" NAME="Sibai 1990" NOTES="&lt;p&gt;2288560&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:19:53 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM</AU>
<TI>Magnesium sulfate is the ideal anticonvulsant in preeclampsia-eclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2006" MODIFIED="2010-05-26 12:20:12 +0200" MODIFIED_BY="Jill V Hampson" NAME="Simon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Simon J, Gray A, Duley L, on behalf of the Magpie Trial Collaborative Group</AU>
<TI>Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Squires-1999" MODIFIED="2010-02-17 19:07:29 +0100" MODIFIED_BY="Lelia Duley" NAME="Squires 1999" TYPE="BOOK">
<AU>Squires J, Potter L, Bricker D</AU>
<SO>The ASQ user's guide for the Ages and Stages Questionnaires: a parent completed, child monitoring system</SO>
<YR>1999</YR>
<EN>2nd</EN>
<PB>Paul Brookes Publishing Co</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vargas-1998" MODIFIED="2010-05-26 12:20:42 +0200" MODIFIED_BY="Jill V Hampson" NAME="Vargas 1998" TYPE="JOURNAL_ARTICLE">
<AU>Vargas AG, Salmeron PI, Sanchez GAR, Jiminez AL, Rubio GAF</AU>
<TI>Efficancy of isosorbide in aerosol in the management of hypertensive crisis of severe preeclampsia</TI>
<TO>Eficacia del isosorbide en aerosol en el manejo de la crisis hipertensiva de la preeclampsia</TO>
<SO>Ginecologia y Obstetricia De Mexico</SO>
<YR>1998</YR>
<VL>66</VL>
<PG>316-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walss-1992" MODIFIED="2010-05-26 11:47:42 +0200" MODIFIED_BY="Jill V Hampson" NAME="Walss 1992" NOTES="&lt;p&gt;[7788]&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 11:47:42 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Walss Rodriguez RJ, Levario AR</AU>
<TI>Anticonvulsant treatment of severe pre-eclampsia: comparison of diazepam and magnesium sulfate</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1992</YR>
<VL>60</VL>
<PG>331-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1988" NAME="WHO 1988" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy</AU>
<TI>Geographic variation in the incidence of hypertension in pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>80-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zuspan-1978" MODIFIED="2010-05-26 12:21:02 +0200" MODIFIED_BY="Jill V Hampson" NAME="Zuspan 1978" NOTES="&lt;p&gt;686045&lt;/p&gt;" NOTES_MODIFIED="2010-05-26 12:21:02 +0200" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="JOURNAL_ARTICLE">
<AU>Zuspan FP</AU>
<TI>Problems encountered in the treatment of pregnancy-induced hypertension. A point of view</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1978</YR>
<VL>131</VL>
<NO>6</NO>
<PG>591-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-05-26 12:22:26 +0200" MODIFIED_BY="Jill V Hampson">
<REFERENCE ID="REF-Duley-2003" MODIFIED="2010-05-26 12:22:26 +0200" MODIFIED_BY="Jill V Hampson" NAME="Duley 2003" TYPE="COCHRANE_REVIEW">
<AU>Duley L, Gülmezoglu AM, Henderson-Smart DJ</AU>
<TI>Anticonvulsants for women with pre-eclampsia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-05-26 12:22:25 +0200" MODIFIED_BY="Jill V Hampson">
<IDENTIFIER MODIFIED="2010-05-26 12:22:25 +0200" MODIFIED_BY="Jill V Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD000025"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-06-21 18:48:48 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-09-19 09:39:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;repke?&lt;/p&gt;" NOTES_MODIFIED="2010-09-19 09:39:32 +0200" NOTES_MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-09-05 19:44:32 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-07-07 13:39:23 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Denmark-2000">
<CHAR_METHODS MODIFIED="2010-07-07 13:39:23 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 nulliparous women with singleton pregnancy and BP &gt; 140/90 mmHg x 2 over 3 hr.<BR/>Excluded: pre-existing HT, cardiac or renal disease, BP &gt; 180/120 mmHg after hydralazine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:53:52 +0200" MODIFIED_BY="[Empty name]">
<P>MgCl<SUB>2</SUB>: 80 mmol IV in first 24 hr, then 40 mmol in next 24 hr. Then 15 mmol/day MgOH<SUB>2</SUB> orally until 3 days after delivery.<BR/>Methyl dopa: 250 mg x 4/day. Day after delivery reduced by 250 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: additional antihypertensive.<BR/>Baby: admission to SCBU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 21:10:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-India-2008">
<CHAR_METHODS MODIFIED="2010-07-07 13:40:10 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-07 13:40:17 +0200" MODIFIED_BY="Denise Atherton">
<P>100 women, 50 with eclampsia and 50 severe pre-eclampsia, regardless of age, parity, gestational age, singleton or multiple pregnancy, or whether delivered. Diagnostic criteria for severe pre-eclampsia not given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-01 21:10:54 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: loading dose 4 g IV over 20-30 minutes and 10 gm IM (5 g into each buttock), maintenance 5 g IM every 4 hours. 
</P>
<P>Phenytoin: loading dose 1000 mg in 200 ml normal saline over 1 hour, maintenance 500 mg orally 10 hours later.</P>
<P>Both regimens continued for 24 hours postpartum.
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-07 13:40:39 +0200" MODIFIED_BY="Denise Atherton">
<P>Woman: eclampsia.</P>
<P>Baby: none reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 11:23:14 +0200" MODIFIED_BY="Lelia Duley">
<P>Only the 50 women with pre-eclampsia are included in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-02 16:46:50 +0200" MODIFIED_BY="Sonja L  Henderson" STUDY_ID="STD-Magpie-Trial-2002">
<CHAR_METHODS MODIFIED="2010-07-07 13:41:00 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-02 16:46:29 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>10141 women with uncertainty about whether to use MgSO<SUB>4</SUB>, before birth or 24 hours postpartum, DBP &#8805;90 mmHg, SBP &#8805;140 mmHg x 2 30-30 min apart, &#8805;1+ proteinuria.<BR/>Excluded: hypersensitivity to Mg, hepatic coma with risk of renal failure, myasthenia gravis.</P>
<P>For follow-up: 4782 women selected, and 3375 (71%) traced; 4483 children selected, and 3283 (73%) traced.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-07 13:42:35 +0200" MODIFIED_BY="Denise Atherton">
<P>MgSO<SUB>4</SUB>: 4 g IV bolus. Then either 1 g/hr IV infusion or 10 g IM with bolus followed by 5 g every 4 hr. Continued for 24 hr.<BR/>2 centres in Bangladesh used 5 g IM then 2.5 g every 4 hr.</P>
<P>Placebo: by identical regimen.</P>
<P>Dose halved if oliguria. Clinical monitoring alone for all women.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-02 16:46:40 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Woman: death, eclampsia, respiratory depression, pneumonia, cardiac arrest, renal failure, coagulopathy, liver failure, pulmonary oedema, stroke, side effects, caesarean section, postpartum haemorrhage, transfusion, admission to high care. For long-term follow-up: death after discharge, stoke, serious renal problems, severe hypertension.</P>
<P>Baby: death, gestation at birth, Apgar &lt; 7 at 5 min, intubation at place of delivery, ventilation, admission SCBU, death or SCBU &gt; 7 days. For long-term follow-up: death or neurosensory disability (defined as 1 or more of blind, deaf, severe cerebral palsy, or developmental delay), cerebral palsy, blind, deaf, developmental delay (&gt; 2 sd below mean), other disability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-02 16:46:50 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Multicentre trial, 175 centres in 33 countries. 85% recruitment in low- and middle-income countries. Trial stopped early after the Data Monitoring Committee revealed data to the Trial Steering Committee.</P>
<P>Outcome at delivery and for the baby only included for women randomised before birth.</P>
<P>
<B>Follow-up</B>
</P>
<P>In a subset of 125 centres in 19 countries. For the women median time from birth to follow-up was 26 months (range from within 12 months to greater than 48 months from delivery, interquartile range 19-36 months). Women were assessed by a brief questionnaire, available in English and Spanish. It was either sent by post, administered in clinic or during a home visit, or completed over the telephone.</P>
<P>Children were assessed at 18 months (corrected for gestational age at birth) using the Ages and Stage Questionnaire (ASQ) (<LINK REF="REF-Squires-1999" TYPE="REFERENCE">Squires 1999</LINK>). The ASQ was available in English and Spanish, and either sent by post, administered in the clinic or during a home visit, or completed over the telephone. It has 30 questions in 5 domains: communication, gross motor, fine motor, problem solving, and personal-social. To pass, a child must pass all 5 domains. An additional section asked about parental concerns, and was not scored.</P>
<P>For some centres the ASQ was not thought feasible for cultural or language reasons, and a short ASQ was developed with 3 questions in 3 domains (gross motor, communication, problem solving). If the family could not be contacted, information about whether the child was 'alive and well' was collected whenever possible.</P>
<P>Children who failed the ASQ were invited for clinical and neurodevelopmental assessment using the Bayley Scales of Infant Development (BSID-II), the Griffiths Tests, or a similar alternative. Where these tests were not available, assessment was by clinical history and examination based on the Health Status Questionnaire (<LINK REF="REF-Jones-2002" TYPE="REFERENCE">Jones 2002</LINK>).</P>
<P>In the UK, the Office of National Statistics provided date and cause of any deaths. For surviving women and children an additional questionnaire was to the general practitioner 18 months after delivery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 21:35:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malaysia-1994">
<CHAR_METHODS MODIFIED="2010-07-07 13:46:28 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 women with PE (DBP &gt; 110mmHg + proteinuria) and 11 women with eclampsia (data not included in this review).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-01 21:35:17 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: "Pritchard's regimen", no other information.</P>
<P>Diazepam: not stated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: death, eclampsia, caesarean section.</P>
<P>Baby: death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Interim data on an ongoing study, published in abstract form only. Additional information from verbal presentation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-07 13:52:09 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Mexico-1992">
<CHAR_METHODS MODIFIED="2010-07-07 13:47:13 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-07 13:51:49 +0200" MODIFIED_BY="Denise Atherton">
<P>38 women &gt; 28 weeks' gestation with SBP &gt;/= 150 mmHg, DBP &gt;/= 110 mmHg, proteinuria 2+, no previous treatment, at least 1 symptom (of headache, blurred vision, epigastric pain) and no epilepsy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:54:55 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 4 g IV over 15 min, then 1 g/hr infusion.</P>
<P>Diazepam: 30 mg in 500 ml 5% glucose IV at 60 microg/hr. If convulsions, bolus of 10 mg IV.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: eclampsia, caesarean section.</P>
<P>Baby: mean Apgar scores (1 and 5 min).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-07 13:52:09 +0200" MODIFIED_BY="Denise Atherton">
<P>Nifedipine for BP control.</P>
<P>Translated from the Spanish.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-07 13:52:50 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Mexico-1998">
<CHAR_METHODS MODIFIED="2010-07-07 13:52:24 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-07 13:52:36 +0200" MODIFIED_BY="Denise Atherton">
<P>36 women with severe pre-eclampsia who were over 36 weeks' gestation.</P>
<P>Excluded: women with mild pre-eclampsia, less than 36 weeks' gestation, or who received anti-hypertensive treatment less than 1 week prior, as well as women a history of diabetes, high blood pressure, alcohol or drug abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-07 13:52:46 +0200" MODIFIED_BY="Denise Atherton">
<P>MgSO<SUB>4</SUB>: 4 g IV for first hour, then 1 g/hour for 5 hours.</P>
<P>Isosorbide gas: as a spray, 1.25 mg repeated in 10 minutes if the average blood pressure reduction was less than 15%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-07 13:52:49 +0200" MODIFIED_BY="Denise Atherton">
<P>Woman: blood pressure, proteinuria, maternal heart rate, mode of delivery.</P>
<P>Baby: Apgar.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-07 13:52:50 +0200" MODIFIED_BY="Denise Atherton">
<P>Translated from the Spanish.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-08 13:24:19 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Nimodipine-SG-2003">
<CHAR_METHODS MODIFIED="2010-07-08 12:42:54 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-08 12:43:00 +0200" MODIFIED_BY="Denise Atherton">
<P>1750 women with PE, planned delivery and no previous MgSO<SUB>4</SUB>. BP &#8805;140/90 mmHg and 1+ proteinuria plus 1 of: headache, clonus, visual disturbance, epigastric pain, oliguria, pulmonary oedema, raised liver enzymes, haemolysis, oligohydramnios, IUGR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-08 13:24:19 +0200" MODIFIED_BY="Denise Atherton">
<P>MgSO<SUB>4</SUB>: according to local protocol. Either 4 g IV then 1 g/hr, or 6 g IV then 2 g/hr.</P>
<P>Nimodipine: 60 mg 4 hourly, orally.</P>
<P>Both regimens continued either for 24 hours total, or until 24 hours after delivery. Serum monitoring not required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: eclampsia, stroke, coagulopathy, respiratory problems, cardiac failure, antihypertensive drugs, side effects, abruption, caesarean section, PPH.</P>
<P>Baby: RDS, hypotonia, intubation, hypotension.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Recruitment at 14 hospitals in 8 countries. Data for stillbirths and neonatal deaths not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-08 12:43:29 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-South-Africa-1994">
<CHAR_METHODS MODIFIED="2010-07-08 12:43:29 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 13:42:56 +0200" MODIFIED_BY="Lelia Duley">
<P>228 women with severe PE: DBP &#8805;110 mmHg for 4-6 hours, proteinuria +, and delivery imminent. Excluded if prior anticonvulsant or antihypertensive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-12 15:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 4 g IV over 20 min and 10 g IM (5 g into each buttock), then 5 g 4 hourly for 24 hours.</P>
<P>Control: no anticonvulsant.</P>
<P>Women being transferred were given phenobarbitone IM before transfer.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: eclampsia, pulmonary oedema, renal failure, caesarean section.</P>
<P>Baby: death (stillbirth, neonatal death).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>For both groups, immediate BP control with dihydralazine (69%) or nifedipine (25%).<BR/>Most women had phenobarbitone before entry.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-05 19:43:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-South-Africa-1998">
<CHAR_METHODS MODIFIED="2010-07-08 12:44:03 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-12 15:30:40 +0100" MODIFIED_BY="[Empty name]">
<P>822 women with severe PE: at least 2 of DBP &gt;/= 110 mmHg, significant proteinuria, symptoms of imminent eclampsia. Also, &gt; 16 years, no previous anticonvulsant. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-05 19:43:05 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 4 g IV in 200 ml saline over 20 min, then 1 g/hr (200 ml over 4 hr) until 24 hr after delivery.<BR/>Placebo: 200 ml over 20 min, then 200 ml over 4 hours until 24 hr after delivery.</P>
<P>Treatment stopped if urine output &lt; 30 ml/hr. Serum monitoring not required.</P>
<P>Women transferred from outlying clinics received 1 g clonazepam IV before transfer. Women not transferred were given 1 g clonazepam IV after randomisation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: death, eclampsia, toxicity, antihypertensive therapy, caesarean section.<BR/>Child: stillbirths.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All women given clonazepam 1 mg. Recruitment over 13 years, 1982-95.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 21:37:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taiwan-1995">
<CHAR_METHODS MODIFIED="2010-09-01 21:37:46 +0200" MODIFIED_BY="[Empty name]">
<P>"Randomised trial".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-29 11:16:06 +0200" MODIFIED_BY="[Empty name]">
<P>64 women with BP <U>&gt;</U> 150/100 mmHg, plus at least one of 11 listed features of severe PE. Excluded if intrauterine death, chronic hypertension or eclampsia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:56:29 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 4 g IV over 10 min, then 1 g/hr until 24 hours after delivery.</P>
<P>Control: no anticonvulsant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: eclampsia, caesarean section, abruption.</P>
<P>Baby: Apgar score (1 min).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-29 15:56:36 +0200" MODIFIED_BY="[Empty name]">
<P>8 women excluded, probably before randomisation but this is not completely clear.<BR/>Women less than 34 weeks (32/64) managed conservatively, and duration of MgSO<SUB>4</SUB> therapy not clear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 22:22:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-_x002d_-Alabama-1995">
<CHAR_METHODS MODIFIED="2010-09-01 22:22:08 +0200" MODIFIED_BY="[Empty name]">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>54 women with singleton pregnancy requiring medical induction of labour for PIH, and with an unfavourable cervix.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:56:44 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 4 g IV and then an infusion of 2 g/hr.</P>
<P>Phenytoin: 15 mg/kg IV over 2 hours, then 200 mg IV every 8 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: caesarean section, mean length of labour.</P>
<P>Baby: mean Apgar scores, cord pH.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-08 12:45:50 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-USA-_x002d_-Maryland-1993">
<CHAR_METHODS MODIFIED="2010-07-08 12:45:50 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-29 15:56:51 +0200" MODIFIED_BY="[Empty name]">
<P>103 women with BP &gt;/= 140/90 mmHg or rise in SBP of &gt;/= 30 mmHg, or rise in DBP of &gt;/= 15 mmHg, plus either &gt;/= + proteinuria , or significant oedema, or eclampsia. Also, 2 women with eclampsia (data not included in this review). Excluded if MgSO<SUB>4</SUB> before admission, history of seizure disorder, cardiac arrhythmia, phenytoin sensitivity or myasthenia gravis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:56:56 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 6 g IV, then infusion of 2 g/hr. Mg levels every 6 hours.</P>
<P>Phenytoin: 1000, 1250 or 1500 mg, depending on weight. Serum levels 1-2 hours later to determine next dose (0-500 mg), once stable checked every 12 hours.</P>
<P>Both regimens continued for 24 hours after delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: eclampsia. No other outcomes reported separately for women with pre-eclampsia and eclampsia.</P>
<P>Baby: none reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 13:03:40 +0200" MODIFIED_BY="Lelia Duley">
<P>Data for the 2 women with eclampsia not included in this review.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-08 13:25:11 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-USA-_x002d_-Memphis-1997">
<CHAR_METHODS MODIFIED="2010-07-08 12:51:57 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-08 12:52:05 +0200" MODIFIED_BY="Denise Atherton">
<P>135 women who were at least 37 weeks' gestation with recent onset PE (BP &gt;/= 140/90 mmHg and proteinuria &gt;/= 300 mg in 24 hr). Excluded if severe PE, fetal malpresentation, congenital anomalies, non-reassuring fetal testing, contraindication to trial of labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-08 12:52:13 +0200" MODIFIED_BY="Denise Atherton">
<P>MgSO<SUB>4</SUB>: 6 g IV bolus over 15-20 min, then infusion of 2 g/hr. Continued until 12 hr postpartum.<BR/>Placebo: saline solution administered by an identical regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-08 12:52:17 +0200" MODIFIED_BY="Denise Atherton">
<P>Woman: duration of labour, use of oxytocin, caesarean, postpartum haemorrhage, infection, side effects, severe pre-eclampsia.<BR/>Baby: Apgar.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-08 13:25:11 +0200" MODIFIED_BY="Denise Atherton">
<P>64% of women had labour induced, and 91% had an epidural. The trial was ended after interim analysis performed at 69% of planned enrolment. Power calculation (with use of actual labour data from control group) indicated that a sample size of 37 in each group would be required to detect 33% increase in length of labour. Sample size was sufficient to evaluate primary outcome.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 22:24:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-_x002d_-Tennessee-2001">
<CHAR_METHODS MODIFIED="2010-07-08 12:52:39 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>222 women with mild pre-eclampsia during labour.</P>
<P>Excluded: chronic HT, severe PE.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 15:57:14 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 6 g IV, then infusion of 2 g/hr.<BR/>Placebo: matching regimen.</P>
<P>Clinical monitoring.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: progression to severe PE, eclampsia, HELLP, caesarean section, toxicity.<BR/>Baby: meconium.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-01 22:24:04 +0200" MODIFIED_BY="[Empty name]">
<P>Abstract only. 33 women who progressed to severe pre-eclampsia were unblinded and given MgSO<SUB>4</SUB>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-01 22:24:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-_x002d_-Texas-1995">
<CHAR_METHODS MODIFIED="2010-07-08 12:53:19 +0200" MODIFIED_BY="Denise Atherton">
<P>Please see details below.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2138 women with BP &gt;/= 140/90 mmHg. Excluded if postpartum or delivery imminent, epilepsy, or eclampsia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-01 22:24:33 +0200" MODIFIED_BY="[Empty name]">
<P>MgSO<SUB>4</SUB>: 10 g (50% solution) IM (5 g in each buttock), then 5 g IM every 4 hours. If severe pre-eclampsia, an additional 4 g IV (20% solution) before the first IM dose.</P>
<P>Phenytoin: 1000 mg IV over 1 hour. 10 hours later, 500 mg orally.</P>
<P>If eclampsia developed, all women received MgSO<SUB>4</SUB>.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Woman: eclampsia, caesarean section, induction of labour.</P>
<P>Baby: death (stillbirth, neonatal death), Apgar score, admission to special care baby unit.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-29 17:23:13 +0200" MODIFIED_BY="[Empty name]">
<P>Only 18% of women had 2+ or more proteinuria, and 4% received an antihypertensive.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>DBP: diastolic BP<BR/>HELLP: haemolysis elevated liver enzymes and low platelets<BR/>hr: hour<BR/>hrly: hourly<BR/>HT: hypertension<BR/>IM: intramuscular<BR/>IUGR: intrauterine growth restriction<BR/>IV: intravenous<BR/>Mg: magnesium<BR/>MgCl<SUB>2:</SUB> magnesium chloride<BR/>MgSO<SUB>4</SUB>: magnesium sulphate<BR/>min: minute<BR/>mmHg: millimeters of mercury<BR/>mmol: millimole<BR/>PE: pre-eclampsia<BR/>PIH: pregnancy-induced hypertension<BR/>SBP: systolic BP<BR/>SCBU: special care baby unit<BR/>sd: standard deviation<BR/>PPH: postpartum haemorrhage<BR/>RDS: respiratory distress syndrome</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-09-19 09:39:32 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:53:56 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Abbade-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:53:56 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial of 29 women to compare magnesium sulphate serum concentrations after treatment with 2 different magnesium sulphate regimens, Zuspan's vs an alternative scheme.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-02 16:29:51 +0200" MODIFIED_BY="Sonja L  Henderson" STUDY_ID="STD-Antartani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-02 16:29:51 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Trial of 113 women with eclampsia to compare efficacy of MgSO<SUB>4 </SUB>versus phenytoin for prevention of recurrence of seizures.</P>
<P>Unlikely to be a randomised study given imbalance in treatment groups (86 MgSo<SUB>4</SUB> and 27 phenytoin).</P>
<P>Published in abstract form only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 13:47:19 +0200" MODIFIED_BY="Lelia Duley" STUDY_ID="STD-Begum-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 13:47:19 +0200" MODIFIED_BY="Lelia Duley">
<P>Trial of 401 women with eclampsia, comparing outcomes in women treated with loading dose of magnesium sulphate versus standard regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 13:27:16 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Begum-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 13:27:16 +0200" MODIFIED_BY="Denise Atherton">
<P>All women with eclampsia (100 women). Comparision of a single IV loading dose of magnesium sulphate with a single combined IV and IM loading dose.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-China-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported.</P>
<P>Participants: 84 women with PE at 34-42 weeks.<BR/>Interventions: magnesium sulphate vs phentolamine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 12:29:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chissell-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 12:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 17 women with severe pre-eclampsia randomised to magnesium sulphate by IM or IV routes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 13:49:00 +0200" MODIFIED_BY="Lelia Duley" STUDY_ID="STD-Chowdhury-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 13:49:00 +0200" MODIFIED_BY="Lelia Duley">
<P>Not a randomised trial. 630 women with eclampsia, allocated by unit to either IM magnesium sulphate or IV magnesium sulphate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 12:31:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehrenberg-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 12:31:17 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 200 women with mild pre-eclampsia randomised to 12 or 24 hours of magnesium sulphate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:54:29 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Fontenot-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:54:29 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial of 98 women with severe pre-eclampsia to assess the use of diuresis as a clinical parameter to determine duration of postpartum therapy (24 hours vs continued therapy until onset of diuresis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:54:46 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Ghahiri-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:54:46 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial of 66 women with mild pre-eclampsia between 27 and 38 weeks' gestation to compare serum levels after IV magnesium sulphate to PO magnesium chloride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 15:25:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hangarga-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 15:25:40 +0200" MODIFIED_BY="[Empty name]">
<P>Described as a series of 90 women with eclampsia. 32 received phenytoin, 34 received (modified) Menon's regimen, and 24 magnesium sulphate.</P>
<P>The study is unlikely to be a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-01 22:28:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laiteerapong-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-01 22:28:26 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 34 women with severe pre-eclampsia randomised to magnesium maintenance dose of 1 g/hr vs 2 g/hr to compare serum magnesium levels.</P>
<P>Published as abstract, only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 13:25:31 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Li-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 13:25:31 +0200" MODIFIED_BY="Denise Atherton">
<P>Study of 28 women with pregnancy-induced hypertension to compare retinal blood flow following treatment with magnesium sulphate vs nimodipine.</P>
<P>None of the pre-specified outcomes for this review were reported in this study, which cannot be clearly identified as a randomised trial.</P>
<P>Pertinent portions of the paper translated from the Chinese prior to review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 13:51:44 +0200" MODIFIED_BY="Lelia Duley" STUDY_ID="STD-Maheshwari-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 13:51:44 +0200" MODIFIED_BY="Lelia Duley">
<P>Trial of 74 women with eclampsia. Comparison of magnesium sulphate with diazepam and phenytoin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 13:27:26 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Muhammad-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 13:27:26 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial of 39 women with eclampsia. Comparison of a low dose magnesium sulphate regimen with the standard regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 13:58:14 +0200" MODIFIED_BY="Lelia Duley" STUDY_ID="STD-Mundle-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 13:58:14 +0200" MODIFIED_BY="Lelia Duley">
<P>
Comparison of alternative regimens for magnesium sulphate: use of a pump to deliver intravenous therapy compared with manual IV loading dose and intramuscular maintenance. Women with pre-eclampsia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 14:52:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nagar-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 14:52:46 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 199 women with eclampsia randomised to magnesium sulphate or lytic cocktail. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 14:55:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neto-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 14:55:20 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 77 women with eclampsia randomised to magnesium sulphate or phenytoin.</P>
<P>Translated from the Spanish prior to review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 14:56:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ola-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 14:56:23 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 60 women with eclampsia randomised to magnesium sulphate or diazepam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 17:25:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodriquez-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 17:25:24 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 44 women with pre-eclampsia or eclampsia randomised to magnesium sulphate or diazepam. One women diagnosed with eclampsia, 43 with pre-eclampsia. Data were not analysed separately by treatment regimen for outcomes of interest.</P>
<P>Pertinent portions of the paper translated from the Spanish prior to review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:55:44 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Rudnicki-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:55:44 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial comparing light and electron microscope changes in the placenta and umbilical cord of 28 women with pregnancy-induced hypertension randomised to magnesium sulphate or placebo.</P>
<P>None of the pre-specified outcomes for this review were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 13:25:34 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Rudnicki-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 13:25:34 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial of 58 women with pregnancy-induced hypertension to determine effects of magnesium vs placebo on maternal blood pressure.</P>
<P>None of the pre-specified outcomes for this review were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:55:59 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Samal-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:55:59 +0200" MODIFIED_BY="Denise Atherton">
<P>Retrospective analysis of 120 women with eclampsia. Comparision of magnesium sulphate plus nifedipine with magnesium plus sedation (pethidine or diazepam).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 15:39:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shilva-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 15:39:02 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 50 women with antepartum eclampsia randomised to low dose (Dhaka maintenance regimen, 2.5 g IM every 4 hours) regimen or higher dose of magnesium sulphate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-02 16:30:24 +0200" MODIFIED_BY="Sonja L  Henderson" STUDY_ID="STD-Smith-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-02 16:30:24 +0200" MODIFIED_BY="Sonja L  Henderson">
<P>Trial of 115 women with pre-eclampsia to determine rates of hypotension in women treated with magnesium vs labetalol.</P>
<P>None of the pre-specified outcomes for this review were reported.</P>
<P>Published in abstract form only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-South-Africa-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported. Outcome for women with eclampsia not reported separately to pre-eclampsia.</P>
<P>Participants: 24 women with eclampsia (also in Collaborative Eclampsia Trial) and 18 with pre-eclampsia.<BR/>Interventions: magnesium sulphate versus phenytoin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-19 09:39:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suneja-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-19 09:39:32 +0200" MODIFIED_BY="[Empty name]">
<P>Trial comparing alternative magnesium sulphate regimens postpartum for 60 women with severe pre-eclampsia. Comparision of individuals criteria for determining duration of treatment with standard 24 hours.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanzania-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi randomised, alternate allocation.</P>
<P>Participants: 59 women &gt;/= 26 weeks' gestation, with DBP 90 mmHg or more, and proteinuria. Excluded if seizures in this pregnancy, any anticonvulsant drugs, or epilepsy.<BR/>Interventions: diazepam 10 mg orally, then 5 mg 8 hourly vs no anticonvulsant.<BR/>Outcomes: death, fits, cerebrovascular accident, cardiac failure. None reported for baby.</P>
<P>All women received nifedipine for BP control, with methyl dopa if required.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-01 22:29:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tongsong-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-01 22:29:42 +0200" MODIFIED_BY="[Empty name]">
<P>Trial of 49 women with severe pre-eclampsia or eclampsia randomised to magnesium maintenance dose of 1 g/hr vs 2 g/hr to compare serum magnesium levels. Pertinent portions of the paper translated from the Thai prior to review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UK-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial abandoned due to excessive maternal sedation with clonazepam, and neonatal feeding difficulties, jitteriness and drowsiness. No data available.</P>
<P>Interventions: phenytoin versus clonazepam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-01 22:29:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-_x002d_-Texas-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-01 22:29:55 +0200" MODIFIED_BY="[Empty name]">
<P>Data for the woman with eclampsia not reported separately from the women with pre-eclampsia.</P>
<P>Methods: "prospectively randomised".<BR/>Participants: 1 woman with eclampsia, 11 with severe PE, 38 with mild PIH.<BR/>Interventions: magnesium sulphate versus phenytoin.<BR/>Outcomes: fits.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-USA-_x002d_-Texas-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported. </P>
<P>Participants: 12 women with pre-eclampsia.<BR/>Intervention: magnesium sulphate vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-29 17:25:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Varma-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-29 17:25:34 +0200" MODIFIED_BY="[Empty name]">
<P>Case control study of 140 women with pre-eclampsia treated with chlormethiazole (sedative/hypnotic) or barbiturates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-08 12:56:57 +0200" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Wang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-08 12:56:57 +0200" MODIFIED_BY="Denise Atherton">
<P>Trial to study the effects of magnesium sulphate on prostacyclin and thromboxane levels in women with severe pre-eclampsia. In all, 50 women were randomised to continuous infusion of magnesium sulphate for 24 hours postpartum vs discontinuation of magnesium infusion when urinary output was <U>&gt;</U> 100 ml/hr for 2 consecutive hours.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>IM: intramuscular<BR/>IV: intravenous<BR/>MgSO<SUB>4</SUB>: magnesium sulphate<BR/>PE: pre-eclampsia<BR/>PIH: pregnancy-induced hypertension<BR/>PO: per os (by mouth, orally)<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-06-29 12:14:17 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-09-02 03:19:56 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-09-02 03:19:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-USA-_x002d_-Utah">
<CHAR_STUDY_NAME MODIFIED="2010-09-02 03:19:13 +0200" MODIFIED_BY="[Empty name]">
<P>Labetalol versus MgSO<SUB>4</SUB> for the prevention of eclampsia trial (LAMPET).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-07-08 13:28:12 +0200" MODIFIED_BY="Denise Atherton">
<P>Multicenter, randomised, controlled, clinical trial comparing the anti-seizure effect of parenteral and/or oral labetalol versus parenteral (intravenous or intramuscular) magnesium sulphate with mild or severe pre-eclampsia who are deemed to be at sufficient risk to warrant seizure prophylaxis with magnesium sulphate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-08 12:58:27 +0200" MODIFIED_BY="Denise Atherton">
<P>Patients with pre-eclampsia (BP &gt; 140 systolic and/or &gt; 90 mmHg diastolic with 1+ or more proteinuria [or a 24 hour specimen with &gt; 300 mg/day]), chronic hypertension (or superimposed pre-eclampsia), or gestational hypertension deemed to be at risk for eclamptic convulsions and who would routinely be treated in the participating institution with some form of anti-seizure prophylaxis during labour and delivery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-08 13:28:22 +0200" MODIFIED_BY="Denise Atherton">
<P>Labetalol: either, 20 mg intravenous loading dose IV followed by 200 mg oral dose every 6 hours from the time of inclusion in the study until 24 hours postpartum or 200 mg oral dose every 6 hours from inclusion.</P>
<P>Magnesium sulphate: intravenous magnesium sulphate as a 4 or 6 gram loading dose over 20 minutes followed by a 1 or 2 g/h continuous infusion until 24 hours postpartum.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-02 03:19:56 +0200" MODIFIED_BY="[Empty name]">
<P>Primary: occurrence of eclamptic seizure(s) after enrolment in the study.</P>
<P>Secondary outcome measures</P>
<P>Maternal: blood pressure, pulse pressure and heart rate changesNeed for additional antihypertensive medication (defined by need to control BP &gt; 160 mmHg systolic and/or 110 mmHg). Subjective assessment of side effects by the patient. Objective assessment of new onset complications and/or side effects by the treating clinicians. Labour and delivery parameters including; induction to delivery interval, rate of cervical dilatation, oxytocin dosages, length of labour, delivery route, blood loss at delivery, and postpartum course. Type of anaesthesia administered (none, local infiltration for delivery only, epidural for labour, epidural for delivery, spinal for delivery, combined/spinal epidural for labour and delivery, general anaesthesia for delivery).</P>
<P>Fetal and neonatal: occurrence of newly diagnosed fetal distress during labour necessitating emergent delivery. Umbilical cord gases at delivery (if available in institution); Apgar scores. Neonatal outcome as defined by NICU admission, hospital survival to discharge, length of hospital survival, days in NICU, need for blood transfusion, need for pressor agents, need for mechanical ventilation, neonatal cardiac dysrhythmias, neonatal cardiac failure, necrotising enterocolitis, sudden infant death, neonatal sepsis, neonatal hypoglycaemia, and there will be an other block for recording any other identified complications not mentioned.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-07-08 13:01:26 +0200" MODIFIED_BY="Denise Atherton">
<P>May 2003.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-07-08 13:01:27 +0200" MODIFIED_BY="Denise Atherton">
<P>Michael A Belfort, MD, PhD, Shalece Kofford, RN, MPH.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-07-08 13:01:28 +0200" MODIFIED_BY="Denise Atherton">
<P>Estimated completion date December 2012.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>IV: intravenous<BR/>NICU: neonatal intensive care unit</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-09-02 16:47:32 +0200" MODIFIED_BY="Sonja L  Henderson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-09-01 22:22:26 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:40:00 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Denmark-2000">
<DESCRIPTION>
<P>"Computer generated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-01 21:11:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-India-2008">
<DESCRIPTION>
<P>"Randomly subdivided"; no other information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 10:10:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magpie-Trial-2002">
<DESCRIPTION>
<P>Computer generated allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:46:41 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Malaysia-1994">
<DESCRIPTION>
<P>"Randomly allocated," nor further information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:52:14 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Mexico-1992">
<DESCRIPTION>
<P>"Permuted block randomisation" using random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:42:40 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Mexico-1998">
<DESCRIPTION>
<P>"Randomly divided equally," no further information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:04:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nimodipine-SG-2003">
<DESCRIPTION>
<P>Randomisation stratified by centre, blocks of 6. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:43:49 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1994">
<DESCRIPTION>
<P>"randomly distributed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:44:35 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-South-Africa-1998">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-01 21:38:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taiwan-1995">
<DESCRIPTION>
<P>"Randomised", no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-01 22:22:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Alabama-1995">
<DESCRIPTION>
<P>"Blinded computer-generated random number tables".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:51:31 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Maryland-1993">
<DESCRIPTION>
<P>Sequence generated from random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:52:32 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Memphis-1997">
<DESCRIPTION>
<P>Computer generated tables of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:52:52 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Tennessee-2001">
<DESCRIPTION>
<P>Computer generated group assignment was devised by simple randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:53:35 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Texas-1995">
<DESCRIPTION>
<P>"Randomly assigned," no further information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-07-08 12:52:58 +0200" MODIFIED_BY="Denise Atherton" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:40:02 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Denmark-2000">
<DESCRIPTION>
<P>"Numbered sealed opaque envelopes opened if the patients accepted participation and gave a signed consent."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:40:50 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-India-2008">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:44:22 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Magpie-Trial-2002">
<DESCRIPTION>
<P>Via central telephone service (2037 women), or consecutively numbered, sealed treatment packs, stratified by centre (8104 women).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:47:06 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Malaysia-1994">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 13:52:16 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Mexico-1992">
<DESCRIPTION>
<P>Allocation was by sealed, numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:42:44 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Mexico-1998">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:04:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nimodipine-SG-2003">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:43:54 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-South-Africa-1994">
<DESCRIPTION>
<P>Consecutively numbered, sealed, opaque envelopes. Envelopes prepared by 1 author not involved in recruitment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:08:53 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-South-Africa-1998">
<DESCRIPTION>
<P>Allocation by sealed opaque envelopes containing card marked solution A or B. Cards, but not envelopes, consecutively numbered. Envelopes distributed in batches of 20, with equal numbers of A and B. Solutions prepared by pharmacy, and identity of A and B changed periodically.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:45:12 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Taiwan-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:45:35 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Alabama-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:47:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Maryland-1993">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 11:47:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Memphis-1997">
<DESCRIPTION>
<P>Sealed, sequentially numbered opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-08 12:52:58 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Tennessee-2001">
<DESCRIPTION>
<P>"Sealed, consecutively numbered, opaque envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 12:01:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Texas-1995">
<DESCRIPTION>
<P>Numbered opaque envelopes, no other information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-01 22:23:20 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-07 13:39:58 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Denmark-2000">
<DESCRIPTION>
<P>Code was kept in the hospital dispensary but treatment regimens different, so unlikely to be blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 11:25:17 +0200" MODIFIED_BY="Lelia Duley" RESULT="NO" STUDY_ID="STD-India-2008">
<DESCRIPTION>
<P>Blinding is not mentioned, but as the interventions are quite different blinding of clinicians and women would not have been possible. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-07 13:44:31 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Magpie-Trial-2002">
<DESCRIPTION>
<P>Solutions of MgSO<SUB>4</SUB> and placebo looked identical in pre-prepared treatment packs. Clinicians were asked not to measure serum magnesium concentrations, unless clinically necessary, and to report if measurements were taken.</P>
<P>In follow-up studies, those involved in finding participants and assessing their outcomes were blinded to treatment group allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-29 17:20:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malaysia-1994">
<DESCRIPTION>
<P>Blinding not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-07 13:52:17 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Mexico-1992">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 11:49:25 +0200" MODIFIED_BY="Lelia Duley" RESULT="NO" STUDY_ID="STD-Mexico-1998">
<DESCRIPTION>
<P>Blinding is not mentioned, but the interventions are different and so blinding of participants and clinicians would have been unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-01 21:36:37 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nimodipine-SG-2003">
<DESCRIPTION>
<P>Unblinded trial, but primary outcome was described as "binary, objective, and not subject to measurement bias".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 12:43:57 +0200" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-South-Africa-1994">
<DESCRIPTION>
<P>Designed as open trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 12:44:44 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-South-Africa-1998">
<DESCRIPTION>
<P>Investigators blinded to identity of solutions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 12:45:14 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Taiwan-1995">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-01 22:22:36 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-USA-_x002d_-Alabama-1995">
<DESCRIPTION>
<P>Nursing staff recorded "patient generated complaints or side effects noted, and date and time of cervical examinations". Magesium sulphate and phenytoin therapy was adjusted at the discretion of the attending physician.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-01 22:23:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-USA-_x002d_-Maryland-1993">
<DESCRIPTION>
<P>Treatment not blinded, but interview for "subjective maternal side effects conducted by 1 author blinded to identity of drug patient received".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 15:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Memphis-1997">
<DESCRIPTION>
<P>Double blinding of the allocated treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-08 12:53:07 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Tennessee-2001">
<DESCRIPTION>
<P>Designed as a double blind study, but if the woman developed severe pre-eclampsia after randomisation, group assignment was revealed. If the woman had been assigned to placebo, she was subsequently treated with magnesium.</P>
<P>Data were collected by blinded chart abstraction, except for women who developed severe pre-eclampsia after randomisation, data collection was unblinded in that circumstance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-29 12:03:41 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-USA-_x002d_-Texas-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-09-02 16:47:32 +0200" MODIFIED_BY="Sonja L  Henderson" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-29 13:40:17 +0200" MODIFIED_BY="Lelia Duley" RESULT="YES" STUDY_ID="STD-Denmark-2000">
<DESCRIPTION>
<P>2 exclusions from MgSO<SUB>4</SUB> group (1 withdrawal, 1 had methyl dopa).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-02 16:46:22 +0200" MODIFIED_BY="Sonja L  Henderson" RESULT="NO" STUDY_ID="STD-India-2008">
<DESCRIPTION>
<P>No losses to follow-up are reported. The only outcome reported is eclampsia. No other outcomes are listed in methods, but it would seem surprising if no other data were collected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-02 16:47:16 +0200" MODIFIED_BY="Sonja L  Henderson" RESULT="YES" STUDY_ID="STD-Magpie-Trial-2002">
<DESCRIPTION>
<P>5 women excluded: 2 each group no data available, 1 in MgSO<SUB>4</SUB> group entered into wrong trial. Compliance 99% (MgSO<SUB>4 </SUB>4999/5055; placebo 4993/5055).</P>
<P>
<B>Follow-up</B>
</P>
<P>7927 women randomised at the 125 centres in 19 countries participating in follow-up. Of these, 2544 were not included in follow-up for logistic reasons (such as giving birth outside a pre-specified time frame, or in a pre-defined geographic area). A further 601 women were excluded: 109 were from centres excluded as &lt; 20% women contacted; 466 were discharged without a surviving child; and 26 opted out. Of the 4782 women included in follow-up, data are available for 3375 (71%): 1650 allocated MgSO<SUB>4</SUB>and 1725 allocated placebo.</P>
<P>6922 children were born to women randomised at the 125 centres in 19 countries participating in follow-up. Of these 2271 were not included for logistic reasons (such as giving birth outside a pre-specified time frame, or in a pre-defined geographic area). A further 168 children were excluded: 101 were from centres excluded as &lt; 20% families contacted; 40 whose death or disability was due to a problem at conception or embryogenesis, and 27 whose parents opted out. Of the 4483 children included in follow-up, data are available for 3283 (73%): 1635 born to women allocated magnesium sulphate and 1648 to women allocated placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-29 13:41:54 +0200" MODIFIED_BY="Lelia Duley" RESULT="NO" STUDY_ID="STD-Malaysia-1994">
<DESCRIPTION>
<P>Interim data for a trial ongoing at the time the abstract was published. No data from the completed trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 13:52:18 +0200" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Mexico-1992">
<DESCRIPTION>
<P>The total number of women eligible for trial entry is not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-02 16:47:22 +0200" MODIFIED_BY="Sonja L  Henderson" RESULT="NO" STUDY_ID="STD-Mexico-1998">
<DESCRIPTION>
<P>No losses to follow-up were reported. Outcomes were only recorded for the duration of the intervention - 5 hours.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 11:04:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nimodipine-SG-2003">
<DESCRIPTION>
<P>Recruitment 1995-2000. 100 women (6%) excluded from analysis: 99 did not get allocated treatment, 1 withdrawn. Recruitment stopped early following interim analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-08 12:43:58 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-South-Africa-1994">
<DESCRIPTION>
<P>Data were complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 15:56:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-South-Africa-1998">
<DESCRIPTION>
<P>123 excluded as envelopes and data sheets lost. Review of hospital records suggests no eclampsia amongst these women. Further 14 post randomisation exclusions (4 delivered before treatment, 3 no solution available, 4 MgSO<SUB>4</SUB> before entry, 2 no consent, 1 anuric). None had eclampsia.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-08 13:24:53 +0200" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Taiwan-1995">
<DESCRIPTION>
<P>72 women eligible, excluded women with intrauterine fetal demise (2), chronic hypertension with superimposed pre-eclampsia (2), and eclampsia (4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-02 16:47:32 +0200" MODIFIED_BY="Sonja L  Henderson" RESULT="NO" STUDY_ID="STD-USA-_x002d_-Alabama-1995">
<DESCRIPTION>
<P>No losses to follow-up are reported, but data are only available for a limited number of outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 17:22:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Maryland-1993">
<DESCRIPTION>
<P>12 post randomisation exclusions because twin pregnancy (8 women), no medical record (1), and lost envelopes (3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 15:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-USA-_x002d_-Memphis-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-29 13:44:31 +0200" MODIFIED_BY="Lelia Duley" RESULT="NO" STUDY_ID="STD-USA-_x002d_-Tennessee-2001">
<DESCRIPTION>
<P>Published as abstract only, there is no information about other outcome data collected but not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 17:23:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-USA-_x002d_-Texas-1995">
<DESCRIPTION>
<P>Of the 1049 women allocated phenytoin, 17 also received MgSO<SUB>4</SUB>, and 139 did not receive it because of 'logistic' problems (not clear if these women had MgSO4 instead). No reporting of compliance for those allocated MgSO4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-03-12 16:04:58 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-09-19 09:34:58 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-09-19 09:34:58 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Magnesium sulphate versus none/placebo (subgroups by severity of pre-eclampsia)</NAME>
<DICH_OUTCOME CHI2="0.10644314801072527" CI_END="1.1018556577092218" CI_START="0.2638606324399609" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5391997131867786" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04212470598020303" LOG_CI_START="-0.5786254009487939" LOG_EFFECT_SIZE="-0.2682503474842954" METHOD="MH" MODIFIED="2010-07-08 13:02:22 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.9481699028071294" P_Q="0.0" P_Z="0.09027405102690893" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5400" TOTAL_2="5395" WEIGHT="100.0" Z="1.6939538601471775">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10636536971323605" CI_END="1.5103452280156178" CI_START="0.19304099475466166" DF="1" EFFECT_SIZE="0.539961614597826" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1790762277472337" LOG_CI_START="-0.7143504531416074" LOG_EFFECT_SIZE="-0.2676371126971868" MODIFIED="2010-07-08 13:02:18 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.7443207066486641" P_Z="0.24028958068205497" STUDIES="2" TAU2="0.0" TOTAL_1="1642" TOTAL_2="1685" WEIGHT="48.31148208525448" Z="1.1742633459097218">
<NAME>Severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.714471657605432" CI_START="0.19359284235066573" EFFECT_SIZE="0.5761158228390303" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.23413031007079063" LOG_CI_START="-0.7131107037687092" LOG_EFFECT_SIZE="-0.23949019684895928" ORDER="86409" O_E="0.0" SE="0.5564140604479626" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1297" TOTAL_2="1345" VAR="0.309596606664189" WEIGHT="41.25709073791827"/>
<DICH_DATA CI_END="8.036092759233755" CI_START="0.013429786541454108" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" ORDER="86410" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="7.054391347336217"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.454545879677525" CI_START="0.19935354996682328" DF="0" EFFECT_SIZE="0.538487590110794" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.16272742443253338" LOG_CI_START="-0.7003760262806181" LOG_EFFECT_SIZE="-0.26882430092404236" MODIFIED="2010-07-08 13:02:22 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.22212000572456436" STUDIES="1" TAU2="0.0" TOTAL_1="3758" TOTAL_2="3710" WEIGHT="51.68851791474551" Z="1.2209103034982276">
<NAME>Not severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.4545458796775248" CI_START="0.1993535499668233" EFFECT_SIZE="0.538487590110794" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.16272742443253332" LOG_CI_START="-0.700376026280618" LOG_EFFECT_SIZE="-0.26882430092404236" ORDER="86411" O_E="0.0" SE="0.506991239379891" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3758" TOTAL_2="3710" VAR="0.25704011680795796" WEIGHT="51.68851791474551"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.686682804651603" CI_END="-0.006915030881887287" CI_START="-0.01533830681870545" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.011126668850296369" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="107" I2="43.85535615047568" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-09-19 09:34:58 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09855620076386118" P_Q="0.0" P_Z="2.2427471618183753E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5722" TOTAL_2="5722" WEIGHT="100.0" Z="5.178002092787276">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.989982729916017" CI_END="-0.008139355823533957" CI_START="-0.025766247243670874" DF="2" EFFECT_SIZE="-0.016952801533602416" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="48" I2="66.61092209813364" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-08 13:02:27 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.05003718052799866" P_Z="1.632334381833233E-4" STUDIES="3" TAU2="0.0" TOTAL_1="1754" TOTAL_2="1801" WEIGHT="31.060148738628037" Z="3.7700215711271503">
<NAME>Severe pre-eclampsia</NAME>
<DICH_DATA CI_END="-0.005443403140881308" CI_START="-0.026444883525804472" EFFECT_SIZE="-0.01594414333334289" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86412" O_E="0.0" SE="0.005357618953863478" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1297" TOTAL_2="1345" VAR="2.8704080854797197E-5" WEIGHT="23.08197402618635"/>
<DICH_DATA CI_END="0.033115053081441914" CI_START="-0.015257910224299061" EFFECT_SIZE="0.008928571428571428" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86413" O_E="0.0" SE="0.012340268414955769" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="1.5228222455315496E-4" WEIGHT="1.9919785875646963"/>
<DICH_DATA CI_END="-0.0098102720531742" CI_START="-0.04909850885049162" EFFECT_SIZE="-0.02945439045183291" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86414" O_E="0.0" SE="0.010022693556416856" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="1.0045438612583996E-4" WEIGHT="5.986196124876989"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.384831537408506" CI_END="-0.0038590947442308883" CI_START="-0.013144433320759607" DF="3" EFFECT_SIZE="-0.008501764032495248" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="59" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-08 13:02:30 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.4964646534115783" P_Z="3.31781261878705E-4" STUDIES="4" TAU2="0.0" TOTAL_1="3968" TOTAL_2="3921" WEIGHT="68.93985126137196" Z="3.589131655547696">
<NAME>Not severe pre-eclampsia</NAME>
<DICH_DATA CI_END="-0.004458875060530536" CI_START="-0.014042105417414807" EFFECT_SIZE="-0.009250490238972672" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="59" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86415" O_E="0.0" SE="0.0024447465444456047" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3758" TOTAL_2="3710" VAR="5.9767856665787255E-6" WEIGHT="65.26342729663176"/>
<DICH_DATA CI_END="0.059261997147362806" CI_START="-0.059261997147362806" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86416" O_E="0.0" SE="0.030236268428814956" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="9.14231928499352E-4" WEIGHT="0.5571391773832524"/>
<DICH_DATA CI_END="0.055164232945277274" CI_START="-0.025313486676620554" EFFECT_SIZE="0.014925373134328358" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86417" O_E="0.0" SE="0.02053040776685077" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="4.214976430731664E-4" WEIGHT="1.1797594037626598"/>
<DICH_DATA CI_END="0.017468889603602645" CI_START="-0.017468889603602645" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86418" O_E="0.0" SE="0.008912862553289252" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="7.943911889382581E-5" WEIGHT="1.939525383594282"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2826830363263444" CI_END="1.315198922089411" CI_START="0.8869623883496632" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.080061098776975" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="183" I2="22.038416999413972" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11899144425709693" LOG_CI_START="-0.052094796040341985" LOG_EFFECT_SIZE="0.03344832410837747" METHOD="MH" MODIFIED="2010-07-08 13:02:44 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.25740087398273537" P_Q="0.0" P_Z="0.4434573692452236" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5164" TOTAL_2="5168" WEIGHT="99.99999999999999" Z="0.7663680081071257">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.657127053249539" CI_START="0.9138318606532093" DF="0" EFFECT_SIZE="1.2305833975841687" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="75" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.21935580739932342" LOG_CI_START="-0.03913370438420448" LOG_EFFECT_SIZE="0.09011105150755948" MODIFIED="2010-07-08 13:02:40 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.1717785458629776" STUDIES="1" TAU2="0.0" TOTAL_1="1297" TOTAL_2="1345" WEIGHT="40.38653366076121" Z="1.36651127038188">
<NAME>Severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.657127053249539" CI_START="0.9138318606532093" EFFECT_SIZE="1.2305833975841687" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="75" LOG_CI_END="0.21935580739932342" LOG_CI_START="-0.03913370438420448" LOG_EFFECT_SIZE="0.09011105150755948" ORDER="86419" O_E="0.0" SE="0.15183801876536385" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1297" TOTAL_2="1345" VAR="0.023054783942590987" WEIGHT="40.38653366076121"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.272910325422745" CI_START="0.7515476181477625" DF="0" EFFECT_SIZE="0.9780862554944514" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="108" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.10479780935212318" LOG_CI_START="-0.12404349725452514" LOG_EFFECT_SIZE="-0.009622843951200971" MODIFIED="2010-07-08 13:02:44 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.8690745483973035" STUDIES="2" TAU2="0.0" TOTAL_1="3867" TOTAL_2="3823" WEIGHT="59.61346633923878" Z="0.16483411891736752">
<NAME>Not severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.272910325422745" CI_START="0.7515476181477625" EFFECT_SIZE="0.9780862554944514" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="108" LOG_CI_END="0.10479780935212318" LOG_CI_START="-0.12404349725452514" LOG_EFFECT_SIZE="-0.009622843951200971" ORDER="86420" O_E="0.0" SE="0.13442251628348223" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3758" TOTAL_2="3710" VAR="0.018069412883983043" WEIGHT="59.61346633923878"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86421" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9981229310249873" CI_START="0.12511742702024656" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3006222039217268" LOG_CI_START="-0.9026821952496892" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-12-18 14:57:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.3267672504258855" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="0.9806462108406248">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9981229310249873" CI_START="0.12511742702024656" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3006222039217268" LOG_CI_START="-0.9026821952496892" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="86431" O_E="0.0" SE="0.70682696052613" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.49960435212660737" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.002122683235331705" CI_END="1.566085162361108" CI_START="0.6027880330446149" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9716055756324213" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.19481537492362053" LOG_CI_START="-0.2198353781793659" LOG_EFFECT_SIZE="-0.012510001627872674" METHOD="MH" MODIFIED="2009-12-18 14:57:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9632524065625132" P_Q="0.0" P_Z="0.9058583881472203" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5276" TOTAL_2="5284" WEIGHT="100.0" Z="0.1182641172296537">
<NAME>Pulmonary oedema</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no magnesium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5744843171514988" CI_START="0.5972191674418614" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" LOG_CI_END="0.1971383391494536" LOG_CI_START="-0.2238662622654166" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="86422" O_E="0.0" SE="0.2473001868774822" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.06115738242963763" WEIGHT="97.10893133711926"/>
<DICH_DATA CI_END="16.357906855676497" CI_START="0.06557709926440897" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2137277309253338" LOG_CI_START="-1.1832477978118598" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="86423" O_E="0.0" SE="1.4079952908004545" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="1.9824507389162562" WEIGHT="2.8910686628807434"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86424" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.067019252298829" CI_START="0.8973837428291517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7829753730805044" LOG_CI_START="-0.04702180249131557" LOG_EFFECT_SIZE="0.36797678529459443" METHOD="MH" MODIFIED="2009-12-18 14:57:49 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.0822304738412074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="1.7378884351681163">
<NAME>Pneumonia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.067019252298829" CI_START="0.8973837428291517" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7829753730805044" LOG_CI_START="-0.04702180249131557" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="86425" O_E="0.0" SE="0.48754444948316805" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.2376995902218454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.167557934093799" CI_START="0.5526549326553136" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8032786885245902" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.06727843941631773" LOG_CI_START="-0.2575459493808245" LOG_EFFECT_SIZE="-0.09513375498225338" METHOD="MH" MODIFIED="2009-12-18 14:57:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.2509443497183955" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="1.1480587043956292">
<NAME>Renal failure</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.167557934093799" CI_START="0.5526549326553136" EFFECT_SIZE="0.8032786885245902" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="61" LOG_CI_END="0.06727843941631773" LOG_CI_START="-0.2575459493808245" LOG_EFFECT_SIZE="-0.09513375498225338" ORDER="86426" O_E="0.0" SE="0.19080345388609785" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.036405958014864265" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22878769749433536" CI_END="2.316925461935" CI_START="0.2093418486455722" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6964405641370046" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.36491206227895756" LOG_CI_START="-0.679143945005228" LOG_EFFECT_SIZE="-0.15711594136313523" METHOD="MH" MODIFIED="2009-12-18 14:56:54 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6324242139333438" P_Q="0.0" P_Z="0.5552612071124696" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5167" TOTAL_2="5171" WEIGHT="100.0" Z="0.5898947648792796">
<NAME>Renal dialysis</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no magnesium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.977434852230732" CI_START="0.21495012712721623" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4738422676774901" LOG_CI_START="-0.6676622936936029" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="86427" O_E="0.0" SE="0.6705254298880896" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.4496043521266074" WEIGHT="77.23304231027535"/>
<DICH_DATA CI_END="8.383995635298003" CI_START="0.014207618386590496" EFFECT_SIZE="0.34513274336283184" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9234510435463206" LOG_CI_START="-1.8474787164601616" LOG_EFFECT_SIZE="-0.4620138364569205" ORDER="86428" O_E="0.0" SE="1.6276578573513336" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="2.6492701005975343" WEIGHT="22.76695768972465"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1125731122986988" CI_START="0.5414128033755586" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.046328560079546714" LOG_CI_START="-0.2664714782116012" LOG_EFFECT_SIZE="-0.11007145906602726" METHOD="MH" MODIFIED="2009-12-18 14:56:53 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.16777557899201184" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="1.3793866309849072">
<NAME>Liver failure</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1125731122986988" CI_START="0.5414128033755585" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="0.046328560079546714" LOG_CI_START="-0.26647147821160133" LOG_EFFECT_SIZE="-0.11007145906602726" ORDER="86429" O_E="0.0" SE="0.18374029087738192" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.033760494491704915" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1567114470262991" CI_START="0.6229078217808784" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8488372093023255" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.06322503346023173" LOG_CI_START="-0.20557621570645543" LOG_EFFECT_SIZE="-0.07117559112311185" METHOD="MH" MODIFIED="2009-12-18 14:56:52 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.29929173114856544" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="1.0379534738928333">
<NAME>Coagulopathy</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1567114470262991" CI_START="0.6229078217808784" EFFECT_SIZE="0.8488372093023255" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="86" LOG_CI_END="0.06322503346023173" LOG_CI_START="-0.20557621570645543" LOG_EFFECT_SIZE="-0.07117559112311185" ORDER="86430" O_E="0.0" SE="0.15789518434815483" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.024930889240337803" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.977434852230732" CI_START="0.21495012712721623" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.4738422676774901" LOG_CI_START="-0.6676622936936029" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.7392934906371007" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="0.33278909548807456">
<NAME>Cardiac arrest</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.977434852230732" CI_START="0.21495012712721623" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4738422676774901" LOG_CI_START="-0.6676622936936029" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="86432" O_E="0.0" SE="0.6705254298880896" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.4496043521266074" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.87967854057749" CI_START="0.4852605583523957" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="1.1099050237539523" LOG_CI_START="-0.314025006409877" LOG_EFFECT_SIZE="0.3979400086720376" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.27330355999753286" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="1.0954865316170266">
<NAME>Respiratory arrest</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.87967854057749" CI_START="0.4852605583523957" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1099050237539523" LOG_CI_START="-0.314025006409877" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="86433" O_E="0.0" SE="0.8364235482855604" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.6996043521266073" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6726134083921534" CI_END="0.9923488193291853" CI_START="0.9494956817930363" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9706857981785246" ESTIMABLE="YES" EVENTS_1="3964" EVENTS_2="4080" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.003335642682879127" LOG_CI_START="-0.02250700604831229" LOG_EFFECT_SIZE="-0.012921324365595701" METHOD="MH" NO="13" P_CHI2="0.4121422704010952" P_Q="0.0" P_Z="0.00824190869648248" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5400" TOTAL_2="5395" WEIGHT="99.99999999999999" Z="2.6419957627833752">
<NAME>Any antihypertensive therapy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9954497199442002" CI_START="0.951169585713465" EFFECT_SIZE="0.9730578080041852" ESTIMABLE="YES" EVENTS_1="3720" EVENTS_2="3823" LOG_CI_END="-0.0019806712490781286" LOG_CI_START="-0.021742045025183128" LOG_EFFECT_SIZE="-0.011861358137130611" ORDER="86434" O_E="0.0" SE="0.0116079287764619" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="1.3474401047941227E-4" WEIGHT="93.65791812480664"/>
<DICH_DATA CI_END="1.024665742311657" CI_START="0.8543795274415171" EFFECT_SIZE="0.9356566852760391" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="257" LOG_CI_END="0.010582216665474656" LOG_CI_START="-0.06834916671264282" LOG_EFFECT_SIZE="-0.028883475023584092" ORDER="86435" O_E="0.0" SE="0.046364685312955345" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="0.002149684044169377" WEIGHT="6.34208187519335"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.210298312656112" CI_END="0.9755903375614134" CI_START="0.8895695626559265" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9315876072146163" ESTIMABLE="YES" EVENTS_1="2541" EVENTS_2="2712" I2="42.421722903795576" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.010732509674974192" LOG_CI_START="-0.050820085245738326" LOG_EFFECT_SIZE="-0.030776297460356254" METHOD="MH" MODIFIED="2010-07-08 13:03:04 +0200" MODIFIED_BY="Denise Atherton" NO="14" P_CHI2="0.15703009822875735" P_Q="0.0" P_Z="0.002617358777747143" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10334" TOTAL_2="10280" WEIGHT="199.99999999999997" Z="3.009432909870534">
<NAME>Rapid acting antihypertensives</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5861626951139822" CI_END="0.9979593229531717" CI_START="0.8613276824054124" DF="1" EFFECT_SIZE="0.927129975124378" ESTIMABLE="YES" EVENTS_1="1045" EVENTS_2="1130" I2="72.11504092208466" ID="CMP-001.14.01" LOG_CI_END="-8.871602927933229E-4" LOG_CI_START="-0.06483159467083915" LOG_EFFECT_SIZE="-0.03285937748181625" MODIFIED="2010-07-08 13:03:01 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.05826279775195142" P_Z="0.04397292879352806" STUDIES="2" TAU2="0.0" TOTAL_1="5167" TOTAL_2="5171" WEIGHT="99.99999999999999" Z="2.0143487715602655">
<NAME>Intravenous or intramuscular hydralazine</NAME>
<DICH_DATA CI_END="1.015772980829605" CI_START="0.8688119630184006" EFFECT_SIZE="0.9394230769230769" ESTIMABLE="YES" EVENTS_1="977" EVENTS_2="1040" LOG_CI_END="0.006796656580125246" LOG_CI_START="-0.061074207740139816" LOG_EFFECT_SIZE="-0.027138775580007286" ORDER="86436" O_E="0.0" SE="0.03986768166792051" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.0015894320415746452" WEIGHT="92.1641791044776"/>
<DICH_DATA CI_END="0.9351981383613264" CI_START="0.6548006562783708" EFFECT_SIZE="0.7825396825396825" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="90" LOG_CI_END="-0.029096366367396764" LOG_CI_START="-0.18389089398530659" LOG_EFFECT_SIZE="-0.10649363017635169" ORDER="86437" O_E="0.0" SE="0.09092707176802982" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="0.008267732380308444" WEIGHT="7.835820895522387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4814225557468992" CI_END="0.9917004474496882" CI_START="0.8810676335180865" DF="1" EFFECT_SIZE="0.934748718315957" ESTIMABLE="YES" EVENTS_1="1496" EVENTS_2="1582" I2="32.497315089426124" ID="CMP-001.14.02" LOG_CI_END="-0.0036194908153075445" LOG_CI_START="-0.05499075250022089" LOG_EFFECT_SIZE="-0.02930512165776422" MODIFIED="2010-07-08 13:03:04 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.2235524206605648" P_Z="0.025341795208319813" STUDIES="2" TAU2="0.0" TOTAL_1="5167" TOTAL_2="5109" WEIGHT="99.99999999999999" Z="2.2361523204967573">
<NAME>Oral nifedipine</NAME>
<DICH_DATA CI_END="0.9872043959728432" CI_START="0.876330902162898" EFFECT_SIZE="0.930117045829212" ESTIMABLE="YES" EVENTS_1="1469" EVENTS_2="1560" LOG_CI_END="-0.005592919414462282" LOG_CI_START="-0.05733187345776821" LOG_EFFECT_SIZE="-0.03146239643611526" ORDER="86438" O_E="0.0" SE="0.030391717716990948" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="4993" VAR="9.236565057892615E-4" WEIGHT="98.64168589404136"/>
<DICH_DATA CI_END="2.0945918389394635" CI_START="0.7713699082817825" EFFECT_SIZE="1.271103896103896" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.32109940707977497" LOG_CI_START="-0.11273730729273912" LOG_EFFECT_SIZE="0.10418104989351792" ORDER="86439" O_E="0.0" SE="0.2548378335487858" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="0.06494232140783865" WEIGHT="1.3583141059586337"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.888959437041027" CI_END="1.546319156031989" CI_START="0.531400822385881" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9064851191202427" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.18929913602373552" LOG_CI_START="-0.27457777781927956" LOG_EFFECT_SIZE="-0.04263932089777201" METHOD="MH" NO="15" P_CHI2="0.34575955653179147" P_Q="0.0" P_Z="0.7186095587965933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="181" WEIGHT="100.0" Z="0.3603177083874515">
<NAME>Progression from mild to severe pre-eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.690606673949541" CI_START="0.49618991204657387" EFFECT_SIZE="1.3532338308457712" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5670977627693481" LOG_CI_START="-0.3043520695419284" LOG_EFFECT_SIZE="0.13137284661370985" ORDER="86440" O_E="0.0" SE="0.5118939452458849" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="0.2620354111793971" WEIGHT="24.196578902418192"/>
<DICH_DATA CI_END="1.4461220485498558" CI_START="0.4035039707453837" EFFECT_SIZE="0.7638821825205215" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1602049477129576" LOG_CI_START="-0.39415218717654726" LOG_EFFECT_SIZE="-0.11697361973179482" ORDER="86441" O_E="0.0" SE="0.3256321251461693" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.10603628092721044" WEIGHT="75.8034210975818"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.762784090408843" CI_END="1.7762254155116406" CI_START="1.0262875812177776" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3501548375586347" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="86" I2="35.590118934550134" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.2494980799677438" LOG_CI_START="0.011269073676017035" LOG_EFFECT_SIZE="0.1303835768218804" METHOD="MH" MODIFIED="2010-07-08 13:03:17 +0200" MODIFIED_BY="Denise Atherton" NO="16" P_CHI2="0.1698028162762364" P_Q="0.0" P_Z="0.031921643872668624" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16141" TOTAL_2="16112" WEIGHT="300.0" Z="2.145390426835455">
<NAME>Toxicity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.45109758071062583" CI_END="1.4231252152454665" CI_START="0.7006835795202272" DF="1" EFFECT_SIZE="0.9985792256619839" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="60" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.15324311364558518" LOG_CI_START="-0.15447806005361442" LOG_EFFECT_SIZE="-6.17473204014612E-4" MODIFIED="2010-07-08 13:03:11 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.5018142186343428" P_Z="0.9937241232599758" STUDIES="2" TAU2="0.0" TOTAL_1="5344" TOTAL_2="5333" WEIGHT="100.0" Z="0.007865726149024761">
<NAME>Absent or reduced tendon reflexes</NAME>
<DICH_DATA CI_END="1.4038208574205633" CI_START="0.6871423097966833" EFFECT_SIZE="0.9821530972861239" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="60" LOG_CI_END="0.14731169070147215" LOG_CI_START="-0.16295330957943205" LOG_EFFECT_SIZE="-0.007820809438979935" ORDER="86442" O_E="0.0" SE="0.1822511970015242" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.03321549880848838" WEIGHT="99.16808428553578"/>
<DICH_DATA CI_END="72.32483483310384" CI_START="0.120868078873087" EFFECT_SIZE="2.9566473988439306" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.859287450530826" LOG_CI_START="-0.9176883806920586" LOG_EFFECT_SIZE="0.47079953491938353" ORDER="86443" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="0.831915714464221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.062311104534560444" CI_END="3.1507045852393625" CI_START="1.2419406427599105" DF="1" EFFECT_SIZE="1.9781274169625096" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.49840768498457133" LOG_CI_START="0.09410083969092316" LOG_EFFECT_SIZE="0.2962542623377472" MODIFIED="2010-07-08 13:03:14 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.8028797460428878" P_Z="0.0040748055843477125" STUDIES="2" TAU2="0.0" TOTAL_1="5344" TOTAL_2="5333" WEIGHT="100.0" Z="2.8723119146139666">
<NAME>Respiratory depression, or other respiratory problem</NAME>
<DICH_DATA CI_END="3.1367944425950527" CI_START="1.2236704005914472" EFFECT_SIZE="1.959184144521212" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="26" LOG_CI_END="0.4964860598607424" LOG_CI_START="0.08766445499853345" LOG_EFFECT_SIZE="0.2920752574296379" ORDER="86444" O_E="0.0" SE="0.2401438343956434" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.0576690611982422" WEIGHT="98.10085510827564"/>
<DICH_DATA CI_END="72.32483483310384" CI_START="0.120868078873087" EFFECT_SIZE="2.9566473988439306" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.859287450530826" LOG_CI_START="-0.9176883806920586" LOG_EFFECT_SIZE="0.47079953491938353" ORDER="86445" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="1.899144891724364"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2607735159871465" CI_END="49.40200546933016" CI_START="0.7197295981291418" DF="1" EFFECT_SIZE="5.962892380650071" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="1.6937445794213215" LOG_CI_START="-0.14283063703760435" LOG_EFFECT_SIZE="0.7754569711918586" MODIFIED="2010-07-08 13:03:17 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.6095892787179591" P_Z="0.09790202514723867" STUDIES="3" TAU2="0.0" TOTAL_1="5453" TOTAL_2="5446" WEIGHT="100.0" Z="1.655110796961523">
<NAME>Respiratory depression and absent tendon reflexes</NAME>
<DICH_DATA CI_END="166.91797633831075" CI_START="0.4841043392248073" EFFECT_SIZE="8.9892" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2225031108202105" LOG_CI_START="-0.31506102458294066" LOG_EFFECT_SIZE="0.953721043118635" ORDER="86446" O_E="0.0" SE="1.4905777342808648" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="2.2218219819338763" WEIGHT="49.833713529991044"/>
<DICH_DATA CI_END="72.32483483310384" CI_START="0.120868078873087" EFFECT_SIZE="2.9566473988439306" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.859287450530826" LOG_CI_START="-0.9176883806920586" LOG_EFFECT_SIZE="0.47079953491938353" ORDER="86447" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="50.16628647000895"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86448" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.25210552615154275" CI_END="2.8849380262380517" CI_START="0.6284119489624822" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3464507149183853" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.4601364881496618" LOG_CI_START="-0.2017555656449009" LOG_EFFECT_SIZE="0.12919046125238046" METHOD="MH" NO="17" P_CHI2="0.6155964336749193" P_Q="0.0" P_Z="0.444208684955262" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5400" TOTAL_2="5395" WEIGHT="100.0" Z="0.7651055780143078">
<NAME>Given calcium gluconate</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8007609507866373" CI_START="0.5783552181734203" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.447276042709808" LOG_CI_START="-0.23780534166978198" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="86449" O_E="0.0" SE="0.4024201963921165" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="5055" TOTAL_2="5055" VAR="0.16194201446426965" WEIGHT="95.62191572820448"/>
<DICH_DATA CI_END="72.32483483310384" CI_START="0.120868078873087" EFFECT_SIZE="2.9566473988439306" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.859287450530826" LOG_CI_START="-0.9176883806920586" LOG_EFFECT_SIZE="0.47079953491938353" ORDER="86450" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="4.378084271795521"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="75.65962173045682" CI_END="6.8562610072545525" CI_START="5.609469279193918" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="6.2016115236549245" ESTIMABLE="YES" EVENTS_1="2597" EVENTS_2="418" I2="88.10461935421355" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.8360873421492077" LOG_CI_START="0.7489217739084537" LOG_EFFECT_SIZE="0.7925045580288307" METHOD="MH" MODIFIED="2010-07-08 13:04:19 +0200" MODIFIED_BY="Denise Atherton" NO="18" P_CHI2="1.1711742686770776E-12" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40126" TOTAL_2="40080" WEIGHT="900.0" Z="35.63976975473011">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.17052260353692" CI_END="11.366384651739656" CI_START="7.74409411832481" DF="1" EFFECT_SIZE="9.3820228377549" ESTIMABLE="YES" EVENTS_1="1032" EVENTS_2="110" I2="91.04786736044586" ID="CMP-001.18.01" LOG_CI_END="1.0556223489901946" LOG_CI_START="0.8889706225571452" LOG_EFFECT_SIZE="0.97229648577367" MODIFIED="2010-07-08 13:03:26 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="8.310752569622437E-4" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="5066" TOTAL_2="5061" WEIGHT="100.0" Z="22.870043235667747">
<NAME>Feeling warm/flushed</NAME>
<DICH_DATA CI_END="12.333839214355782" CI_START="8.204284839412578" EFFECT_SIZE="10.059340439516475" ESTIMABLE="YES" EVENTS_1="987" EVENTS_2="98" LOG_CI_END="1.0910982826038909" LOG_CI_START="0.9140407299554318" LOG_EFFECT_SIZE="1.0025695062796613" ORDER="86451" O_E="0.0" SE="0.10400448287472552" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.010816932458039075" WEIGHT="89.1687590799438"/>
<DICH_DATA CI_END="6.531434158685094" CI_START="2.2177990966576115" EFFECT_SIZE="3.8059701492537314" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="12" LOG_CI_END="0.8150085532224491" LOG_CI_START="0.3459222022438084" LOG_EFFECT_SIZE="0.5804653777331288" ORDER="86452" O_E="0.0" SE="0.2755436445797399" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="0.07592430006828602" WEIGHT="10.831240920056208"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.429601185370737" CI_START="5.462575917835212" DF="0" EFFECT_SIZE="8.878220088462136" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="18" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="1.1592543279482193" LOG_CI_START="0.7373974857620571" LOG_EFFECT_SIZE="0.9483259068551382" MODIFIED="2010-07-08 13:03:32 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="1.230191038299398E-18" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="8.811921188288482">
<NAME>Nausea and/or vomiting</NAME>
<DICH_DATA CI_END="14.429601185370737" CI_START="5.46257591783521" EFFECT_SIZE="8.878220088462136" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="18" LOG_CI_END="1.1592543279482193" LOG_CI_START="0.7373974857620569" LOG_EFFECT_SIZE="0.9483259068551382" ORDER="86453" O_E="0.0" SE="0.24780079732519908" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.06140523515500439" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.4237999629299" CI_START="0.1262077453606798" DF="0" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" MODIFIED="2010-07-08 13:03:36 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.49305190121294695" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="0.6854628484988398">
<NAME>Slurred speech</NAME>
<DICH_DATA CI_END="73.4237999629299" CI_START="0.1262077453606798" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" ORDER="86454" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.53909067818973" CI_START="5.216386408245242" DF="0" EFFECT_SIZE="11.985597119423884" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="6" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="1.4399495960529205" LOG_CI_START="0.7173697546473682" LOG_EFFECT_SIZE="1.0786596753501443" MODIFIED="2010-07-08 13:03:40 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="1.0" P_Z="4.86785253348442E-9" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="99.99999999999999" Z="5.8516277208884375">
<NAME>Muscle weakness</NAME>
<DICH_DATA CI_END="27.53909067818973" CI_START="5.216386408245243" EFFECT_SIZE="11.985597119423884" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="6" LOG_CI_END="1.4399495960529205" LOG_CI_START="0.7173697546473683" LOG_EFFECT_SIZE="1.0786596753501443" ORDER="86455" O_E="0.0" SE="0.42444697566952266" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.18015523515500437" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2565786034132005" CI_START="1.1058659734356826" DF="0" EFFECT_SIZE="1.8977195439087817" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="20" I2="0.0" ID="CMP-001.18.05" LOG_CI_END="0.5127615651192304" LOG_CI_START="0.043702495391466555" LOG_EFFECT_SIZE="0.2782320302553485" MODIFIED="2010-07-08 13:03:43 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="1.0" P_Z="0.02006202401060373" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="2.3251858618252133">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="3.2565786034132005" CI_START="1.1058659734356826" EFFECT_SIZE="1.8977195439087817" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="20" LOG_CI_END="0.5127615651192304" LOG_CI_START="0.043702495391466555" LOG_EFFECT_SIZE="0.2782320302553485" ORDER="86456" O_E="0.0" SE="0.27552761943793047" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.07591546907313304" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.893634122677602E-31" CI_END="7.4229615931608395" CI_START="1.8398528643279466" DF="0" EFFECT_SIZE="3.695559111822365" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="10" I2="100.0" ID="CMP-001.18.06" LOG_CI_END="0.8705772134933468" LOG_CI_START="0.2647830932456824" LOG_EFFECT_SIZE="0.5676801533695146" MODIFIED="2010-07-08 13:03:49 +0200" MODIFIED_BY="Denise Atherton" NO="6" P_CHI2="0.0" P_Z="2.3943535929721947E-4" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="3.673302919769342">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="7.422961593160836" CI_START="1.8398528643279461" EFFECT_SIZE="3.6955591118223645" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="10" LOG_CI_END="0.8705772134933466" LOG_CI_START="0.2647830932456823" LOG_EFFECT_SIZE="0.5676801533695146" ORDER="86457" O_E="0.0" SE="0.3558464649627362" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.12662670662647585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.8696974242660644" CI_START="1.011648993148845" DF="0" EFFECT_SIZE="2.219555022115534" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" I2="0.0" ID="CMP-001.18.07" LOG_CI_END="0.6875019774253185" LOG_CI_START="0.005029853629033071" LOG_EFFECT_SIZE="0.3462659155271758" MODIFIED="2010-07-08 13:04:08 +0200" MODIFIED_BY="Denise Atherton" NO="7" P_CHI2="1.0" P_Z="0.046717314922785635" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="1.9888540493988958">
<NAME>Drowsiness or confusion</NAME>
<DICH_DATA CI_END="4.869697424266064" CI_START="1.0116489931488453" EFFECT_SIZE="2.219555022115534" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6875019774253184" LOG_CI_START="0.005029853629033166" LOG_EFFECT_SIZE="0.3462659155271758" ORDER="86458" O_E="0.0" SE="0.40088750380943516" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.1607107907105599" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.760493311882305" CI_START="1.189649966682694" DF="0" EFFECT_SIZE="2.1151053740159798" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="17" I2="0.0" ID="CMP-001.18.08" LOG_CI_END="0.5752448206125702" LOG_CI_START="0.07541919677049556" LOG_EFFECT_SIZE="0.3253320086915329" MODIFIED="2010-07-08 13:04:15 +0200" MODIFIED_BY="Denise Atherton" NO="8" P_CHI2="1.0" P_Z="0.010727697673339389" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="2.551445902881303">
<NAME>Headache</NAME>
<DICH_DATA CI_END="3.7604933118823043" CI_START="1.189649966682694" EFFECT_SIZE="2.1151053740159798" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="17" LOG_CI_END="0.5752448206125702" LOG_CI_START="0.07541919677049556" LOG_EFFECT_SIZE="0.3253320086915329" ORDER="86459" O_E="0.0" SE="0.29360004562157566" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.08620098678899131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.027979609364941" CI_START="4.591994982337342" DF="0" EFFECT_SIZE="5.261221542554125" ESTIMABLE="YES" EVENTS_1="1201" EVENTS_2="228" I2="0.0" ID="CMP-001.18.09" LOG_CI_END="0.7801717745723775" LOG_CI_START="0.6620014048375663" LOG_EFFECT_SIZE="0.7210865897049719" MODIFIED="2010-07-08 13:04:19 +0200" MODIFIED_BY="Denise Atherton" NO="9" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="23.91976514464975">
<NAME>Any reported side effects</NAME>
<DICH_DATA CI_END="6.027979609364941" CI_START="4.591994982337342" EFFECT_SIZE="5.261221542554125" ESTIMABLE="YES" EVENTS_1="1201" EVENTS_2="228" LOG_CI_END="0.7801717745723775" LOG_CI_START="0.6620014048375663" LOG_EFFECT_SIZE="0.7210865897049719" ORDER="86460" O_E="0.0" SE="0.06941386013499229" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4999" TOTAL_2="4993" VAR="0.004818283978840272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.878469554324795" CI_END="2.084403562475937" CI_START="1.5197777261926368" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.779839910398548" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="222" I2="92.23510219299168" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.3189818067526006" LOG_CI_START="0.1817800752166216" LOG_EFFECT_SIZE="0.25038094098461117" METHOD="MH" MODIFIED="2010-07-08 13:04:29 +0200" MODIFIED_BY="Denise Atherton" NO="19" P_CHI2="3.323866501847572E-4" P_Q="0.0" P_Z="8.458080040904221E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4999" TOTAL_2="4993" WEIGHT="100.0" Z="7.15351943814788">
<NAME>Problems at injection site</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4785780504706111E-30" CI_END="1.785143388882804" CI_START="1.2480658601665984" DF="0" EFFECT_SIZE="1.492640787050499" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="181" I2="100.0" ID="CMP-001.19.01" LOG_CI_END="0.25167310588211106" LOG_CI_START="0.09623750357736534" LOG_EFFECT_SIZE="0.1739553047297382" MODIFIED="2010-07-08 13:04:25 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.0" P_Z="1.1493744091911896E-5" STUDIES="1" TAU2="0.0" TOTAL_1="2280" TOTAL_2="2273" WEIGHT="81.55741872881389" Z="4.386976048402616">
<NAME>Intramuscular injection</NAME>
<DICH_DATA CI_END="1.7851433888828043" CI_START="1.2480658601665984" EFFECT_SIZE="1.4926407870504992" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="181" LOG_CI_END="0.2516731058821111" LOG_CI_START="0.09623750357736534" LOG_EFFECT_SIZE="0.17395530472973825" ORDER="86461" O_E="0.0" SE="0.09130364221244809" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2280" TOTAL_2="2273" VAR="0.008336355081258733" WEIGHT="81.55741872881389"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.32244950501154" CI_START="2.151997571682201" DF="0" EFFECT_SIZE="3.049901775222239" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="41" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.635729928534059" LOG_CI_START="0.33284177693598005" LOG_EFFECT_SIZE="0.48428585273501945" MODIFIED="2010-07-08 13:04:29 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="3.667804564466471E-10" STUDIES="1" TAU2="0.0" TOTAL_1="2719" TOTAL_2="2720" WEIGHT="18.442581271186107" Z="6.267546779726374">
<NAME>Intravenous injection</NAME>
<DICH_DATA CI_END="4.32244950501154" CI_START="2.151997571682201" EFFECT_SIZE="3.049901775222239" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="41" LOG_CI_END="0.635729928534059" LOG_CI_START="0.33284177693598005" LOG_EFFECT_SIZE="0.48428585273501945" ORDER="86462" O_E="0.0" SE="0.1779179995692427" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2719" TOTAL_2="2720" VAR="0.03165481457072105" WEIGHT="18.442581271186107"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6161952442875824" CI_END="0.8347678766260561" CI_START="0.49735877641823717" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6443439529567925" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="141" I2="38.12628743126891" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-0.07843427172022804" LOG_CI_START="-0.30333021407214567" LOG_EFFECT_SIZE="-0.19088224289618688" METHOD="MH" NO="20" P_CHI2="0.20362317986518563" P_Q="0.0" P_Z="8.776418414071075E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4449" TOTAL_2="4389" WEIGHT="100.0" Z="3.3270704437995198">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8182312938076923" CI_START="0.4853812887126964" EFFECT_SIZE="0.6302016818871834" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="141" LOG_CI_END="-0.08712391463463609" LOG_CI_START="-0.31391696958928095" LOG_EFFECT_SIZE="-0.2005204421119585" ORDER="86463" O_E="0.0" SE="0.13321936312408617" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="0.017747398711187128" WEIGHT="99.62767523930617"/>
<DICH_DATA CI_END="88.74028766110072" CI_START="0.22100722698644365" EFFECT_SIZE="4.428571428571429" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9481208321946697" LOG_CI_START="-0.6555935245546378" LOG_EFFECT_SIZE="0.6462636538200158" ORDER="86464" O_E="0.0" SE="1.5294347017484735" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="2.3391705069124424" WEIGHT="0.3723247606938342"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3624576130876194" CI_END="1.0981162074977417" CI_START="1.0135521269548076" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0549872121276556" ESTIMABLE="YES" EVENTS_1="2525" EVENTS_2="2366" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.04064830150254592" LOG_CI_START="0.005846089355296878" LOG_EFFECT_SIZE="0.023247195428921393" METHOD="MH" MODIFIED="2009-06-29 16:35:54 +0200" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.928375546159411" P_Q="0.0" P_Z="0.008833410982405355" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5073" TOTAL_2="5023" WEIGHT="100.0" Z="2.6184350345012013">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.100633952007299" CI_START="1.010595900119068" EFFECT_SIZE="1.0546545213625282" ESTIMABLE="YES" EVENTS_1="2224" EVENTS_2="2082" LOG_CI_END="0.04164290566030033" LOG_CI_START="0.004577532018897858" LOG_EFFECT_SIZE="0.023110218839599107" ORDER="86465" O_E="0.0" SE="0.021772383953518427" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="4.740367030194267E-4" WEIGHT="88.05597813710577"/>
<DICH_DATA CI_END="1.411636633357677" CI_START="0.8434997965659659" EFFECT_SIZE="1.0911989795918366" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="56" LOG_CI_END="0.14972292020270578" LOG_CI_START="-0.07391501781734455" LOG_EFFECT_SIZE="0.037903951192680606" ORDER="86466" O_E="0.0" SE="0.13136603181862463" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="0.0172570343157719" WEIGHT="2.312151277296166"/>
<DICH_DATA CI_END="1.2027143786777068" CI_START="0.8877311487544546" EFFECT_SIZE="1.0332894158981116" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="165" LOG_CI_END="0.08016250307383203" LOG_CI_START="-0.05171854130609167" LOG_EFFECT_SIZE="0.014221980883870167" ORDER="86467" O_E="0.0" SE="0.07746757829046544" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="0.006001225686189392" WEIGHT="6.984856857240431"/>
<DICH_DATA CI_END="1.4652600996245417" CI_START="0.8606779026171246" EFFECT_SIZE="1.1229946524064172" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.16591472353332973" LOG_CI_START="-0.06515934713848912" LOG_EFFECT_SIZE="0.05037768819742031" ORDER="86468" O_E="0.0" SE="0.13573405294772378" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="0.018423733129615483" WEIGHT="0.9823509432676911"/>
<DICH_DATA CI_END="1.6284785340131176" CI_START="0.3904950029748623" EFFECT_SIZE="0.7974413646055437" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.21178203823334843" LOG_CI_START="-0.4083845192625546" LOG_EFFECT_SIZE="-0.09830124051460311" ORDER="86469" O_E="0.0" SE="0.36428890574706335" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="0.1327064068503928" WEIGHT="0.5840017015869086"/>
<DICH_DATA CI_END="1.9050417581301464" CI_START="0.7841440504485644" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.2799044997632047" LOG_CI_START="-0.10560414832540434" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-06-29 16:35:54 +0200" MODIFIED_BY="[Empty name]" ORDER="86470" O_E="0.0" SE="0.2264496881858336" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="100" TOTAL_2="110" VAR="0.05127946127946127" WEIGHT="1.0806610835030368"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0359209116813728" CI_START="0.9409915469879899" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9873159682899207" ESTIMABLE="YES" EVENTS_1="1892" EVENTS_2="1892" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.015326600069948288" LOG_CI_START="-0.026414277861755084" LOG_EFFECT_SIZE="-0.005543838895903416" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.6026262868122951" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4415" TOTAL_2="4359" WEIGHT="100.0" Z="0.5206275052403809">
<NAME>Induction of labour</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0359209116813728" CI_START="0.9409915469879899" EFFECT_SIZE="0.9873159682899207" ESTIMABLE="YES" EVENTS_1="1892" EVENTS_2="1892" LOG_CI_END="0.015326600069948288" LOG_CI_START="-0.026414277861755084" LOG_EFFECT_SIZE="-0.005543838895903416" ORDER="86471" O_E="0.0" SE="0.02451879831776065" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="6.011714709470224E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7099409374457053" CI_END="1.0523407985424382" CI_START="0.8769493418230682" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9606505975927737" ESTIMABLE="YES" EVENTS_1="754" EVENTS_2="775" I2="41.51844791237111" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.02215640802870403" LOG_CI_START="-0.05702549352351357" LOG_EFFECT_SIZE="-0.01743454274740475" METHOD="MH" NO="23" P_CHI2="0.1909931258913875" P_Q="0.0" P_Z="0.3880807436610805" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4482" TOTAL_2="4427" WEIGHT="99.99999999999999" Z="0.8631031890362653">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.0481485387226046" CI_START="0.8732329091797443" EFFECT_SIZE="0.9567015196607759" ESTIMABLE="YES" EVENTS_1="750" EVENTS_2="774" LOG_CI_END="0.020422833197673573" LOG_CI_START="-0.05886990557186556" LOG_EFFECT_SIZE="-0.01922353618709598" ORDER="86472" O_E="0.0" SE="0.046576947258614464" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="0.002169412015931753" WEIGHT="99.87273354925823"/>
<DICH_DATA CI_END="35.384984512861934" CI_START="0.4657675122768252" EFFECT_SIZE="4.059701492537314" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5488190098612973" LOG_CI_START="-0.3318308071945526" LOG_EFFECT_SIZE="0.6084941013333723" ORDER="86473" O_E="0.0" SE="1.1047030119053403" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="1.2203687445127305" WEIGHT="0.12726645074176246"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1227158733319662" CI_START="0.7246626219630623" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9019923660920264" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.050269862889627134" LOG_CI_START="-0.13986413897678115" LOG_EFFECT_SIZE="-0.04479713804357696" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.3557116355422183" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4415" TOTAL_2="4359" WEIGHT="100.00000000000001" Z="0.9235673400233847">
<NAME>Manual removal of retained placenta</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1227158733319662" CI_START="0.7246626219630623" EFFECT_SIZE="0.9019923660920264" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="162" LOG_CI_END="0.050269862889627134" LOG_CI_START="-0.13986413897678115" LOG_EFFECT_SIZE="-0.04479713804357696" ORDER="86474" O_E="0.0" SE="0.11168565387481658" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="0.01247368528144533" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1125513184192175" CI_START="0.9325373115592993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0185752870801505" ESTIMABLE="YES" EVENTS_1="810" EVENTS_2="783" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.04632005272466117" LOG_CI_START="-0.030333782704112296" LOG_EFFECT_SIZE="0.007993135010274455" METHOD="MH" MODIFIED="2010-02-17 21:06:03 +0100" MODIFIED_BY="Lelia Duley" NO="25" P_CHI2="1.0" P_Q="0.0" P_Z="0.6827206647807775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="0.4087533691190488">
<NAME>In special care baby unit &gt; 7 days</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1125513184192175" CI_START="0.9325373115592993" EFFECT_SIZE="1.0185752870801505" ESTIMABLE="YES" EVENTS_1="810" EVENTS_2="783" LOG_CI_END="0.04632005272466117" LOG_CI_START="-0.030333782704112296" LOG_EFFECT_SIZE="0.007993135010274455" ORDER="86492" O_E="0.0" SE="0.04502684237346647" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="0.0020274165341249957" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.241142141530414" CI_END="1.0559998119168466" CI_START="0.7026728633848497" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8614072274908502" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="198" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.02366384084601035" LOG_CI_START="-0.1532468182142869" LOG_EFFECT_SIZE="-0.06479148868413827" METHOD="MH" MODIFIED="2010-07-08 13:05:00 +0200" MODIFIED_BY="Denise Atherton" NO="26" P_CHI2="0.5152454079316304" P_Q="0.0" P_Z="0.15110810538566097" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="9876" TOTAL_2="10323" WEIGHT="600.0" Z="1.4356284126708634">
<NAME>Outcome for the women 2 years after the birth</NAME>
<GROUP_LABEL_1>Magnesium sulphate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.531114797013624" CI_START="0.7058070127922997" DF="0" EFFECT_SIZE="1.7883211678832116" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="0.6562050652862255" LOG_CI_START="-0.15131403086997414" LOG_EFFECT_SIZE="0.25244551720812564" MODIFIED="2010-07-08 13:04:43 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.22040855427011696" STUDIES="1" TAU2="0.0" TOTAL_1="1644" TOTAL_2="1715" WEIGHT="100.0" Z="1.225442529202569">
<NAME>Death after discharge from hospital</NAME>
<DICH_DATA CI_END="4.531114797013624" CI_START="0.7058070127922997" EFFECT_SIZE="1.7883211678832116" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6562050652862255" LOG_CI_START="-0.15131403086997414" LOG_EFFECT_SIZE="0.25244551720812564" MODIFIED="2009-12-21 15:44:41 +0100" MODIFIED_BY="Lelia Duley" ORDER="199" O_E="0.0" SE="0.47434071436614494" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1644" TOTAL_2="1715" VAR="0.2249991133053847" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.260571145377929" CI_START="0.554910474348267" DF="0" EFFECT_SIZE="0.8363636363636363" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" I2="0.0" ID="CMP-001.26.02" LOG_CI_END="0.10056736185149973" LOG_CI_START="-0.25577707747683937" LOG_EFFECT_SIZE="-0.0776048578126698" MODIFIED="2010-07-08 13:04:46 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.39328025607804995" STUDIES="1" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1725" WEIGHT="99.99999999999999" Z="0.853683737144195">
<NAME>Morbidity potentially related to pre-eclampsia</NAME>
<DICH_DATA CI_END="1.260571145377929" CI_START="0.554910474348267" EFFECT_SIZE="0.8363636363636363" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="50" LOG_CI_END="0.10056736185149973" LOG_CI_START="-0.25577707747683937" LOG_EFFECT_SIZE="-0.0776048578126698" MODIFIED="2009-12-29 13:50:23 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.20931848759488939" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1650" TOTAL_2="1725" VAR="0.043814229249011856" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.199627293404256" CI_START="0.5052476999441995" DF="0" EFFECT_SIZE="0.7785299806576402" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" I2="0.0" ID="CMP-001.26.03" LOG_CI_END="0.07904633808116932" LOG_CI_START="-0.29649565486127966" LOG_EFFECT_SIZE="-0.10872465839005518" MODIFIED="2010-07-08 13:04:49 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.256428149969825" STUDIES="1" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1725" WEIGHT="100.0" Z="1.1348739617973183">
<NAME>Hypertension</NAME>
<DICH_DATA CI_END="1.199627293404256" CI_START="0.5052476999441994" EFFECT_SIZE="0.7785299806576402" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="47" LOG_CI_END="0.07904633808116932" LOG_CI_START="-0.2964956548612797" LOG_EFFECT_SIZE="-0.10872465839005518" MODIFIED="2009-12-29 13:56:42 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.2205952256172406" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1650" TOTAL_2="1725" VAR="0.04866225356512128" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8890682336341547" CI_START="0.007720288985463854" DF="0" EFFECT_SIZE="0.14934671627585014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.26.04" LOG_CI_END="0.4607577990753672" LOG_CI_START="-2.1123664428710867" LOG_EFFECT_SIZE="-0.8258043218978597" MODIFIED="2010-07-08 13:04:53 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="1.0" P_Z="0.2083772819013644" STUDIES="1" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1725" WEIGHT="100.0" Z="1.2580400921278236">
<NAME>Stroke</NAME>
<DICH_DATA CI_END="2.8890682336341547" CI_START="0.007720288985463854" EFFECT_SIZE="0.14934671627585014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4607577990753672" LOG_CI_START="-2.1123664428710867" LOG_EFFECT_SIZE="-0.8258043218978597" MODIFIED="2009-12-29 13:56:49 +0100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.511465916889767" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1650" TOTAL_2="1725" VAR="2.2845292179194243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.993235729314342" CI_START="0.2141961604458646" DF="0" EFFECT_SIZE="0.6534090909090909" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-001.26.05" LOG_CI_END="0.2995586634202447" LOG_CI_START="-0.6691883183413209" LOG_EFFECT_SIZE="-0.18481482746053812" MODIFIED="2010-07-08 13:04:56 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="1.0" P_Z="0.4545609941001564" STUDIES="1" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1725" WEIGHT="100.0" Z="0.7478328448011485">
<NAME>Renal problems</NAME>
<DICH_DATA CI_END="1.993235729314342" CI_START="0.2141961604458646" EFFECT_SIZE="0.6534090909090909" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2995586634202447" LOG_CI_START="-0.6691883183413209" LOG_EFFECT_SIZE="-0.18481482746053812" MODIFIED="2009-12-29 13:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.5690467724616421" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1650" TOTAL_2="1725" VAR="0.3238142292490119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.256411168178016E-31" CI_END="1.2199955786953576" CI_START="0.6569581122751442" DF="0" EFFECT_SIZE="0.8952575005905978" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="83" I2="100.0" ID="CMP-001.26.06" LOG_CI_END="0.0863582567799217" LOG_CI_START="-0.18246232022363096" LOG_EFFECT_SIZE="-0.048052031721854634" MODIFIED="2010-07-08 13:05:00 +0200" MODIFIED_BY="Denise Atherton" NO="6" P_CHI2="0.0" P_Z="0.48349507961172855" STUDIES="1" TAU2="0.0" TOTAL_1="1632" TOTAL_2="1708" WEIGHT="100.00000000000001" Z="0.7006922803946413">
<NAME>Depression</NAME>
<DICH_DATA CI_END="1.2199955786953574" CI_START="0.6569581122751442" EFFECT_SIZE="0.8952575005905977" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="83" LOG_CI_END="0.08635825677992162" LOG_CI_START="-0.18246232022363096" LOG_EFFECT_SIZE="-0.04805203172185469" MODIFIED="2009-12-29 13:57:07 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.15790653761520396" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1632" TOTAL_2="1708" VAR="0.024934474621621825" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4980698718179966" CI_END="1.14826938001555" CI_START="0.9343395613293637" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.035796074916134" ESTIMABLE="YES" EVENTS_1="634" EVENTS_2="611" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.060043783994412105" LOG_CI_START="-0.02949526208749474" LOG_EFFECT_SIZE="0.015274260953458673" METHOD="MH" MODIFIED="2010-07-08 13:05:06 +0200" MODIFIED_BY="Denise Atherton" NO="27" P_CHI2="0.47564028064720043" P_Q="0.0" P_Z="0.5036922688556578" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5003" TOTAL_2="4958" WEIGHT="100.00000000000001" Z="0.6686915411598252">
<NAME>Stillbirths and neonatal deaths</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.42360583052434" CI_END="1.1834422256922075" CI_START="0.8831528325386814" DF="2" EFFECT_SIZE="1.022330843595142" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="293" I2="17.478330229660088" ID="CMP-001.27.01" LOG_CI_END="0.07314706101835991" LOG_CI_START="-0.053964133812324955" LOG_EFFECT_SIZE="0.009591463603017488" MODIFIED="2010-07-08 13:05:03 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.29766020792933723" P_Z="0.7673927071064545" STUDIES="3" TAU2="0.0" TOTAL_1="1650" TOTAL_2="1691" WEIGHT="47.311773012104986" Z="0.29578705866122434">
<NAME>Severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.1785759757685152" CI_START="0.8535370112010304" EFFECT_SIZE="1.0029746835443039" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="240" LOG_CI_END="0.07135758413949281" LOG_CI_START="-0.06877764219790057" LOG_EFFECT_SIZE="0.0012899709707960966" ORDER="86476" O_E="0.0" SE="0.08231612563114277" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1185" TOTAL_2="1219" VAR="0.006775944538922079" WEIGHT="38.69956016467087"/>
<DICH_DATA CI_END="1.3700427593012603" CI_START="0.4751581068458393" EFFECT_SIZE="0.8068376068376069" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.13673412178326494" LOG_CI_START="-0.3231618566794502" LOG_EFFECT_SIZE="-0.09321386744809265" ORDER="86477" O_E="0.0" SE="0.2701451742708076" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.072978415181805" WEIGHT="4.071635652660565"/>
<DICH_DATA CI_END="2.1982456779839024" CI_START="0.8670076685312144" EFFECT_SIZE="1.3805418719211822" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.34207622795565035" LOG_CI_START="-0.061977061248054695" LOG_EFFECT_SIZE="0.14004958335379783" ORDER="86478" O_E="0.0" SE="0.23734290217429502" STUDY_ID="STD-South-Africa-1998" TOTAL_1="348" TOTAL_2="354" VAR="0.05633165321251697" WEIGHT="4.540577194773549"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2112565797213657" CI_START="0.9065525524515712" DF="0" EFFECT_SIZE="1.0478872763900533" ESTIMABLE="YES" EVENTS_1="342" EVENTS_2="318" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.08323614921582508" LOG_CI_START="-0.04260701497918572" LOG_EFFECT_SIZE="0.020314567118319655" MODIFIED="2010-07-08 13:05:06 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.5268741964032084" STUDIES="1" TAU2="0.0" TOTAL_1="3353" TOTAL_2="3267" WEIGHT="52.68822698789503" Z="0.6327847868117529">
<NAME>Not severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.2112565797213657" CI_START="0.9065525524515712" EFFECT_SIZE="1.0478872763900533" ESTIMABLE="YES" EVENTS_1="342" EVENTS_2="318" LOG_CI_END="0.08323614921582508" LOG_CI_START="-0.04260701497918572" LOG_EFFECT_SIZE="0.020314567118319655" ORDER="86479" O_E="0.0" SE="0.07392089758185864" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3353" TOTAL_2="3267" VAR="0.005464299099307636" WEIGHT="52.68822698789503"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.775667176451973" CI_END="1.0918096467199838" CI_START="0.9345746593887247" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.010137430600734" ESTIMABLE="YES" EVENTS_1="1165" EVENTS_2="1141" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.038146927210049676" LOG_CI_START="-0.029385998870067886" LOG_EFFECT_SIZE="0.004380464169990887" METHOD="MH" MODIFIED="2010-07-08 13:05:27 +0200" MODIFIED_BY="Denise Atherton" NO="28" P_CHI2="0.5728908796627343" P_Q="0.0" P_Z="0.7992926155885225" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17982" TOTAL_2="17758" WEIGHT="400.0" Z="0.2542626984225394">
<NAME>Mortality for the fetus or infant (by time of death)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.176080219331744" CI_END="1.1220828968869676" CI_START="0.8676847960356527" DF="2" EFFECT_SIZE="0.9867189415028288" ESTIMABLE="YES" EVENTS_1="424" EVENTS_2="426" I2="8.091623542528081" ID="CMP-001.28.01" LOG_CI_END="0.05002494277636771" LOG_CI_START="-0.061638012385313745" LOG_EFFECT_SIZE="-0.00580653480447302" MODIFIED="2010-07-08 13:05:14 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.33687632663138845" P_Z="0.8384797835874329" STUDIES="3" TAU2="0.0" TOTAL_1="5003" TOTAL_2="4958" WEIGHT="99.99999999999999" Z="0.2038384005737086">
<NAME>Stillbirth</NAME>
<DICH_DATA CI_END="1.100530071523546" CI_START="0.8378048233315247" EFFECT_SIZE="0.9602236209049508" ESTIMABLE="YES" EVENTS_1="373" EVENTS_2="384" LOG_CI_END="0.04160191396643057" LOG_CI_START="-0.07685714368805341" LOG_EFFECT_SIZE="-0.017627614860811415" ORDER="86480" O_E="0.0" SE="0.06958343684803629" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4538" TOTAL_2="4486" VAR="0.004841854683584655" WEIGHT="90.25478917498732"/>
<DICH_DATA CI_END="1.9053842031003845" CI_START="0.460299352600514" EFFECT_SIZE="0.9365079365079365" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.27998256030700924" LOG_CI_START="-0.33695963592988426" LOG_EFFECT_SIZE="-0.028488537811437512" ORDER="86481" O_E="0.0" SE="0.3623948999826755" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.13133006353345336" WEIGHT="3.257764316188392"/>
<DICH_DATA CI_END="2.1982456779839024" CI_START="0.8670076685312144" EFFECT_SIZE="1.3805418719211822" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.34207622795565035" LOG_CI_START="-0.061977061248054695" LOG_EFFECT_SIZE="0.14004958335379783" ORDER="86482" O_E="0.0" SE="0.23734290217429502" STUDY_ID="STD-South-Africa-1998" TOTAL_1="348" TOTAL_2="354" VAR="0.05633165321251697" WEIGHT="6.48744650882428"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5608394662942389" CI_END="1.1005906600987891" CI_START="0.8795467265586852" DF="1" EFFECT_SIZE="0.9838805376522866" ESTIMABLE="YES" EVENTS_1="538" EVENTS_2="541" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="0.04162582295381423" LOG_CI_START="-0.05574108338384425" LOG_EFFECT_SIZE="-0.007057630215015018" MODIFIED="2010-07-08 13:05:20 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.45392231445194686" P_Z="0.7763064841728426" STUDIES="2" TAU2="0.0" TOTAL_1="4655" TOTAL_2="4604" WEIGHT="100.00000000000001" Z="0.2841355766128734">
<NAME>Perinatal death</NAME>
<DICH_DATA CI_END="1.1129909961225313" CI_START="0.8848262955204917" EFFECT_SIZE="0.9923727626485731" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="516" LOG_CI_END="0.04649165099228488" LOG_CI_START="-0.053141979360177984" LOG_EFFECT_SIZE="-0.003325164183946577" ORDER="86483" O_E="0.0" SE="0.05852528766346106" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4538" TOTAL_2="4486" VAR="0.0034252092960908673" WEIGHT="95.42284859213474"/>
<DICH_DATA CI_END="1.3700427593012603" CI_START="0.4751581068458393" EFFECT_SIZE="0.8068376068376069" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.13673412178326494" LOG_CI_START="-0.3231618566794502" LOG_EFFECT_SIZE="-0.09321386744809265" ORDER="86484" O_E="0.0" SE="0.2701451742708076" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.072978415181805" WEIGHT="4.577151407865268"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4243157800688295" CI_START="0.94150457548667" DF="0" EFFECT_SIZE="1.1580154678900747" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="159" I2="0.0" ID="CMP-001.28.03" LOG_CI_END="0.15360628588628586" LOG_CI_START="-0.02617756507505472" LOG_EFFECT_SIZE="0.06371436040561558" MODIFIED="2010-07-08 13:05:24 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.16477197955841336" STUDIES="1" TAU2="0.0" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="1.389199875575746">
<NAME>Neonatal death</NAME>
<DICH_DATA CI_END="1.4243157800688295" CI_START="0.94150457548667" EFFECT_SIZE="1.1580154678900747" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="159" LOG_CI_END="0.15360628588628586" LOG_CI_START="-0.02617756507505472" LOG_EFFECT_SIZE="0.06371436040561558" ORDER="86485" O_E="0.0" SE="0.10560592399910654" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="0.011152611183705065" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.121506627858851" CI_START="0.5199394981810022" DF="0" EFFECT_SIZE="1.050264296011533" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-001.28.04" LOG_CI_END="0.32664439289642655" LOG_CI_START="-0.28404718931680323" LOG_EFFECT_SIZE="0.02129860178981161" MODIFIED="2010-07-08 13:05:27 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="1.0" P_Z="0.8912582922082406" STUDIES="1" TAU2="0.0" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="0.13671219202925097">
<NAME>Infant death (from 28 days to 1 year)</NAME>
<DICH_DATA CI_END="2.121506627858851" CI_START="0.5199394981810022" EFFECT_SIZE="1.050264296011533" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.32664439289642655" LOG_CI_START="-0.28404718931680323" LOG_EFFECT_SIZE="0.02129860178981161" ORDER="86486" O_E="0.0" SE="0.358723258364137" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="0.1286823760913834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.321410585788908" CI_END="1.0832229870772243" CI_START="0.9544629194449409" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.016806852187571" ESTIMABLE="YES" EVENTS_1="1330" EVENTS_2="1302" I2="81.2079901770679" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.03471786760294734" LOG_CI_START="-0.020240939133341265" LOG_EFFECT_SIZE="0.007238464234803033" METHOD="MH" MODIFIED="2010-07-08 13:05:35 +0200" MODIFIED_BY="Denise Atherton" NO="29" P_CHI2="0.02106501460898247" P_Q="0.0" P_Z="0.6056572680494302" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4538" TOTAL_2="4486" WEIGHT="100.0" Z="0.516282286537624">
<NAME>Death or in special care baby unit &gt; 7 days</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.020083330903146" CI_START="0.8485305164114165" DF="0" EFFECT_SIZE="0.93036113179449" ESTIMABLE="YES" EVENTS_1="492" EVENTS_2="544" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="0.008635650853266695" LOG_CI_START="-0.07133253417038729" LOG_EFFECT_SIZE="-0.031348441658560315" MODIFIED="2010-07-08 13:05:31 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.12437744286386317" STUDIES="1" TAU2="0.0" TOTAL_1="1185" TOTAL_2="1219" WEIGHT="41.12293869390339" Z="1.536656524192948">
<NAME>Severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.020083330903146" CI_START="0.8485305164114165" EFFECT_SIZE="0.93036113179449" ESTIMABLE="YES" EVENTS_1="492" EVENTS_2="544" LOG_CI_END="0.008635650853266695" LOG_CI_START="-0.07133253417038729" LOG_EFFECT_SIZE="-0.031348441658560315" ORDER="86487" O_E="0.0" SE="0.04697370773179436" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1185" TOTAL_2="1219" VAR="0.002206529218072037" WEIGHT="41.12293869390339"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.173475010544067" CI_START="0.988796550035894" DF="0" EFFECT_SIZE="1.0771852403274507" ESTIMABLE="YES" EVENTS_1="838" EVENTS_2="758" I2="0.0" ID="CMP-001.29.02" LOG_CI_END="0.06947384561899735" LOG_CI_START="-0.004893057529316666" LOG_EFFECT_SIZE="0.032290394044840326" MODIFIED="2010-07-08 13:05:35 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.08874642104869751" STUDIES="1" TAU2="0.0" TOTAL_1="3353" TOTAL_2="3267" WEIGHT="58.87706130609661" Z="1.7020477307835427">
<NAME>Not severe pre-eclampsia</NAME>
<DICH_DATA CI_END="1.173475010544067" CI_START="0.988796550035894" EFFECT_SIZE="1.0771852403274507" ESTIMABLE="YES" EVENTS_1="838" EVENTS_2="758" LOG_CI_END="0.06947384561899735" LOG_CI_START="-0.004893057529316666" LOG_EFFECT_SIZE="0.032290394044840326" ORDER="86488" O_E="0.0" SE="0.043683487031427236" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3353" TOTAL_2="3267" VAR="0.0019082470392248712" WEIGHT="58.87706130609661"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2169705299698024" CI_START="0.8537755332348557" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0193231397138363" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="227" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.08528006152796085" LOG_CI_START="-0.06865629499159769" LOG_EFFECT_SIZE="0.008311883268181585" METHOD="MH" MODIFIED="2009-12-21 15:44:14 +0100" MODIFIED_BY="Lelia Duley" NO="30" P_CHI2="1.0" P_Q="0.0" P_Z="0.8323732368340525" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="0.21165879481196015">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2169705299698024" CI_START="0.8537755332348557" EFFECT_SIZE="1.0193231397138363" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="227" LOG_CI_END="0.08528006152796085" LOG_CI_START="-0.06865629499159769" LOG_EFFECT_SIZE="0.008311883268181585" ORDER="86489" O_E="0.0" SE="0.09042297781684278" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="0.008176314917265242" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2385180467571677" CI_START="0.8198252569020886" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0076548892654509" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="171" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.09290233918180898" LOG_CI_START="-0.08627870621439176" LOG_EFFECT_SIZE="0.0033118164837086235" METHOD="MH" MODIFIED="2009-12-21 15:44:13 +0100" MODIFIED_BY="Lelia Duley" NO="31" P_CHI2="1.0" P_Q="0.0" P_Z="0.9422419504915658" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="0.0724523179013958">
<NAME>Intubated at place of birth</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2385180467571677" CI_START="0.8198252569020886" EFFECT_SIZE="1.0076548892654509" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="171" LOG_CI_END="0.09290233918180898" LOG_CI_START="-0.08627870621439176" LOG_EFFECT_SIZE="0.0033118164837086235" ORDER="86490" O_E="0.0" SE="0.10525183302620776" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="0.011077948355376718" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.064039437105784" CI_START="0.9551769659938871" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0081398520208127" ESTIMABLE="YES" EVENTS_1="1629" EVENTS_2="1591" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="0.026957724763559905" LOG_CI_START="-0.01991615906056797" LOG_EFFECT_SIZE="0.0035207828514959437" METHOD="MH" MODIFIED="2009-12-21 15:44:12 +0100" MODIFIED_BY="Lelia Duley" NO="32" P_CHI2="1.0" P_Q="0.0" P_Z="0.7684271038275825" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4162" TOTAL_2="4098" WEIGHT="100.0" Z="0.294432934646916">
<NAME>Admission to special care baby unit</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.064039437105784" CI_START="0.9551769659938871" EFFECT_SIZE="1.0081398520208127" ESTIMABLE="YES" EVENTS_1="1629" EVENTS_2="1591" LOG_CI_END="0.026957724763559905" LOG_CI_START="-0.01991615906056797" LOG_EFFECT_SIZE="0.0035207828514959437" ORDER="86491" O_E="0.0" SE="0.02753395138775975" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4162" TOTAL_2="4098" VAR="7.581184790235169E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0906583648535395" CI_START="0.7657533269689516" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9138792433757944" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="242" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="0.03768873455344383" LOG_CI_START="-0.11591110763778756" LOG_EFFECT_SIZE="-0.03911118654217188" METHOD="MH" MODIFIED="2010-02-17 21:06:03 +0100" MODIFIED_BY="Lelia Duley" NO="33" P_CHI2="1.0" P_Q="0.0" P_Z="0.3182150009108714" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4415" TOTAL_2="4359" WEIGHT="100.0" Z="0.9981327574522819">
<NAME>Blood transfusion</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0906583648535395" CI_START="0.7657533269689516" EFFECT_SIZE="0.9138792433757944" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="242" LOG_CI_END="0.03768873455344383" LOG_CI_START="-0.11591110763778756" LOG_EFFECT_SIZE="-0.03911118654217188" ORDER="86475" O_E="0.0" SE="0.09022530763461062" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4415" TOTAL_2="4359" VAR="0.008140606137760126" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.436866195841496" CI_END="1.1703031141077351" CI_START="0.8662522705983735" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.006865298778428" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="300" I2="0.0" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="0.06829836066505719" LOG_CI_START="-0.062355614017017814" LOG_EFFECT_SIZE="0.0029713733240196655" METHOD="MH" MODIFIED="2010-07-08 13:06:03 +0200" MODIFIED_BY="Denise Atherton" NO="34" P_CHI2="0.6177753882454908" P_Q="0.0" P_Z="0.9289641151721358" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10425" TOTAL_2="10616" WEIGHT="700.0" Z="0.08914822092282813">
<NAME>Outcome for the children at 18 months (corrected for gestation at birth)</NAME>
<GROUP_LABEL_1>magnesium sulphate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8390363038164323" CI_START="0.5691314475202515" DF="0" EFFECT_SIZE="1.0230607966457024" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-001.34.01" LOG_CI_END="0.2645903025885541" LOG_CI_START="-0.24478741666336062" LOG_EFFECT_SIZE="0.009901442962596728" MODIFIED="2010-07-08 13:05:43 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.9392625425698583" STUDIES="1" TAU2="0.0" TOTAL_1="1431" TOTAL_2="1464" WEIGHT="100.0" Z="0.07619678234127715">
<NAME>Death after discharge</NAME>
<DICH_DATA CI_END="1.8390363038164323" CI_START="0.5691314475202515" EFFECT_SIZE="1.0230607966457024" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.2645903025885541" LOG_CI_START="-0.24478741666336062" LOG_EFFECT_SIZE="0.009901442962596728" MODIFIED="2009-12-29 14:00:39 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.2992109937489506" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1431" TOTAL_2="1464" VAR="0.08952721878023456" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.060389138638895" CI_START="0.20683259033214588" DF="0" EFFECT_SIZE="1.0230607966457024" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.34.02" LOG_CI_END="0.704183914915967" LOG_CI_START="-0.6843810289907737" LOG_EFFECT_SIZE="0.009901442962596728" MODIFIED="2010-07-08 13:05:46 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.9777005633455054" STUDIES="1" TAU2="0.0" TOTAL_1="1431" TOTAL_2="1464" WEIGHT="100.0" Z="0.02795183860405819">
<NAME>Blind</NAME>
<DICH_DATA CI_END="5.060389138638895" CI_START="0.20683259033214588" EFFECT_SIZE="1.0230607966457024" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.704183914915967" LOG_CI_START="-0.6843810289907737" LOG_EFFECT_SIZE="0.009901442962596728" MODIFIED="2009-12-29 14:02:11 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.8156499215581463" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1431" TOTAL_2="1464" VAR="0.6652847945378102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.540100588187034" CI_START="0.18574067840351635" DF="0" EFFECT_SIZE="2.0461215932914047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.34.03" LOG_CI_END="1.3529558498111125" LOG_CI_START="-0.7310929725579566" LOG_EFFECT_SIZE="0.3109314386265779" MODIFIED="2010-07-08 13:05:50 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.5586573318445552" STUDIES="1" TAU2="0.0" TOTAL_1="1431" TOTAL_2="1464" WEIGHT="100.0" Z="0.5848369911762041">
<NAME>Deaf</NAME>
<DICH_DATA CI_END="22.540100588187034" CI_START="0.18574067840351635" EFFECT_SIZE="2.0461215932914047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3529558498111125" LOG_CI_START="-0.7310929725579566" LOG_EFFECT_SIZE="0.3109314386265779" MODIFIED="2009-12-29 14:02:16 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="1.2241805944676396" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1431" TOTAL_2="1464" VAR="1.4986181278711437" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2570860533180048" CI_START="0.09251142450261235" DF="0" EFFECT_SIZE="0.34102026554856746" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-001.34.04" LOG_CI_END="0.09936500815689707" LOG_CI_START="-1.0338046316710283" LOG_EFFECT_SIZE="-0.46721981175706573" MODIFIED="2010-07-08 13:05:53 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="1.0" P_Z="0.1060435952725027" STUDIES="1" TAU2="0.0" TOTAL_1="1431" TOTAL_2="1464" WEIGHT="100.0" Z="1.616234624934867">
<NAME>Severe cerebral palsy</NAME>
<DICH_DATA CI_END="1.257086053318005" CI_START="0.09251142450261232" EFFECT_SIZE="0.34102026554856746" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.09936500815689714" LOG_CI_START="-1.0338046316710283" LOG_EFFECT_SIZE="-0.46721981175706573" MODIFIED="2009-12-29 14:02:27 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.6656294557151059" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1431" TOTAL_2="1464" VAR="0.4430625723155881" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.627831313562383" CI_START="0.3457771892223378" DF="0" EFFECT_SIZE="0.7502445842068484" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-001.34.05" LOG_CI_END="0.21160939847411933" LOG_CI_START="-0.4612036603438383" LOG_EFFECT_SIZE="-0.12479713093485949" MODIFIED="2010-07-08 13:05:56 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="1.0" P_Z="0.46717072316144603" STUDIES="1" TAU2="0.0" TOTAL_1="1431" TOTAL_2="1464" WEIGHT="100.0" Z="0.7270901740105336">
<NAME>Developmental delay</NAME>
<DICH_DATA CI_END="1.627831313562383" CI_START="0.3457771892223378" EFFECT_SIZE="0.7502445842068484" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.21160939847411933" LOG_CI_START="-0.4612036603438383" LOG_EFFECT_SIZE="-0.12479713093485949" MODIFIED="2010-02-17 22:39:00 +0100" MODIFIED_BY="Lelia Duley" ORDER="300" O_E="0.0" SE="0.39521372122802273" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1431" TOTAL_2="1464" VAR="0.15619388544690124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5817516782828276" CI_START="0.3756033513665631" DF="0" EFFECT_SIZE="0.7707861126101817" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-001.34.06" LOG_CI_END="0.1991383039300386" LOG_CI_START="-0.42527054134332865" LOG_EFFECT_SIZE="-0.11306611870664503" MODIFIED="2010-07-08 13:06:00 +0200" MODIFIED_BY="Denise Atherton" NO="6" P_CHI2="1.0" P_Z="0.4778225695087588" STUDIES="1" TAU2="0.0" TOTAL_1="1635" TOTAL_2="1648" WEIGHT="100.0" Z="0.7098090368650543">
<NAME>Neurosensory disability</NAME>
<DICH_DATA CI_END="1.5817516782828276" CI_START="0.3756033513665631" EFFECT_SIZE="0.7707861126101817" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.1991383039300386" LOG_CI_START="-0.42527054134332865" LOG_EFFECT_SIZE="-0.11306611870664503" MODIFIED="2009-12-29 14:02:21 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.366780846587209" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1635" TOTAL_2="1648" VAR="0.13452818942322975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2509809755043013" CI_START="0.8979424894097341" DF="0" EFFECT_SIZE="1.059862713443845" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="233" I2="0.0" ID="CMP-001.34.07" LOG_CI_END="0.09725070514000089" LOG_CI_START="-0.04675147773338975" LOG_EFFECT_SIZE="0.025249613703305564" MODIFIED="2010-07-08 13:06:03 +0200" MODIFIED_BY="Denise Atherton" NO="7" P_CHI2="1.0" P_Z="0.49187634881240583" STUDIES="1" TAU2="0.0" TOTAL_1="1635" TOTAL_2="1648" WEIGHT="100.0" Z="0.6873275459378138">
<NAME>Death or neurosensory disability</NAME>
<DICH_DATA CI_END="1.2509809755043013" CI_START="0.8979424894097341" EFFECT_SIZE="1.059862713443845" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="233" LOG_CI_END="0.09725070514000089" LOG_CI_START="-0.04675147773338975" LOG_EFFECT_SIZE="0.025249613703305564" MODIFIED="2010-02-17 22:41:26 +0100" MODIFIED_BY="Lelia Duley" ORDER="301" O_E="0.0" SE="0.08458759504213115" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1635" TOTAL_2="1648" VAR="0.007155061235011569" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-07-08 13:06:29 +0200" MODIFIED_BY="Denise Atherton" NO="2">
<NAME>Magnesium sulphate versus none/placebo (subgroups by whether delivered at trial entry)</NAME>
<DICH_OUTCOME CHI2="0.24489675594267774" CI_END="1.0922418302396848" CI_START="0.2609240560009147" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5338465776606619" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.0383188049539633" LOG_CI_START="-0.583485879095109" LOG_EFFECT_SIZE="-0.2725835370705728" METHOD="MH" MODIFIED="2010-07-08 13:06:14 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.884751580651432" P_Q="0.0" P_Z="0.08572407262838944" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5400" TOTAL_2="5395" WEIGHT="100.0" Z="1.7183978478833675">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11516295394014357" CI_END="1.1933093399485897" CI_START="0.2629725420471248" DF="1" EFFECT_SIZE="0.5601853180643502" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.07675303982978207" LOG_CI_START="-0.5800895954644436" LOG_EFFECT_SIZE="-0.25166827781733075" MODIFIED="2010-07-08 13:06:10 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.7343410993119066" P_Z="0.13311917446345345" STUDIES="2" TAU2="0.0" TOTAL_1="4761" TOTAL_2="4699" WEIGHT="86.6380863203034" Z="1.5019145654338897">
<NAME>Antepartum at trial entry</NAME>
<DICH_DATA CI_END="1.2666255526646562" CI_START="0.26617638387543585" EFFECT_SIZE="0.5806425831202046" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.10264824515452368" LOG_CI_START="-0.5748304793179888" LOG_EFFECT_SIZE="-0.2360911170817325" ORDER="86493" O_E="0.0" SE="0.3979543563289257" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4416" TOTAL_2="4359" VAR="0.15836766972116953" WEIGHT="79.60835970986923"/>
<DICH_DATA CI_END="8.036092759233755" CI_START="0.013429786541454108" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" ORDER="86494" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="7.029726610434171"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4814727788254" CI_START="0.0378626711632275" DF="0" EFFECT_SIZE="0.3630672926447575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.5417630038338345" LOG_CI_START="-1.4217887503688353" LOG_EFFECT_SIZE="-0.4400128732675004" MODIFIED="2010-07-08 13:06:14 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.37971704950333274" STUDIES="1" TAU2="0.0" TOTAL_1="639" TOTAL_2="696" WEIGHT="13.3619136796966" Z="0.8784177778787221">
<NAME>Postpartum at trial entry</NAME>
<DICH_DATA CI_END="3.4814727788254" CI_START="0.0378626711632275" EFFECT_SIZE="0.36306729264475746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5417630038338345" LOG_CI_START="-1.4217887503688353" LOG_EFFECT_SIZE="-0.44001287326750044" ORDER="86495" O_E="0.0" SE="1.1534000201565895" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="639" TOTAL_2="696" VAR="1.3303316064972208" WEIGHT="13.3619136796966"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.438801627270843" CI_END="0.5751090087148132" CI_START="0.28658685135044826" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40597866937913846" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="107" I2="26.454386938043644" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.24024982940368456" LOG_CI_START="-0.5427437389803333" LOG_EFFECT_SIZE="-0.391496784192009" METHOD="MH" MODIFIED="2010-07-08 13:06:21 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.24516166789830285" P_Q="0.0" P_Z="3.909968270724542E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5722" TOTAL_2="5722" WEIGHT="100.0" Z="5.073289562447582">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.225966530759755" CI_END="0.569286741075662" CI_START="0.274667853602224" DF="3" EFFECT_SIZE="0.3954298512447652" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="99" I2="42.59435106707701" ID="CMP-002.02.01" LOG_CI_END="-0.24466893096929165" LOG_CI_START="-0.5611921662806201" LOG_EFFECT_SIZE="-0.4029305486249559" MODIFIED="2010-07-08 13:06:18 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.15597914344955532" P_Z="6.037160714640573E-7" STUDIES="6" TAU2="0.0" TOTAL_1="5083" TOTAL_2="5026" WEIGHT="92.92837620517577" Z="4.990024588868556">
<NAME>Antepartum at trial entry</NAME>
<DICH_DATA CI_END="0.5937415358075305" CI_START="0.27463623349432786" EFFECT_SIZE="0.40381052371541504" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="88" LOG_CI_END="-0.22640256848839865" LOG_CI_START="-0.561242165684281" LOG_EFFECT_SIZE="-0.3938223670863399" ORDER="86496" O_E="0.0" SE="0.19668643687559895" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4416" TOTAL_2="4359" VAR="0.03868555445081897" WEIGHT="81.78509844095876"/>
<DICH_DATA CI_END="75.45596071768202" CI_START="0.1278685654793144" EFFECT_SIZE="3.106194690265487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8776935529856453" LOG_CI_START="-0.8932362070208368" LOG_EFFECT_SIZE="0.49222867298240436" ORDER="86497" O_E="0.0" SE="1.6276578573513336" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="2.6492701005975343" WEIGHT="0.45365967866240126"/>
<DICH_DATA CI_END="0.6901371054307739" CI_START="0.011630513657496754" EFFECT_SIZE="0.08959156785243742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.16106462199174001" LOG_CI_START="-1.9344011043867484" LOG_EFFECT_SIZE="-1.047732863189244" ORDER="86498" O_E="0.0" SE="1.0416666279159879" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="1.0850693637138649" WEIGHT="10.231299025139899"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86499" O_E="0.0" SE="0.0" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.4237999629299" CI_START="0.1262077453606798" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" ORDER="86500" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="0.45831906041469905"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 21:13:16 +0100" MODIFIED_BY="Lelia Duley" ORDER="295" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.799866720149403" CI_START="0.16478452510042912" DF="0" EFFECT_SIZE="0.5446009389671361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.2552403468551322" LOG_CI_START="-0.7830835752787708" LOG_EFFECT_SIZE="-0.26392161421181926" MODIFIED="2010-07-08 13:06:21 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.3190709264575773" STUDIES="1" TAU2="0.0" TOTAL_1="639" TOTAL_2="696" WEIGHT="7.071623794824234" Z="0.996368951095267">
<NAME>Postpartum at trial entry</NAME>
<DICH_DATA CI_END="1.7998667201494025" CI_START="0.16478452510042915" EFFECT_SIZE="0.5446009389671361" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.25524034685513214" LOG_CI_START="-0.7830835752787707" LOG_EFFECT_SIZE="-0.26392161421181926" ORDER="86501" O_E="0.0" SE="0.6099166116477625" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="639" TOTAL_2="696" VAR="0.3719982731638875" WEIGHT="7.071623794824234"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22480160808672403" CI_END="1.3001260326880253" CI_START="0.8755131344650428" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0669008473510055" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.11398545434366388" LOG_CI_START="-0.05773733423741324" LOG_EFFECT_SIZE="0.028124060053125313" METHOD="MH" MODIFIED="2010-07-08 13:06:29 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.6354054576800445" P_Q="0.0" P_Z="0.5208797683918103" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5055" TOTAL_2="5055" WEIGHT="100.0" Z="0.6419898635310352">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.333085893715458" CI_START="0.8804704599182013" DF="0" EFFECT_SIZE="1.083394088016967" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="164" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.12485813288337486" LOG_CI_START="-0.05528521017907563" LOG_EFFECT_SIZE="0.03478646135214962" MODIFIED="2010-07-08 13:06:26 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.4490767671774599" STUDIES="1" TAU2="0.0" TOTAL_1="4416" TOTAL_2="4359" WEIGHT="90.07456438984309" Z="0.7569551029834242">
<NAME>Antepartum at trial entry</NAME>
<DICH_DATA CI_END="1.333085893715458" CI_START="0.8804704599182013" EFFECT_SIZE="1.083394088016967" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="164" LOG_CI_END="0.12485813288337486" LOG_CI_START="-0.05528521017907563" LOG_EFFECT_SIZE="0.03478646135214962" ORDER="86502" O_E="0.0" SE="0.10581709143881314" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4416" TOTAL_2="4359" VAR="0.011197256840570142" WEIGHT="90.07456438984309"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7680981667736795" CI_START="0.4758205037611747" DF="0" EFFECT_SIZE="0.9172226340499136" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2475063738583719" LOG_CI_START="-0.32255684754785635" LOG_EFFECT_SIZE="-0.03752523684474221" MODIFIED="2010-07-08 13:06:29 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.7963799470665698" STUDIES="1" TAU2="0.0" TOTAL_1="639" TOTAL_2="696" WEIGHT="9.925435610156908" Z="0.258034933548606">
<NAME>Postpartum at trial entry</NAME>
<DICH_DATA CI_END="1.7680981667736797" CI_START="0.47582050376117463" EFFECT_SIZE="0.9172226340499136" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.24750637385837196" LOG_CI_START="-0.3225568475478564" LOG_EFFECT_SIZE="-0.03752523684474221" ORDER="86503" O_E="0.0" SE="0.3348579581124749" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="639" TOTAL_2="696" VAR="0.11212985211125596" WEIGHT="9.925435610156908"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-07-08 13:07:04 +0200" MODIFIED_BY="Denise Atherton" NO="3">
<NAME>Magnesium sulphate versus none/placebo (subgroups by gestation at trial entry)</NAME>
<DICH_OUTCOME CHI2="0.14602921198045327" CI_END="1.1971159852774118" CI_START="0.26399530407119437" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5621681230217502" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.0781362300435804" LOG_CI_START="-0.5784037982593586" LOG_EFFECT_SIZE="-0.25013378410788917" METHOD="MH" MODIFIED="2010-07-08 13:06:43 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.9295872686572395" P_Q="0.0" P_Z="0.1353207435467707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4761" TOTAL_2="4699" WEIGHT="100.0" Z="1.4934449905070182">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9050216239071973" CI_START="0.20505016588674127" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2798999097178183" LOG_CI_START="-0.6881398750296679" LOG_EFFECT_SIZE="-0.2041199826559248" NO="1" P_CHI2="1.0" P_Z="0.4084908015263077" STUDIES="1" TAU2="0.0" TOTAL_1="1206" TOTAL_2="1206" WEIGHT="43.03032598389515" Z="0.8265524223984474">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="1.9050216239071978" CI_START="0.2050501658867412" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2798999097178184" LOG_CI_START="-0.688139875029668" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="86504" O_E="0.0" SE="0.5686313614348903" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1206" TOTAL_2="1206" VAR="0.32334162520729687" WEIGHT="43.03032598389515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.626462367316216" CI_START="0.1830833487081035" DF="0" EFFECT_SIZE="0.5456905503634476" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.2112440191358662" LOG_CI_START="-0.7373511526564132" LOG_EFFECT_SIZE="-0.26305356676027347" NO="2" P_CHI2="1.0" P_Z="0.2770237435452473" STUDIES="1" TAU2="0.0" TOTAL_1="3210" TOTAL_2="3153" WEIGHT="48.84276747111154" Z="1.0870296037472094">
<NAME>&gt;/= 34 weeks</NAME>
<DICH_DATA CI_END="1.626462367316216" CI_START="0.1830833487081035" EFFECT_SIZE="0.5456905503634476" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.2112440191358662" LOG_CI_START="-0.7373511526564132" LOG_EFFECT_SIZE="-0.26305356676027347" ORDER="86505" O_E="0.0" SE="0.5572094995326153" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3210" TOTAL_2="3153" VAR="0.3104824263693876" WEIGHT="48.84276747111154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.036092759233755" CI_START="0.013429786541454108" DF="0" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" MODIFIED="2010-07-08 13:06:43 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.49497392036302035" STUDIES="1" TAU2="0.0" TOTAL_1="345" TOTAL_2="340" WEIGHT="8.126906544993298" Z="0.6824192043621354">
<NAME>Gestation not specified</NAME>
<DICH_DATA CI_END="8.036092759233755" CI_START="0.013429786541454108" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" ORDER="86506" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="8.126906544993298"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.280571074043159" CI_END="0.5696004705852702" CI_START="0.2748911589240415" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3956995495105653" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="99" I2="36.311524018388766" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.24442966057116197" LOG_CI_START="-0.560839227752921" LOG_EFFECT_SIZE="-0.4026344441620415" METHOD="MH" MODIFIED="2010-07-08 13:06:48 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.17915220658235875" P_Q="0.0" P_Z="6.096059281493116E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5083" TOTAL_2="5026" WEIGHT="100.0" Z="4.988148851008567">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0587719517373437" CI_START="0.27711612240608724" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.02480242774921498" LOG_CI_START="-0.5573382065587538" LOG_EFFECT_SIZE="-0.2662678894047693" NO="1" P_CHI2="1.0" P_Z="0.07298039835022542" STUDIES="1" TAU2="0.0" TOTAL_1="1206" TOTAL_2="1206" WEIGHT="23.84707795180166" Z="1.7929532580842156">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="1.058771951737344" CI_START="0.27711612240608724" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="0.02480242774921507" LOG_CI_START="-0.5573382065587538" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="86507" O_E="0.0" SE="0.3419522902351152" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1206" TOTAL_2="1206" VAR="0.11693136879704044" WEIGHT="23.84707795180166"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7235019220443308" CI_END="0.5931375909428448" CI_START="0.23522072785961956" DF="1" EFFECT_SIZE="0.37352142624282914" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="64" I2="41.97859676223334" ID="CMP-003.02.02" LOG_CI_END="-0.22684455106073217" LOG_CI_START="-0.628524410493812" LOG_EFFECT_SIZE="-0.42768448077727206" NO="2" P_CHI2="0.18924299283413548" P_Z="2.996886350729323E-5" STUDIES="2" TAU2="0.0" TOTAL_1="3277" TOTAL_2="3221" WEIGHT="64.65505707165138" Z="4.173702810259119">
<NAME>&gt;/= 34 weeks</NAME>
<DICH_DATA CI_END="0.5670224389511055" CI_START="0.21975226246218277" EFFECT_SIZE="0.3529935747663551" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="64" LOG_CI_END="-0.24639975429965227" LOG_CI_START="-0.6580666449468712" LOG_EFFECT_SIZE="-0.4522331996232617" ORDER="86508" O_E="0.0" SE="0.24181516935014996" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3210" TOTAL_2="3153" VAR="0.05847457612784171" WEIGHT="64.16186932812263"/>
<DICH_DATA CI_END="73.4237999629299" CI_START="0.1262077453606798" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" ORDER="86509" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="0.4931877435287448"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3933693891506285" CI_END="0.8434830669928213" CI_START="0.05617204113640817" DF="1" EFFECT_SIZE="0.21766985445160864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="70.53076499136148" ID="CMP-003.02.03" LOG_CI_END="-0.07392363149263252" LOG_CI_START="-1.2504797947784236" LOG_EFFECT_SIZE="-0.662201713135528" MODIFIED="2010-07-08 13:06:48 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.06545914665005803" P_Z="0.027366144397806245" STUDIES="4" TAU2="0.0" TOTAL_1="600" TOTAL_2="599" WEIGHT="11.49786497654696" Z="2.206255083687145">
<NAME>Gestation not specified</NAME>
<DICH_DATA CI_END="75.45596071768202" CI_START="0.1278685654793144" EFFECT_SIZE="3.106194690265487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8776935529856453" LOG_CI_START="-0.8932362070208368" LOG_EFFECT_SIZE="0.49222867298240436" ORDER="86510" O_E="0.0" SE="1.6276578573513336" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="2.6492701005975343" WEIGHT="0.4881738783611571"/>
<DICH_DATA CI_END="0.6901371054307739" CI_START="0.011630513657496754" EFFECT_SIZE="0.08959156785243742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.16106462199174001" LOG_CI_START="-1.9344011043867484" LOG_EFFECT_SIZE="-1.047732863189244" ORDER="86511" O_E="0.0" SE="1.0416666279159879" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="1.0850693637138649" WEIGHT="11.009691098185803"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86512" O_E="0.0" SE="0.0" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 21:14:57 +0100" MODIFIED_BY="Lelia Duley" ORDER="296" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.885026209013604" CI_END="1.3376190075132266" CI_START="0.8857730900339351" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0884975523964746" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="164" I2="74.26014790634072" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1263324314462107" LOG_CI_START="-0.05267751780525964" LOG_EFFECT_SIZE="0.036827456820475495" METHOD="MH" MODIFIED="2010-07-08 13:06:54 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.04871855799205471" P_Q="0.0" P_Z="0.41998857177531046" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4416" TOTAL_2="4359" WEIGHT="100.00000000000001" Z="0.806441086790522">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1845725009255197" CI_START="0.6790994678434723" DF="0" EFFECT_SIZE="0.8969072164948454" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="97" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.07356164656009599" LOG_CI_START="-0.16806660985534858" LOG_EFFECT_SIZE="-0.047252481647626306" NO="1" P_CHI2="1.0" P_Z="0.44333389669339407" STUDIES="1" TAU2="0.0" TOTAL_1="1206" TOTAL_2="1206" WEIGHT="58.930673671004286" Z="0.7665755949523769">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="1.1845725009255195" CI_START="0.6790994678434723" EFFECT_SIZE="0.8969072164948454" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="97" LOG_CI_END="0.07356164656009591" LOG_CI_START="-0.16806660985534858" LOG_EFFECT_SIZE="-0.047252481647626306" ORDER="86513" O_E="0.0" SE="0.14193363389759148" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1206" TOTAL_2="1206" VAR="0.02014515643137553" WEIGHT="58.930673671004286"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8592881805915096" CI_START="0.9997869411962351" DF="0" EFFECT_SIZE="1.3634119124006137" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="67" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.2693467085136723" LOG_CI_START="-9.254012138987686E-5" LOG_EFFECT_SIZE="0.13462708419614122" NO="2" P_CHI2="1.0" P_Z="0.050157578935969636" STUDIES="1" TAU2="0.0" TOTAL_1="3210" TOTAL_2="3153" WEIGHT="41.06932632899573" Z="1.9586176676543894">
<NAME>&gt;/= 34 weeks</NAME>
<DICH_DATA CI_END="1.8592881805915096" CI_START="0.9997869411962351" EFFECT_SIZE="1.3634119124006137" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="67" LOG_CI_END="0.2693467085136723" LOG_CI_START="-9.254012138987686E-5" LOG_EFFECT_SIZE="0.13462708419614122" ORDER="86514" O_E="0.0" SE="0.15826994839402667" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3210" TOTAL_2="3153" VAR="0.025049376564647865" WEIGHT="41.06932632899573"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:06:54 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gestation not specified</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.404880844851299" CI_END="1.1441783654124067" CI_START="0.9445550480763295" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0395861921697556" ESTIMABLE="YES" EVENTS_1="634" EVENTS_2="611" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.058493731691457426" LOG_CI_START="-0.02477272659431165" LOG_EFFECT_SIZE="0.01686050254857289" METHOD="MH" MODIFIED="2010-07-08 13:06:59 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="0.4927268968691486" P_Q="0.0" P_Z="0.42734655758594553" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5003" TOTAL_2="4958" WEIGHT="100.0" Z="0.7937404433135709">
<NAME>Stillbirths and neonatal deaths</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1425258431803929" CI_START="0.918246006279566" DF="0" EFFECT_SIZE="1.0242654893003031" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="418" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.05786603230749294" LOG_CI_START="-0.037040951852277744" LOG_EFFECT_SIZE="0.010412540227607594" NO="1" P_CHI2="1.0" P_Z="0.6671465551259467" STUDIES="1" TAU2="0.0" TOTAL_1="1217" TOTAL_2="1226" WEIGHT="68.22605798230387" Z="0.43006748163716374">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="1.1425258431803929" CI_START="0.918246006279566" EFFECT_SIZE="1.0242654893003031" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="418" LOG_CI_END="0.05786603230749294" LOG_CI_START="-0.037040951852277744" LOG_EFFECT_SIZE="0.010412540227607594" ORDER="86515" O_E="0.0" SE="0.05574883229259768" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1217" TOTAL_2="1226" VAR="0.0031079323019881817" WEIGHT="68.22605798230387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3256709089617438" CI_START="0.8455894310224491" DF="0" EFFECT_SIZE="1.058760270142384" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="140" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.12243572605942424" LOG_CI_START="-0.07284045389045392" LOG_EFFECT_SIZE="0.02479763608448516" NO="2" P_CHI2="1.0" P_Z="0.6186377788669326" STUDIES="1" TAU2="0.0" TOTAL_1="3321" TOTAL_2="3260" WEIGHT="23.147916465743048" Z="0.4977818967965948">
<NAME>&gt;/= 34 weeks</NAME>
<DICH_DATA CI_END="1.3256709089617438" CI_START="0.8455894310224491" EFFECT_SIZE="1.058760270142384" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="140" LOG_CI_END="0.12243572605942424" LOG_CI_START="-0.07284045389045392" LOG_EFFECT_SIZE="0.02479763608448516" ORDER="86516" O_E="0.0" SE="0.11470619473523883" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3321" TOTAL_2="3260" VAR="0.013157511110638532" WEIGHT="23.147916465743048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.238272081468806" CI_END="1.569524699667146" CI_START="0.7840377297228014" DF="1" EFFECT_SIZE="1.1093090562466759" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="53" I2="55.32267912023561" ID="CMP-003.04.03" LOG_CI_END="0.19576815459785848" LOG_CI_START="-0.10566303755006619" LOG_EFFECT_SIZE="0.04505255852389614" MODIFIED="2010-07-08 13:06:59 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.13463145253909892" P_Z="0.5579555428117635" STUDIES="2" TAU2="0.0" TOTAL_1="465" TOTAL_2="472" WEIGHT="8.626025551953074" Z="0.5858809202127054">
<NAME>Gestation not specified</NAME>
<DICH_DATA CI_END="1.3700427593012603" CI_START="0.4751581068458393" EFFECT_SIZE="0.8068376068376069" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.13673412178326494" LOG_CI_START="-0.3231618566794502" LOG_EFFECT_SIZE="-0.09321386744809265" ORDER="86517" O_E="0.0" SE="0.2701451742708076" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.072978415181805" WEIGHT="4.078165948784844"/>
<DICH_DATA CI_END="2.1982456779839024" CI_START="0.8670076685312144" EFFECT_SIZE="1.3805418719211822" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.34207622795565035" LOG_CI_START="-0.061977061248054695" LOG_EFFECT_SIZE="0.14004958335379783" ORDER="86518" O_E="0.0" SE="0.23734290217429502" STUDY_ID="STD-South-Africa-1998" TOTAL_1="348" TOTAL_2="354" VAR="0.05633165321251697" WEIGHT="4.547859603168231"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03437077963446994" CI_END="1.0743485201296543" CI_START="0.9700704725912304" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0208789235995925" ESTIMABLE="YES" EVENTS_1="1330" EVENTS_2="1302" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.03114518994429143" LOG_CI_START="-0.013196714449466643" LOG_EFFECT_SIZE="0.008974237747412387" METHOD="MH" MODIFIED="2010-07-08 13:07:04 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="0.8529203997273567" P_Q="0.0" P_Z="0.42757767478770226" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4538" TOTAL_2="4486" WEIGHT="100.0" Z="0.7933435883779563">
<NAME>Death or in special care baby unit &gt; 7 days</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.065671177997569" CI_START="0.9713200568858482" DF="0" EFFECT_SIZE="1.017402471608069" ESTIMABLE="YES" EVENTS_1="915" EVENTS_2="906" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.02762322006497813" LOG_CI_START="-0.0126376433810452" LOG_EFFECT_SIZE="0.00749278834196647" NO="1" P_CHI2="1.0" P_Z="0.4656823455188933" STUDIES="1" TAU2="0.0" TOTAL_1="1217" TOTAL_2="1226" WEIGHT="69.31118173864479" Z="0.7295221233257682">
<NAME>&lt; 34 weeks</NAME>
<DICH_DATA CI_END="1.065671177997569" CI_START="0.9713200568858482" EFFECT_SIZE="1.017402471608069" ESTIMABLE="YES" EVENTS_1="915" EVENTS_2="906" LOG_CI_END="0.02762322006497813" LOG_CI_START="-0.0126376433810452" LOG_EFFECT_SIZE="0.00749278834196647" ORDER="86519" O_E="0.0" SE="0.023649430482682338" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="1217" TOTAL_2="1226" VAR="5.592955621552246E-4" WEIGHT="69.31118173864479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.170290831878644" CI_START="0.9042936219771364" DF="0" EFFECT_SIZE="1.0287305454423792" ESTIMABLE="YES" EVENTS_1="415" EVENTS_2="396" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.06829380275843785" LOG_CI_START="-0.043690532246169575" LOG_EFFECT_SIZE="0.012301635256134143" NO="2" P_CHI2="1.0" P_Z="0.6667522972615657" STUDIES="1" TAU2="0.0" TOTAL_1="3321" TOTAL_2="3260" WEIGHT="30.688818261355205" Z="0.4306095500228508">
<NAME>&gt;/= 34 weeks</NAME>
<DICH_DATA CI_END="1.170290831878644" CI_START="0.9042936219771364" EFFECT_SIZE="1.0287305454423792" ESTIMABLE="YES" EVENTS_1="415" EVENTS_2="396" LOG_CI_END="0.06829380275843785" LOG_CI_START="-0.043690532246169575" LOG_EFFECT_SIZE="0.012301635256134143" ORDER="86520" O_E="0.0" SE="0.0657801527131048" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="3321" TOTAL_2="3260" VAR="0.0043270284909593905" WEIGHT="30.688818261355205"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:07:04 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gestation not specified</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-07-08 13:10:23 +0200" MODIFIED_BY="Denise Atherton" NO="4">
<NAME>Magnesium sulphate versus none/placebo (subgroups by whether anticonvulsant before trial entry)</NAME>
<DICH_OUTCOME CHI2="0.7554459741353001" CI_END="1.0892683257735103" CI_START="0.26066973493489476" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5328595366063721" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.037134875208996714" LOG_CI_START="-0.583909389674707" LOG_EFFECT_SIZE="-0.2733872572328551" METHOD="MH" MODIFIED="2010-07-08 13:07:14 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.6854205012110953" P_Q="0.0" P_Z="0.08442392956598414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5374" TOTAL_2="5358" WEIGHT="100.0" Z="1.7255748367917785">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.88245369971785" CI_START="0.2010996616317398" DF="0" EFFECT_SIZE="0.9908883826879271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.6886381335671854" LOG_CI_START="-0.6965886601421536" LOG_EFFECT_SIZE="-0.003975263287484037" MODIFIED="2010-07-08 13:07:10 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.9910245960591615" STUDIES="1" TAU2="0.0" TOTAL_1="439" TOTAL_2="435" WEIGHT="13.992864561240012" Z="0.01124923789796094">
<NAME>Anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="4.882453699717848" CI_START="0.20109966163173987" EFFECT_SIZE="0.9908883826879271" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6886381335671853" LOG_CI_START="-0.6965886601421534" LOG_EFFECT_SIZE="-0.003975263287484037" ORDER="86521" O_E="0.0" SE="0.8136890756080825" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="439" TOTAL_2="435" VAR="0.6620899117639357" WEIGHT="13.992864561240012"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04504670698620425" CI_END="1.031471824707786" CI_START="0.20366660868654557" DF="1" EFFECT_SIZE="0.458340886779652" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.01345736944823478" LOG_CI_START="-0.6910801681127068" LOG_EFFECT_SIZE="-0.338811399332236" MODIFIED="2010-07-08 13:07:14 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.8319183123662321" P_Z="0.05941776191190331" STUDIES="2" TAU2="0.0" TOTAL_1="4935" TOTAL_2="4923" WEIGHT="86.00713543875999" Z="1.8850894518458805">
<NAME>No anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.0876640340733053" CI_START="0.20298395339515168" EFFECT_SIZE="0.46987056260412663" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.0364947678985953" LOG_CI_START="-0.6925382932562053" LOG_EFFECT_SIZE="-0.32802176267880495" ORDER="86522" O_E="0.0" SE="0.4282376288941841" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4590" TOTAL_2="4583" VAR="0.18338746680091292" WEIGHT="78.9918893707524"/>
<DICH_DATA CI_END="8.036092759233755" CI_START="0.013429786541454108" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" ORDER="86523" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="7.015246068007587"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.549795296553935" CI_END="0.5758697730316308" CI_START="0.28680382536895427" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4064008536160119" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="107" I2="65.36735156515316" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.23967571666037876" LOG_CI_START="-0.5424150603768015" LOG_EFFECT_SIZE="-0.39104538851859016" METHOD="MH" MODIFIED="2010-07-08 13:09:58 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.021032825678587885" P_Q="0.0" P_Z="4.1199181601057965E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5696" TOTAL_2="5685" WEIGHT="100.0" Z="5.063331831325053">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1086191945231625" CI_START="0.49351683853907663" DF="0" EFFECT_SIZE="1.2386104783599088" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.4925675242797709" LOG_CI_START="-0.30669802483862624" LOG_EFFECT_SIZE="0.09293474972057233" MODIFIED="2010-07-08 13:07:18 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.6485407451625298" STUDIES="1" TAU2="0.0" TOTAL_1="439" TOTAL_2="435" WEIGHT="7.429496129722995" Z="0.45579035044229965">
<NAME>Anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="3.1086191945231625" CI_START="0.49351683853907663" EFFECT_SIZE="1.2386104783599088" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4925675242797709" LOG_CI_START="-0.30669802483862624" LOG_EFFECT_SIZE="0.09293474972057233" ORDER="86524" O_E="0.0" SE="0.46949253998042306" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="439" TOTAL_2="435" VAR="0.22042324509726913" WEIGHT="7.429496129722995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4972861236087316" CI_END="0.48357533998333896" CI_START="0.21995624837866232" DF="2" EFFECT_SIZE="0.32613711470970513" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="99" I2="42.81280028823414" ID="CMP-004.02.02" LOG_CI_END="-0.3155358541764988" LOG_CI_START="-0.657663696347587" LOG_EFFECT_SIZE="-0.48659977526204296" MODIFIED="2010-07-08 13:07:21 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.17401024651643882" P_Z="2.472252078020069E-8" STUDIES="3" TAU2="0.0" TOTAL_1="5047" TOTAL_2="5039" WEIGHT="92.1116497497001" Z="5.5752143897248905">
<NAME>No anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="0.5141074378262211" CI_START="0.22537078712628197" EFFECT_SIZE="0.3403891859774213" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="88" LOG_CI_END="-0.28894611295164213" LOG_CI_START="-0.6471023784943193" LOG_EFFECT_SIZE="-0.4680242457229808" ORDER="86525" O_E="0.0" SE="0.21038276328187605" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4590" TOTAL_2="4583" VAR="0.0442609070861179" WEIGHT="81.41421699401806"/>
<DICH_DATA CI_END="75.45596071768202" CI_START="0.1278685654793144" EFFECT_SIZE="3.106194690265487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8776935529856453" LOG_CI_START="-0.8932362070208368" LOG_EFFECT_SIZE="0.49222867298240436" ORDER="86526" O_E="0.0" SE="1.6276578573513336" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="2.6492701005975343" WEIGHT="0.45418929927435286"/>
<DICH_DATA CI_END="0.6901371054307739" CI_START="0.011630513657496754" EFFECT_SIZE="0.08959156785243742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.16106462199174001" LOG_CI_START="-1.9344011043867484" LOG_EFFECT_SIZE="-1.047732863189244" ORDER="86527" O_E="0.0" SE="1.0416666279159879" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="1.0850693637138649" WEIGHT="10.243243456407697"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.4237999629299" CI_START="0.1262077453606798" DF="0" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" MODIFIED="2010-07-08 13:09:58 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.49305190121294695" STUDIES="3" TAU2="0.0" TOTAL_1="210" TOTAL_2="211" WEIGHT="0.4588541205768929" Z="0.6854628484988398">
<NAME>Unclear whether anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 21:38:21 +0100" MODIFIED_BY="Lelia Duley" ORDER="299" O_E="0.0" SE="0.0" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.4237999629299" CI_START="0.1262077453606798" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" MODIFIED="2010-02-17 21:38:15 +0100" MODIFIED_BY="Lelia Duley" ORDER="298" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="0.4588541205768929"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-17 21:38:07 +0100" MODIFIED_BY="Lelia Duley" ORDER="297" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07664623373340385" CI_END="1.2948926739744502" CI_START="0.8720816943315258" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0626627861636628" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.11223377379775919" LOG_CI_START="-0.059442829590914445" LOG_EFFECT_SIZE="0.026395472103422378" METHOD="MH" MODIFIED="2010-07-08 13:10:07 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.7818948628084362" P_Q="0.0" P_Z="0.5467127011740778" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5029" TOTAL_2="5018" WEIGHT="100.0" Z="0.6026933624789169">
<NAME>Serious maternal morbidity</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8476747139556478" CI_START="0.6940773177194317" DF="0" EFFECT_SIZE="1.1324438659290597" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.2666255153858358" LOG_CI_START="-0.15859214800543023" LOG_EFFECT_SIZE="0.05401668369020275" MODIFIED="2010-07-08 13:10:04 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.6185120362042495" STUDIES="1" TAU2="0.0" TOTAL_1="439" TOTAL_2="435" WEIGHT="15.349901607191626" Z="0.4979602858109498">
<NAME>Anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.8476747139556478" CI_START="0.6940773177194317" EFFECT_SIZE="1.1324438659290597" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.2666255153858358" LOG_CI_START="-0.15859214800543023" LOG_EFFECT_SIZE="0.05401668369020275" ORDER="86530" O_E="0.0" SE="0.24977496033741023" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="439" TOTAL_2="435" VAR="0.06238753081155485" WEIGHT="15.349901607191626"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.303228321610018" CI_START="0.8459908121782546" DF="0" EFFECT_SIZE="1.0500091362709958" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="155" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.11502050944141233" LOG_CI_START="-0.07263435355902897" LOG_EFFECT_SIZE="0.021193077941191667" MODIFIED="2010-07-08 13:10:07 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.6579806962928993" STUDIES="1" TAU2="0.0" TOTAL_1="4590" TOTAL_2="4583" WEIGHT="84.65009839280837" Z="0.4427028303144829">
<NAME>No anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.303228321610018" CI_START="0.8459908121782546" EFFECT_SIZE="1.0500091362709958" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="155" LOG_CI_END="0.11502050944141233" LOG_CI_START="-0.07263435355902897" LOG_EFFECT_SIZE="0.021193077941191667" ORDER="86531" O_E="0.0" SE="0.11022939543301227" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4590" TOTAL_2="4583" VAR="0.012150519617527387" WEIGHT="84.65009839280837"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.63803928267" CI_END="1.1402251697615033" CI_START="0.9254492049356012" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0272392500305585" ESTIMABLE="YES" EVENTS_1="628" EVENTS_2="604" I2="68.87333707599376" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.05699062355452109" LOG_CI_START="-0.03364741334713164" LOG_EFFECT_SIZE="0.011671605103694742" METHOD="MH" MODIFIED="2010-07-08 13:10:14 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="0.0219073237310784" P_Q="0.0" P_Z="0.6137165980644927" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4978" TOTAL_2="4923" WEIGHT="100.0" Z="0.5047753995342424">
<NAME>Stillbirths and neonatal deaths</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.997661755657796" CI_START="1.1087183725595875" DF="0" EFFECT_SIZE="1.488235294117647" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="60" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.300521955317883" LOG_CI_START="0.04482124427720507" LOG_EFFECT_SIZE="0.172671599797544" MODIFIED="2010-07-08 13:10:11 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.008119014779123074" STUDIES="1" TAU2="0.0" TOTAL_1="408" TOTAL_2="396" WEIGHT="10.02299074912836" Z="2.647079981738972">
<NAME>Anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.997661755657796" CI_START="1.1087183725595875" EFFECT_SIZE="1.488235294117647" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="60" LOG_CI_END="0.300521955317883" LOG_CI_START="0.04482124427720507" LOG_EFFECT_SIZE="0.172671599797544" ORDER="86532" O_E="0.0" SE="0.15019986340422745" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="408" TOTAL_2="396" VAR="0.022559998966648582" WEIGHT="10.02299074912836"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6911433359064105" CI_END="1.0914149683082137" CI_START="0.8725871069058903" DF="2" EFFECT_SIZE="0.9758865864586151" ESTIMABLE="YES" EVENTS_1="536" EVENTS_2="544" I2="25.68214508253329" ID="CMP-004.04.02" LOG_CI_END="0.037989905658492" LOG_CI_START="-0.05919120831114444" LOG_EFFECT_SIZE="-0.01060065132632621" MODIFIED="2010-07-08 13:10:14 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.26039100034765084" P_Z="0.6689487714613895" STUDIES="3" TAU2="0.0" TOTAL_1="4570" TOTAL_2="4527" WEIGHT="89.97700925087165" Z="0.4275912049898446">
<NAME>No anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.0823520167655756" CI_START="0.8544362640798554" EFFECT_SIZE="0.9616656454425704" ESTIMABLE="YES" EVENTS_1="478" EVENTS_2="491" LOG_CI_END="0.03436853071092141" LOG_CI_START="-0.06832032754919014" LOG_EFFECT_SIZE="-0.016975898419134345" ORDER="86533" O_E="0.0" SE="0.060319943660035985" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4105" TOTAL_2="4055" VAR="0.0036384956031499153" WEIGHT="81.31046778865583"/>
<DICH_DATA CI_END="1.3700427593012603" CI_START="0.4751581068458393" EFFECT_SIZE="0.8068376068376069" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.13673412178326494" LOG_CI_START="-0.3231618566794502" LOG_EFFECT_SIZE="-0.09321386744809265" ORDER="86534" O_E="0.0" SE="0.2701451742708076" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.072978415181805" WEIGHT="4.097320842846121"/>
<DICH_DATA CI_END="2.1982456779839024" CI_START="0.8670076685312144" EFFECT_SIZE="1.3805418719211822" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.34207622795565035" LOG_CI_START="-0.061977061248054695" LOG_EFFECT_SIZE="0.14004958335379783" ORDER="86535" O_E="0.0" SE="0.23734290217429502" STUDY_ID="STD-South-Africa-1998" TOTAL_1="348" TOTAL_2="354" VAR="0.05633165321251697" WEIGHT="4.569220619369694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.676895759744256" CI_END="1.0775859295257573" CI_START="0.9472695513992769" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0103288276873212" ESTIMABLE="YES" EVENTS_1="1320" EVENTS_2="1288" I2="72.80314522515715" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.03245191199368167" LOG_CI_START="-0.023526422234344598" LOG_EFFECT_SIZE="0.004462744879668519" METHOD="MH" MODIFIED="2010-07-08 13:10:23 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="0.05517169595187399" P_Q="0.0" P_Z="0.7546550113245933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4513" TOTAL_2="4452" WEIGHT="100.0" Z="0.3125073068702224">
<NAME>Death or in special care baby unit &gt; 7 days</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3933322446226382" CI_START="0.9976999969142225" DF="0" EFFECT_SIZE="1.1790367153572838" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="149" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.14405468770999091" LOG_CI_START="-0.001000029124905261" LOG_EFFECT_SIZE="0.07152732929254282" MODIFIED="2010-07-08 13:10:19 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.05324366236899517" STUDIES="1" TAU2="0.0" TOTAL_1="408" TOTAL_2="396" WEIGHT="11.658949813471896" Z="1.9329394091098548">
<NAME>Anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.3933322446226382" CI_START="0.9976999969142225" EFFECT_SIZE="1.1790367153572838" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="149" LOG_CI_END="0.14405468770999091" LOG_CI_START="-0.001000029124905261" LOG_EFFECT_SIZE="0.07152732929254282" ORDER="86536" O_E="0.0" SE="0.08520585870124663" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="408" TOTAL_2="396" VAR="0.007260038357016805" WEIGHT="11.658949813471896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.059420996726174" CI_START="0.9215119973248581" DF="0" EFFECT_SIZE="0.9880633373934227" ESTIMABLE="YES" EVENTS_1="1139" EVENTS_2="1139" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.025068575992397663" LOG_CI_START="-0.03549900625275766" LOG_EFFECT_SIZE="-0.005215215130180009" MODIFIED="2010-07-08 13:10:23 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.735718750178393" STUDIES="1" TAU2="0.0" TOTAL_1="4105" TOTAL_2="4056" WEIGHT="88.34105018652811" Z="0.33752821056676047">
<NAME>No anticonvulsant before trial entry</NAME>
<DICH_DATA CI_END="1.059420996726174" CI_START="0.9215119973248581" EFFECT_SIZE="0.9880633373934227" ESTIMABLE="YES" EVENTS_1="1139" EVENTS_2="1139" LOG_CI_END="0.025068575992397663" LOG_CI_START="-0.03549900625275766" LOG_EFFECT_SIZE="-0.005215215130180009" ORDER="86537" O_E="0.0" SE="0.035577697625171704" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="4105" TOTAL_2="4056" VAR="0.0012657725683081484" WEIGHT="88.34105018652811"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-07-08 13:11:08 +0200" MODIFIED_BY="Denise Atherton" NO="5">
<NAME>Magnesium sulphate versus none/placebo (subgroups by dose and route of administration for maintenance therapy)</NAME>
<DICH_OUTCOME CHI2="0.2821458985628312" CI_END="1.090627266592198" CI_START="0.2610623640948651" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.533593227620891" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.03767635121115837" LOG_CI_START="-0.5832557334779112" LOG_EFFECT_SIZE="-0.27278969113337637" METHOD="MH" MODIFIED="2010-07-08 13:10:36 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.8684259680397419" P_Q="0.0" P_Z="0.08504883919930149" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5400" TOTAL_2="5395" WEIGHT="100.0" Z="1.722114167261793">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4760924261728288" CI_START="0.2545515270736689" DF="0" EFFECT_SIZE="0.6129776351419115" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.16911355187734753" LOG_CI_START="-0.594224293253716" LOG_EFFECT_SIZE="-0.21255537068818423" MODIFIED="2010-07-08 13:10:29 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.2750422994901255" STUDIES="1" TAU2="0.0" TOTAL_1="2301" TOTAL_2="2292" WEIGHT="60.513314273051876" Z="1.0915242154615623">
<NAME>Intramuscular maintenance regimen</NAME>
<DICH_DATA CI_END="1.4760924261728288" CI_START="0.2545515270736689" EFFECT_SIZE="0.6129776351419115" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.16911355187734753" LOG_CI_START="-0.594224293253716" LOG_EFFECT_SIZE="-0.21255537068818423" ORDER="86538" O_E="0.0" SE="0.4483884288132603" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2301" TOTAL_2="2292" VAR="0.20105218309362421" WEIGHT="60.513314273051876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.02310532147178877" CI_END="1.4285961531632287" CI_START="0.1187822278652403" DF="1" EFFECT_SIZE="0.4119366866308953" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.15490947634834998" LOG_CI_START="-0.9252485334073167" LOG_EFFECT_SIZE="-0.3851695285294833" MODIFIED="2010-07-08 13:10:33 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.8791835212962379" P_Z="0.16217537530833973" STUDIES="2" TAU2="0.0" TOTAL_1="3099" TOTAL_2="3103" WEIGHT="39.48668572694812" Z="1.3977925396874553">
<NAME>Intravenous maintenance regimen - 1 g/hour</NAME>
<DICH_DATA CI_END="1.6610308359036474" CI_START="0.1113019139396022" EFFECT_SIZE="0.42997198879551823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.22037769490683842" LOG_CI_START="-0.9534973675048142" LOG_EFFECT_SIZE="-0.3665598362989879" ORDER="86539" O_E="0.0" SE="0.6895400224358786" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2754" TOTAL_2="2763" VAR="0.47546544254087203" WEIGHT="32.46731734978827"/>
<DICH_DATA CI_END="8.036092759233755" CI_START="0.013429786541454108" EFFECT_SIZE="0.3285163776493256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050449410915008" LOG_CI_START="-1.8719308901313836" LOG_EFFECT_SIZE="-0.48344297451994134" ORDER="86540" O_E="0.0" SE="1.6312093495123836" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="2.660843941936614" WEIGHT="7.019368377159851"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:10:36 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravenous maintenance regimen - 2 g/hour</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.698531484455678" CI_END="0.5769361124998024" CI_START="0.28743617978987407" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4072251369448652" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="107" I2="29.80647714396056" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.23887227614232626" LOG_CI_START="-0.5414585678156619" LOG_EFFECT_SIZE="-0.3901654219789941" METHOD="MH" MODIFIED="2010-07-08 13:10:46 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.22282177382661383" P_Q="0.0" P_Z="4.3153515879655177E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5722" TOTAL_2="5722" WEIGHT="100.0" Z="5.0544931884572115">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6727973367962294" CI_END="0.6460908332924531" CI_START="0.2397255869170734" DF="1" EFFECT_SIZE="0.3935536865699194" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="54" I2="40.21989526147756" ID="CMP-005.02.01" LOG_CI_END="-0.18970642066660434" LOG_CI_START="-0.6202856094213153" LOG_EFFECT_SIZE="-0.40499601504395977" MODIFIED="2010-07-08 13:10:41 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.1958843488866524" P_Z="2.2689319948193332E-4" STUDIES="2" TAU2="0.0" TOTAL_1="2413" TOTAL_2="2408" WEIGHT="50.503671542416264" Z="3.687022615580227">
<NAME>Intramuscular maintenance regimen</NAME>
<DICH_DATA CI_END="0.6142208802590621" CI_START="0.22158679954317545" EFFECT_SIZE="0.36892172485392827" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="54" LOG_CI_END="-0.2116754239281916" LOG_CI_START="-0.654456115136365" LOG_EFFECT_SIZE="-0.4330657695322783" ORDER="86541" O_E="0.0" SE="0.2600915698154514" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2301" TOTAL_2="2292" VAR="0.06764762468906582" WEIGHT="50.04920298203915"/>
<DICH_DATA CI_END="75.45596071768202" CI_START="0.1278685654793144" EFFECT_SIZE="3.106194690265487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8776935529856453" LOG_CI_START="-0.8932362070208368" LOG_EFFECT_SIZE="0.49222867298240436" ORDER="86542" O_E="0.0" SE="1.6276578573513336" STUDY_ID="STD-South-Africa-1994" TOTAL_1="112" TOTAL_2="116" VAR="2.6492701005975343" WEIGHT="0.45446856037711597"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.513692049995603" CI_END="0.6556853711214155" CI_START="0.239908322451071" DF="1" EFFECT_SIZE="0.39661615882544005" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="53" I2="60.217879513055344" ID="CMP-005.02.02" LOG_CI_END="-0.183304505691603" LOG_CI_START="-0.6199546860384911" LOG_EFFECT_SIZE="-0.4016295958650471" MODIFIED="2010-07-08 13:10:44 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.1128615353878285" P_Z="3.1150616547423406E-4" STUDIES="3" TAU2="0.0" TOTAL_1="3133" TOTAL_2="3133" WEIGHT="49.03719220770983" Z="3.6055386139793186">
<NAME>Intravenous maintenance regimen - 1 g/hour</NAME>
<DICH_DATA CI_END="0.8115451728239569" CI_START="0.28124357492208313" EFFECT_SIZE="0.47774665421724244" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="42" LOG_CI_END="-0.09068730114623733" LOG_CI_START="-0.5509173903303882" LOG_EFFECT_SIZE="-0.3208023457383128" ORDER="86543" O_E="0.0" SE="0.27034143256245363" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2754" TOTAL_2="2763" VAR="0.07308449015991968" WEIGHT="38.787650629642116"/>
<DICH_DATA CI_END="0.6901371054307739" CI_START="0.011630513657496754" EFFECT_SIZE="0.08959156785243742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.16106462199174001" LOG_CI_START="-1.9344011043867484" LOG_EFFECT_SIZE="-1.047732863189244" ORDER="86544" O_E="0.0" SE="1.0416666279159879" STUDY_ID="STD-South-Africa-1998" TOTAL_1="345" TOTAL_2="340" VAR="1.0850693637138649" WEIGHT="10.249541578067713"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86545" O_E="0.0" SE="0.0" STUDY_ID="STD-Taiwan-1995" TOTAL_1="34" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.4237999629299" CI_START="0.1262077453606798" DF="0" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" MODIFIED="2010-07-08 13:10:46 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.49305190121294695" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="181" WEIGHT="0.45913624987391605" Z="0.6854628484988398">
<NAME>Intravenous maintenance regimen - 2 g/hour</NAME>
<DICH_DATA CI_END="73.4237999629299" CI_START="0.1262077453606798" EFFECT_SIZE="3.0441176470588234" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8658368571528006" LOG_CI_START="-0.8989139916514377" LOG_EFFECT_SIZE="0.48346143275068143" ORDER="86546" O_E="0.0" SE="1.6240283343250317" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="2.637468030690537" WEIGHT="0.45913624987391605"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86547" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Tennessee-2001" TOTAL_1="109" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3543699567457415" CI_END="1.1434577563451176" CI_START="0.9306985146113745" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0316076944998307" ESTIMABLE="YES" EVENTS_1="635" EVENTS_2="611" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.05822012475816263" LOG_CI_START="-0.031190979217686866" LOG_EFFECT_SIZE="0.013514572770237888" METHOD="MH" MODIFIED="2010-07-08 13:10:57 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.502185313846447" P_Q="0.0" P_Z="0.5535152795792934" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5003" TOTAL_2="4958" WEIGHT="100.0" Z="0.5925008129474961">
<NAME>Stillbirths and neonatal deaths</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.751482866546358" CI_END="1.1496537866516348" CI_START="0.892579007490724" DF="1" EFFECT_SIZE="1.0129939959582528" ESTIMABLE="YES" EVENTS_1="400" EVENTS_2="393" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.060567074106305234" LOG_CI_START="-0.04935333151985557" LOG_EFFECT_SIZE="0.005606871293224811" MODIFIED="2010-07-08 13:10:51 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.38600718537043466" P_Z="0.841520066385743" STUDIES="2" TAU2="0.0" TOTAL_1="2288" TOTAL_2="2277" WEIGHT="64.22922120679212" Z="0.1999495132513727">
<NAME>Intramuscular maintenance regimen</NAME>
<DICH_DATA CI_END="1.1699093729034455" CI_START="0.9013738889375318" EFFECT_SIZE="1.0269010474035207" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="368" LOG_CI_END="0.06815222040225322" LOG_CI_START="-0.04509502675604679" LOG_EFFECT_SIZE="0.011528596823103246" ORDER="86548" O_E="0.0" SE="0.06652199356369985" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2171" TOTAL_2="2159" VAR="0.004425175627688924" WEIGHT="60.17021403451808"/>
<DICH_DATA CI_END="1.3700427593012603" CI_START="0.4751581068458393" EFFECT_SIZE="0.8068376068376069" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.13673412178326494" LOG_CI_START="-0.3231618566794502" LOG_EFFECT_SIZE="-0.09321386744809265" ORDER="86549" O_E="0.0" SE="0.2701451742708076" STUDY_ID="STD-South-Africa-1994" TOTAL_1="117" TOTAL_2="118" VAR="0.072978415181805" WEIGHT="4.05900717227404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3980098324611487" CI_END="1.2704390701685608" CI_START="0.8928322614832442" DF="1" EFFECT_SIZE="1.0650300409355908" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="218" I2="28.46974486298612" ID="CMP-005.03.02" LOG_CI_END="0.10395384126823841" LOG_CI_START="-0.04923012538340909" LOG_EFFECT_SIZE="0.027361857942414677" MODIFIED="2010-07-08 13:10:54 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.23705728811506843" P_Z="0.4838142427898411" STUDIES="2" TAU2="0.0" TOTAL_1="2715" TOTAL_2="2681" WEIGHT="35.77077879320788" Z="0.7001810605830426">
<NAME>Intravenous maintenance regimen - 1 g/hour</NAME>
<DICH_DATA CI_END="1.2337273921182712" CI_START="0.8421749002137093" EFFECT_SIZE="1.0193204811775955" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="190" LOG_CI_END="0.09121920736503425" LOG_CI_START="-0.07459770623221186" LOG_EFFECT_SIZE="0.008310750566411205" ORDER="86550" O_E="0.0" SE="0.09740167585398246" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2367" TOTAL_2="2327" VAR="0.009487086459164271" WEIGHT="31.244284535843097"/>
<DICH_DATA CI_END="2.1982456779839024" CI_START="0.8670076685312144" EFFECT_SIZE="1.3805418719211822" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.34207622795565035" LOG_CI_START="-0.061977061248054695" LOG_EFFECT_SIZE="0.14004958335379783" ORDER="86551" O_E="0.0" SE="0.23734290217429502" STUDY_ID="STD-South-Africa-1998" TOTAL_1="348" TOTAL_2="354" VAR="0.05633165321251697" WEIGHT="4.526494257364788"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:10:57 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravenous maintenance regimen - 2 g/hour</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7864953684523397" CI_END="5.88835469951227" CI_START="4.519997444748089" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="5.159006512456236" ESTIMABLE="YES" EVENTS_1="1239" EVENTS_2="240" I2="47.18070919449023" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.7699939629125282" LOG_CI_START="0.6551381892954267" LOG_EFFECT_SIZE="0.7125660761039774" METHOD="MH" MODIFIED="2010-07-08 13:11:08 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="0.15058208325654854" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5066" TOTAL_2="5061" WEIGHT="100.0" Z="24.319262354624456">
<NAME>Any reported side effects</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.089156318696569" CI_START="4.803115013274378" DF="0" EFFECT_SIZE="5.835240624497023" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="109" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.8505945528224574" LOG_CI_START="0.6815229861876541" LOG_EFFECT_SIZE="0.7660587695050558" MODIFIED="2010-07-08 13:11:01 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="1.4146227515610228E-70" STUDIES="1" TAU2="0.0" TOTAL_1="2280" TOTAL_2="2273" WEIGHT="45.47572719935734" Z="17.761089320407443">
<NAME>Intramuscular maintenance regimen</NAME>
<DICH_DATA CI_END="7.089156318696569" CI_START="4.803115013274378" EFFECT_SIZE="5.835240624497023" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="109" LOG_CI_END="0.8505945528224574" LOG_CI_START="0.6815229861876541" LOG_EFFECT_SIZE="0.7660587695050558" ORDER="86552" O_E="0.0" SE="0.09931347515903595" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2280" TOTAL_2="2273" VAR="0.009863166348164452" WEIGHT="45.47572719935734"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.655955075641361" CI_START="3.8625054213538337" DF="0" EFFECT_SIZE="4.673987285241423" ESTIMABLE="YES" EVENTS_1="556" EVENTS_2="119" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.7525059512700057" LOG_CI_START="0.586869102002445" LOG_EFFECT_SIZE="0.6696875266362253" MODIFIED="2010-07-08 13:11:04 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="1.4354487772564136E-56" STUDIES="1" TAU2="0.0" TOTAL_1="2719" TOTAL_2="2720" WEIGHT="49.56248441503858" Z="15.848688729673501">
<NAME>Intravenous maintenance regimen - 1 g/hour</NAME>
<DICH_DATA CI_END="5.655955075641361" CI_START="3.8625054213538337" EFFECT_SIZE="4.673987285241423" ESTIMABLE="YES" EVENTS_1="556" EVENTS_2="119" LOG_CI_END="0.7525059512700057" LOG_CI_START="0.586869102002445" LOG_EFFECT_SIZE="0.6696875266362253" ORDER="86553" O_E="0.0" SE="0.09729590517539254" STUDY_ID="STD-Magpie-Trial-2002" TOTAL_1="2719" TOTAL_2="2720" VAR="0.009466493163898975" WEIGHT="49.56248441503858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.531434158685094" CI_START="2.2177990966576115" DF="0" EFFECT_SIZE="3.8059701492537314" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="12" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="0.8150085532224491" LOG_CI_START="0.3459222022438084" LOG_EFFECT_SIZE="0.5804653777331288" MODIFIED="2010-07-08 13:11:08 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="1.230459408712076E-6" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="4.961788385604075" Z="4.850668676484999">
<NAME>Intravenous maintenance regimen - 2 g/hour</NAME>
<DICH_DATA CI_END="6.531434158685094" CI_START="2.2177990966576115" EFFECT_SIZE="3.8059701492537314" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="12" LOG_CI_END="0.8150085532224491" LOG_CI_START="0.3459222022438084" LOG_EFFECT_SIZE="0.5804653777331288" ORDER="86554" O_E="0.0" SE="0.2755436445797399" STUDY_ID="STD-USA-_x002d_-Memphis-1997" TOTAL_1="67" TOTAL_2="68" VAR="0.07592430006828602" WEIGHT="4.961788385604075"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-07-08 13:14:54 +0200" MODIFIED_BY="Denise Atherton" NO="6">
<NAME>Magnesium sulphate versus phenytoin</NAME>
<DICH_OUTCOME CHI2="0.477153684865931" CI_END="0.601408346250073" CI_START="0.010333249739675952" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07883211678832118" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.2208305491234303" LOG_CI_START="-1.9857630742154835" LOG_EFFECT_SIZE="-1.103296811669457" METHOD="MH" MODIFIED="2010-06-23 13:03:49 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48971445610900677" P_Q="0.0" P_Z="0.014268560834798863" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1134" TOTAL_2="1157" WEIGHT="100.0" Z="2.45043023955516">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phenytoin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9664412916709404" CI_START="0.010084606592815406" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5984010305641998" LOG_CI_START="-1.9963410392362373" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-06-23 13:03:49 +0200" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-India-2008" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="19.525547445255476"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86555" O_E="0.0" SE="0.0" STUDY_ID="STD-USA-_x002d_-Maryland-1993" TOTAL_1="60" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8425135686743809" CI_START="0.0029004067312475715" EFFECT_SIZE="0.04943310657596372" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.07442309609109456" LOG_CI_START="-2.537541095635373" LOG_EFFECT_SIZE="-1.3059820958632338" ORDER="86556" O_E="0.0" SE="1.446847705563047" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1049" TOTAL_2="1089" VAR="2.093368283093054" WEIGHT="80.47445255474453"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5135785952997851" CI_END="1.0472306671789704" CI_START="0.881126113553554" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9605947573068997" ESTIMABLE="YES" EVENTS_1="669" EVENTS_2="723" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.02004235164009172" LOG_CI_START="-0.05496192756907292" LOG_EFFECT_SIZE="-0.017459787964490606" METHOD="MH" MODIFIED="2010-07-08 13:14:38 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.473593861759078" P_Q="0.0" P_Z="0.36150763965961397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2098" TOTAL_2="2178" WEIGHT="200.0" Z="0.9124960855280408">
<NAME>Complications of labour</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magneisum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phenytoin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7975960875198224E-30" CI_END="1.0540571818888087" CI_START="0.8198843786157237" DF="0" EFFECT_SIZE="0.9296262784572877" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="354" I2="100.0" ID="CMP-006.02.01" LOG_CI_END="0.0228641716973574" LOG_CI_START="-0.08624738818899587" LOG_EFFECT_SIZE="-0.03169160824581927" MODIFIED="2010-07-08 13:14:35 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.0" P_Z="0.2548914664748807" STUDIES="1" TAU2="0.0" TOTAL_1="1049" TOTAL_2="1089" WEIGHT="100.0" Z="1.138548671445162">
<NAME>Induction of labour</NAME>
<DICH_DATA CI_END="1.0540571818888087" CI_START="0.8198843786157237" EFFECT_SIZE="0.9296262784572878" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="354" LOG_CI_END="0.0228641716973574" LOG_CI_START="-0.08624738818899587" LOG_EFFECT_SIZE="-0.031691608245819215" ORDER="86557" O_E="0.0" SE="0.06409267038817613" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1049" TOTAL_2="1089" VAR="0.004107870397487391" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1153232020602692" CI_START="0.8792991247085948" DF="0" EFFECT_SIZE="0.9903043549024623" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="369" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.04740073691929221" LOG_CI_START="-0.0558633591567167" LOG_EFFECT_SIZE="-0.0042313111187122585" MODIFIED="2010-07-08 13:14:38 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.8723915142293472" STUDIES="1" TAU2="0.0" TOTAL_1="1049" TOTAL_2="1089" WEIGHT="100.0" Z="0.16062150767204858">
<NAME>Augmentation of labour</NAME>
<DICH_DATA CI_END="1.1153232020602692" CI_START="0.8792991247085948" EFFECT_SIZE="0.9903043549024623" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="369" LOG_CI_END="0.04740073691929221" LOG_CI_START="-0.0558633591567167" LOG_EFFECT_SIZE="-0.0042313111187122585" ORDER="86558" O_E="0.0" SE="0.06065784120056718" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1049" TOTAL_2="1089" VAR="0.003679373699113225" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4079256841916224" CI_END="1.4006552219206247" CI_START="1.043924875235477" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2092058665882364" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="249" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.1463312447469687" LOG_CI_START="0.018669246324659945" LOG_EFFECT_SIZE="0.08250024553581432" METHOD="MH" MODIFIED="2009-06-29 16:34:43 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5230242427069278" P_Q="0.0" P_Z="0.011302228688943941" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1077" TOTAL_2="1115" WEIGHT="100.0" Z="2.5332128897278965">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1122046040134155" CI_START="0.4082203477451123" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3247359849271708" LOG_CI_START="-0.3891053516699733" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2009-06-29 16:34:43 +0200" MODIFIED_BY="[Empty name]" ORDER="86559" O_E="0.0" SE="0.4193139346887673" STUDY_ID="STD-USA-_x002d_-Alabama-1995" TOTAL_1="28" TOTAL_2="26" VAR="0.17582417582417584" WEIGHT="3.389184236930383"/>
<DICH_DATA CI_END="1.4155035081394534" CI_START="1.0498629726729087" EFFECT_SIZE="1.2190507458199669" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="241" LOG_CI_END="0.1509109500442644" LOG_CI_START="0.021132618979013466" LOG_EFFECT_SIZE="0.08602178451163894" ORDER="86560" O_E="0.0" SE="0.07623243408082787" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1049" TOTAL_2="1089" VAR="0.005811384005887766" WEIGHT="96.61081576306962"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5415965200219386" CI_END="1.167250646323318" CI_START="0.25410900581172935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5446181242580134" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.06716412307795402" LOG_CI_START="-0.5949799429581673" LOG_EFFECT_SIZE="-0.2639079099401066" METHOD="MH" MODIFIED="2010-07-08 13:14:47 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="0.4617719157097342" P_Q="0.0" P_Z="0.11820583793002755" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2128" TOTAL_2="2202" WEIGHT="200.0" Z="1.5623488157624963">
<NAME>Mortality for the fetus or infant (by time of death)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phenytoin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4126177608654897" CI_START="0.2728784380105277" DF="0" EFFECT_SIZE="0.6208646616541353" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.1500246623408778" LOG_CI_START="-0.5640307795481458" LOG_EFFECT_SIZE="-0.20700305860363397" MODIFIED="2010-07-08 13:14:44 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.2557983101029434" STUDIES="1" TAU2="0.0" TOTAL_1="1064" TOTAL_2="1101" WEIGHT="100.0" Z="1.136378257910714">
<NAME>Stillbirth</NAME>
<DICH_DATA CI_END="1.4126177608654897" CI_START="0.2728784380105277" EFFECT_SIZE="0.6208646616541353" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.1500246623408778" LOG_CI_START="-0.5640307795481458" LOG_EFFECT_SIZE="-0.20700305860363397" ORDER="86561" O_E="0.0" SE="0.4194397011970556" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1064" TOTAL_2="1101" VAR="0.17592966294027526" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3107564619444276" CI_START="0.028961244705468552" DF="0" EFFECT_SIZE="0.2586936090225564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.36375417619869077" LOG_CI_START="-1.5381827768291707" LOG_EFFECT_SIZE="-0.5872143003152399" MODIFIED="2010-07-08 13:14:47 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.226179255813293" STUDIES="1" TAU2="0.0" TOTAL_1="1064" TOTAL_2="1101" WEIGHT="100.0" Z="1.2102597596545022">
<NAME>Neonatal death</NAME>
<DICH_DATA CI_END="2.3107564619444285" CI_START="0.028961244705468528" EFFECT_SIZE="0.2586936090225564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.363754176198691" LOG_CI_START="-1.538182776829171" LOG_EFFECT_SIZE="-0.5872143003152399" MODIFIED="2009-06-29 16:43:38 +0200" MODIFIED_BY="[Empty name]" ORDER="86562" O_E="0.0" SE="1.1172071809483224" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1064" TOTAL_2="1101" VAR="1.2481518851624975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3113383186518512" CI_END="1.2952454101761808" CI_START="0.5815662941996333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8679119040981322" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="51" I2="23.742028599601138" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.11235206199858025" LOG_CI_START="-0.23540077179704647" LOG_EFFECT_SIZE="-0.061524354899233115" METHOD="MH" MODIFIED="2010-07-08 13:14:54 +0200" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="0.25215261760315677" P_Q="0.0" P_Z="0.4879878041550344" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2110" TOTAL_2="2172" WEIGHT="200.0" Z="0.6935127944661125">
<NAME>Infant morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3045276617343669" CI_START="0.2570079114097234" DF="0" EFFECT_SIZE="0.5790284360189574" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.115453292490457" LOG_CI_START="-0.5900535076854234" LOG_EFFECT_SIZE="-0.2373001075974832" MODIFIED="2010-07-08 13:14:51 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="0.1873417246681983" STUDIES="1" TAU2="0.0" TOTAL_1="1055" TOTAL_2="1086" WEIGHT="100.0" Z="1.3184838595534418">
<NAME>Low Apgar at 5 minutes</NAME>
<DICH_DATA CI_END="1.3045276617343666" CI_START="0.25700791140972346" EFFECT_SIZE="0.5790284360189574" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.11545329249045692" LOG_CI_START="-0.5900535076854234" LOG_EFFECT_SIZE="-0.2373001075974832" ORDER="86563" O_E="0.0" SE="0.4144181867382963" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1055" TOTAL_2="1086" VAR="0.1717424334994574" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5908350032398846" CI_START="0.6285666551536232" DF="0" EFFECT_SIZE="0.9999729180771835" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.20162513822712308" LOG_CI_START="-0.2016486616049307" LOG_EFFECT_SIZE="-1.1761688903843068E-5" MODIFIED="2010-07-08 13:14:54 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.9999087804704654" STUDIES="1" TAU2="0.0" TOTAL_1="1055" TOTAL_2="1086" WEIGHT="100.0" Z="1.1432672620188654E-4">
<NAME>Admission to special care baby unit</NAME>
<DICH_DATA CI_END="1.5908350032398846" CI_START="0.6285666551536232" EFFECT_SIZE="0.9999729180771835" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.20162513822712308" LOG_CI_START="-0.2016486616049307" LOG_EFFECT_SIZE="-1.1761688903843068E-5" ORDER="86564" O_E="0.0" SE="0.23688502625885247" STUDY_ID="STD-USA-_x002d_-Texas-1995" TOTAL_1="1055" TOTAL_2="1086" VAR="0.05611451566565722" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-07-08 13:15:05 +0200" MODIFIED_BY="Denise Atherton" NO="7">
<NAME>Magnesium sulphate versus diazepam</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.31319328145675" CI_START="0.1298454099994229" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4928768494435124" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="37" WEIGHT="100.0" Z="0.6857403698646046">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86565" O_E="0.0" SE="0.0" STUDY_ID="STD-Malaysia-1994" TOTAL_1="10" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="86566" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Mexico-1992" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.872597498479757" CI_END="1.2734646853337555" CI_START="0.7579480442837512" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="65.18830081383756" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.10498690597231998" LOG_CI_START="-0.12036056330490194" LOG_EFFECT_SIZE="-0.0076868286662910065" METHOD="MH" NO="2" P_CHI2="0.09009947296507193" P_Q="0.0" P_Z="0.89362977582246" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="37" WEIGHT="100.0" Z="0.133712682814524">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5891472758702716" CI_START="0.7570059912258946" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.41315675467536045" LOG_CI_START="-0.12090068331888443" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="86567" O_E="0.0" SE="0.3137079827047734" STUDY_ID="STD-Malaysia-1994" TOTAL_1="10" TOTAL_2="18" VAR="0.0984126984126984" WEIGHT="26.315789473684212"/>
<DICH_DATA CI_END="1.0756429962650063" CI_START="0.6456086702147357" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.031668153785016834" LOG_CI_START="-0.19003064588026639" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="86568" O_E="0.0" SE="0.13022697235014483" STUDY_ID="STD-Mexico-1992" TOTAL_1="19" TOTAL_2="19" VAR="0.016959064327485382" WEIGHT="73.6842105263158"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-08 13:15:05 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Stillbirths and neonatal deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:15:02 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Stillbirth</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86569" O_E="0.0" SE="0.0" STUDY_ID="STD-Malaysia-1994" TOTAL_1="10" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-08 13:15:05 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Serinatal death</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86570" O_E="0.0" SE="0.0" STUDY_ID="STD-Malaysia-1994" TOTAL_1="10" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-07-08 13:15:34 +0200" MODIFIED_BY="Denise Atherton" NO="8">
<NAME>Magnesium sulphate versus nimodipine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7685722133822408" CI_START="0.14042310356973975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3285198555956679" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-0.11431532087726962" LOG_CI_START="-0.8525614326094402" LOG_EFFECT_SIZE="-0.48343837674335494" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.010259629988474944" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="2.5669537356269467">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7685722133822407" CI_START="0.14042310356973975" EFFECT_SIZE="0.3285198555956679" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.11431532087726967" LOG_CI_START="-0.8525614326094402" LOG_EFFECT_SIZE="-0.48343837674335494" ORDER="86571" O_E="0.0" SE="0.43364942040866705" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.18805181982077288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="0.0" Z="0.0">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magneisum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86572" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.466319657789349" CI_START="0.14178127980383853" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5913357400722021" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.392049364480752" LOG_CI_START="-0.8483811077608499" LOG_EFFECT_SIZE="-0.2281658716400489" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.47088798815886834" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.7210349969999498">
<NAME>Coagulopathy</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4663196577893487" CI_START="0.14178127980383856" EFFECT_SIZE="0.5913357400722021" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39204936448075195" LOG_CI_START="-0.8483811077608497" LOG_EFFECT_SIZE="-0.2281658716400489" ORDER="86573" O_E="0.0" SE="0.7286349996245828" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.5309089626779158" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.905909424532759" CI_START="1.0118590119010693" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6137184115523464" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="1.1107886128427278" LOG_CI_START="0.00512000398701247" LOG_EFFECT_SIZE="0.55795430841487" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.04791562879944668" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="1.978115939537911">
<NAME>Respiratory problems</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magneisum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.905909424532759" CI_START="1.011859011901069" EFFECT_SIZE="3.6137184115523464" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1107886128427278" LOG_CI_START="0.005120003987012375" LOG_EFFECT_SIZE="0.55795430841487" ORDER="86574" O_E="0.0" SE="0.6494752139897308" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.42181805358700664" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="102.48749927325451" CI_START="0.23694642717154893" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.927884615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="2.0106708963407693" LOG_CI_START="-0.6253498354827463" LOG_EFFECT_SIZE="0.6926605304290115" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.3029961241289143" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="1.0300296023955284">
<NAME>Cardiac failure</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magneisum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="102.48749927325451" CI_START="0.23694642717154893" EFFECT_SIZE="4.927884615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0106708963407693" LOG_CI_START="-0.6253498354827463" LOG_EFFECT_SIZE="0.6926605304290115" ORDER="86575" O_E="0.0" SE="1.5484116263861993" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="2.3975785647279553" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.905909424532759" CI_START="1.0118590119010693" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6137184115523464" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="1.1107886128427278" LOG_CI_START="0.00512000398701247" LOG_EFFECT_SIZE="0.55795430841487" METHOD="MH" MODIFIED="2010-07-08 13:15:14 +0200" MODIFIED_BY="Denise Atherton" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.04791562879944668" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="1.978115939537911">
<NAME>Respiratory depression</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.905909424532759" CI_START="1.011859011901069" EFFECT_SIZE="3.6137184115523464" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1107886128427278" LOG_CI_START="0.005120003987012375" LOG_EFFECT_SIZE="0.55795430841487" ORDER="86576" O_E="0.0" SE="0.6494752139897308" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.42181805358700664" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.30997701256757" CI_START="1.07823136393062" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1884688893607984" ESTIMABLE="YES" EVENTS_1="451" EVENTS_2="374" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.11726367473771054" LOG_CI_START="0.03271196056986522" LOG_EFFECT_SIZE="0.07498781765378784" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="5.079412834901161E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.00000000000001" Z="3.476533227674631">
<NAME>Antihypertensive drug</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.30997701256757" CI_START="1.07823136393062" EFFECT_SIZE="1.1884688893607984" ESTIMABLE="YES" EVENTS_1="451" EVENTS_2="374" LOG_CI_END="0.11726367473771054" LOG_CI_START="0.03271196056986522" LOG_EFFECT_SIZE="0.07498781765378784" ORDER="86577" O_E="0.0" SE="0.04966609543992755" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.0024667210362479923" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6817246971140212" CI_START="0.7909344952670122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1533143866656426" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.2257549020980092" LOG_CI_START="-0.10185948302834145" LOG_EFFECT_SIZE="0.061947709534833875" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.45856705055272506" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.7412084763384051">
<NAME>Oliguria</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magneisum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6817246971140212" CI_START="0.7909344952670123" EFFECT_SIZE="1.1533143866656426" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="47" LOG_CI_END="0.2257549020980092" LOG_CI_START="-0.1018594830283414" LOG_EFFECT_SIZE="0.061947709534833875" ORDER="86578" O_E="0.0" SE="0.19244231154057945" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.03703404327108144" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.79095448393299" CI_END="1.8418408750889148" CI_START="1.1589837736780746" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4610488314649437" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="114" I2="84.8415598023051" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.26525210682936057" LOG_CI_START="0.06407735567765618" LOG_EFFECT_SIZE="0.16466473125350836" METHOD="MH" MODIFIED="2010-07-08 13:15:34 +0200" MODIFIED_BY="Denise Atherton" NO="9" P_CHI2="1.875448494018661E-4" P_Q="0.0" P_Z="0.0013341847723169064" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3324" TOTAL_2="3276" WEIGHT="400.0" Z="3.2085233453324356">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.090918710747752" CI_START="2.472778618151754" DF="0" EFFECT_SIZE="4.472924187725631" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="13" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.9079978378489799" LOG_CI_START="0.3931852367742498" LOG_EFFECT_SIZE="0.6505915373116149" MODIFIED="2010-07-08 13:15:22 +0200" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Z="7.278288135834025E-7" STUDIES="1" TAU2="0.0" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="4.953786986236622">
<NAME>Flushing</NAME>
<DICH_DATA CI_END="8.090918710747752" CI_START="2.472778618151754" EFFECT_SIZE="4.472924187725631" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="13" LOG_CI_END="0.9079978378489799" LOG_CI_START="0.3931852367742498" LOG_EFFECT_SIZE="0.6505915373116149" ORDER="86579" O_E="0.0" SE="0.3024034702347713" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.09144785881003223" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6852775990416675" CI_START="0.8075290134401861" DF="0" EFFECT_SIZE="1.1665807117070655" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="49" I2="0.0" ID="CMP-008.09.02" LOG_CI_END="0.22667144811663276" LOG_CI_START="-0.0928418650951706" LOG_EFFECT_SIZE="0.0669147915107311" MODIFIED="2010-07-08 13:15:26 +0200" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Z="0.411680625275205" STUDIES="1" TAU2="0.0" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.8209396977903116">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="1.6852775990416675" CI_START="0.8075290134401861" EFFECT_SIZE="1.1665807117070655" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="49" LOG_CI_END="0.22667144811663276" LOG_CI_START="-0.0928418650951706" LOG_EFFECT_SIZE="0.0669147915107311" ORDER="86580" O_E="0.0" SE="0.18768370179702168" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.03522517192023336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.403812545468976" CI_START="0.6342872014720748" DF="0" EFFECT_SIZE="0.9436208618173438" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" I2="0.0" ID="CMP-008.09.03" LOG_CI_END="0.14730911925841664" LOG_CI_START="-0.1977140516265493" LOG_EFFECT_SIZE="-0.02520246618406632" MODIFIED="2010-07-08 13:15:30 +0200" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Z="0.7746223476795636" STUDIES="1" TAU2="0.0" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.2863339636909643">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.403812545468976" CI_START="0.6342872014720748" EFFECT_SIZE="0.9436208618173438" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" LOG_CI_END="0.14730911925841664" LOG_CI_START="-0.1977140516265493" LOG_EFFECT_SIZE="-0.02520246618406632" ORDER="86581" O_E="0.0" SE="0.20266831847006941" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.04107444731148548" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.329704115761054" CI_START="0.43970723219933383" DF="0" EFFECT_SIZE="1.3797833935018051" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-008.09.04" LOG_CI_END="0.6364582184589272" LOG_CI_START="-0.3568363911498363" LOG_EFFECT_SIZE="0.13981091365454554" MODIFIED="2010-07-08 13:15:34 +0200" MODIFIED_BY="Denise Atherton" NO="4" P_CHI2="1.0" P_Z="0.5811207475290625" STUDIES="1" TAU2="0.0" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.5517483992316853">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="4.329704115761054" CI_START="0.43970723219933383" EFFECT_SIZE="1.3797833935018051" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6364582184589272" LOG_CI_START="-0.3568363911498363" LOG_EFFECT_SIZE="0.13981091365454554" ORDER="86582" O_E="0.0" SE="0.5834661705718038" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.3404327722017253" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.770582548474675" CI_START="0.45796762333929675" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3140794223826715" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="0.5764084531350081" LOG_CI_START="-0.3391652239657932" LOG_EFFECT_SIZE="0.11862161458460745" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.6115477483739991" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.5078653923516525">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.770582548474675" CI_START="0.45796762333929675" EFFECT_SIZE="1.3140794223826715" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5764084531350081" LOG_CI_START="-0.3391652239657932" LOG_EFFECT_SIZE="0.11862161458460745" ORDER="86583" O_E="0.0" SE="0.5378125100918061" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.28924229601124907" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1263608991863312" CI_START="0.9430999380250891" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0306652677841204" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="437" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.05167756583713752" LOG_CI_START="-0.025442283685665885" LOG_EFFECT_SIZE="0.01311764107573582" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.5049272960005358" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="0.6667571119407669">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1263608991863312" CI_START="0.9430999380250891" EFFECT_SIZE="1.0306652677841204" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="437" LOG_CI_END="0.05167756583713752" LOG_CI_START="-0.025442283685665885" LOG_EFFECT_SIZE="0.01311764107573582" ORDER="86584" O_E="0.0" SE="0.045300581359106626" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.0020521426714730385" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.561999302691428" CI_START="1.0914776400809745" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.463898916967509" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="0.7452309300805887" LOG_CI_START="0.03801484321610154" LOG_EFFECT_SIZE="0.3916228866483451" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.02995604484165372" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="831" TOTAL_2="819" WEIGHT="100.0" Z="2.1706710794870405">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.561999302691428" CI_START="1.0914776400809745" EFFECT_SIZE="2.463898916967509" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.7452309300805887" LOG_CI_START="0.03801484321610154" LOG_EFFECT_SIZE="0.3916228866483451" ORDER="86585" O_E="0.0" SE="0.41542223020028957" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="831" TOTAL_2="819" VAR="0.1725756293445824" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8116298014271153" CI_START="0.836359697163358" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.230924104928365" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-008.13" LOG_CI_END="0.2580694562419282" LOG_CI_START="-0.07760690330687639" LOG_EFFECT_SIZE="0.09023127646752589" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.2920231364292063" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="797" TOTAL_2="767" WEIGHT="100.00000000000001" Z="1.0536938162290501">
<NAME>Respiratory distress syndrome</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8116298014271153" CI_START="0.836359697163358" EFFECT_SIZE="1.230924104928365" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="43" LOG_CI_END="0.2580694562419282" LOG_CI_START="-0.07760690330687639" LOG_EFFECT_SIZE="0.09023127646752589" ORDER="86586" O_E="0.0" SE="0.1971779552237459" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="797" TOTAL_2="767" VAR="0.038879146026217545" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.463799841294091" CI_START="0.9112909890304942" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7766624843161858" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-008.14" LOG_CI_END="0.539552787983579" LOG_CI_START="-0.0403429240683032" LOG_EFFECT_SIZE="0.24960493195763792" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.09155386100849927" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="797" TOTAL_2="767" WEIGHT="100.0" Z="1.6872574389954165">
<NAME>Neonatal hypotonia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.463799841294091" CI_START="0.9112909890304942" EFFECT_SIZE="1.7766624843161858" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.539552787983579" LOG_CI_START="-0.0403429240683032" LOG_EFFECT_SIZE="0.24960493195763792" ORDER="86587" O_E="0.0" SE="0.3406336117893456" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="797" TOTAL_2="767" VAR="0.11603125748065458" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.046272553302412" CI_START="0.9139678779820654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3675625701644325" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-008.15" LOG_CI_END="0.3109634790886887" LOG_CI_START="-0.039069067570634795" LOG_EFFECT_SIZE="0.13594720575902697" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.12789908046904888" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="797" TOTAL_2="767" WEIGHT="100.0" Z="1.5224391538989015">
<NAME>Baby intubated</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodipine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.046272553302412" CI_START="0.9139678779820655" EFFECT_SIZE="1.3675625701644325" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" LOG_CI_END="0.3109634790886887" LOG_CI_START="-0.03906906757063474" LOG_EFFECT_SIZE="0.13594720575902697" ORDER="86588" O_E="0.0" SE="0.20561085059673703" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="797" TOTAL_2="767" VAR="0.04227582188311372" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5844700652121633" CI_START="0.06494527155065094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3207862818904224" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.16" LOG_CI_END="0.19988403864403434" LOG_CI_START="-1.187452462977622" LOG_EFFECT_SIZE="-0.4937842121667938" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.16295843653763178" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="797" TOTAL_2="767" WEIGHT="100.0" Z="1.3951903822182161">
<NAME>Neonatal hypotension</NAME>
<GROUP_LABEL_1>Magneisum</GROUP_LABEL_1>
<GROUP_LABEL_2>Nimodipine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nimodpine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5844700652121633" CI_START="0.06494527155065094" EFFECT_SIZE="0.3207862818904224" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19988403864403434" LOG_CI_START="-1.187452462977622" LOG_EFFECT_SIZE="-0.4937842121667938" ORDER="86589" O_E="0.0" SE="0.8149283284790004" STUDY_ID="STD-Nimodipine-SG-2003" TOTAL_1="797" TOTAL_2="767" VAR="0.6641081805575777" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-05-20 11:48:06 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Magnesium chloride versus methyl dopa</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4264829096404277" CI_START="0.6116295984242748" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.15426657284320527" LOG_CI_START="-0.21351150605680705" LOG_EFFECT_SIZE="-0.029622466606800863" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.752208770118145" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.31572826665590686">
<NAME>Other antihypertensive therapy</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>alpha blocker</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alphablocker</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.426482909640428" CI_START="0.6116295984242748" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.15426657284320536" LOG_CI_START="-0.21351150605680705" LOG_EFFECT_SIZE="-0.029622466606800863" ORDER="86590" O_E="0.0" SE="0.21603466407671895" STUDY_ID="STD-Denmark-2000" TOTAL_1="14" TOTAL_2="17" VAR="0.0466709760827408" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.71099765155883" CI_START="0.08325278027398925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="1.2482430254680852" LOG_CI_START="-1.0796012540680135" LOG_EFFECT_SIZE="0.08432088570003587" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.8870875010912058" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.1419905107651991">
<NAME>Admission to special care baby unit</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Alpha blocker</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours magnesium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alphablocker</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.71099765155883" CI_START="0.08325278027398925" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2482430254680852" LOG_CI_START="-1.0796012540680135" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="86591" O_E="0.0" SE="1.3673872528145288" STUDY_ID="STD-Denmark-2000" TOTAL_1="14" TOTAL_2="17" VAR="1.8697478991596639" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-05-20 11:48:06 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Magnesium sulphate versus nitrate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-01 15:48:18 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Magnesium</GROUP_LABEL_1>
<GROUP_LABEL_2>Isosorbide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-01 15:48:18 +0200" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.0" STUDY_ID="STD-Mexico-1998" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2010-07-05 12:20:09 +0200" MODIFIED_BY="Lelia Duley">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2010-07-05 12:20:09 +0200" MODIFIED_BY="Lelia Duley" NO="1">
<TITLE>Alford, February 2004</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY NOTES="&lt;p&gt;thyroid&lt;/p&gt;">
<P>Pre-eclampsia can be prevented if the mother is checked for reverse T3 hypothyroidism and treated properly with liothyronine (Cytomel--T3). It normalizes the incubator temperature and prevents the hypotension that leads to the pre-eclampsia.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2010-07-05 12:20:09 +0200" MODIFIED_BY="Lelia Duley">
<P>Although there is an association between subclinical hypothyroidism and pre-eclampsia, it is unclear whether hypothyroidism influences the risk of pre-eclampsia (<LINK REF="REF-North-2009" TYPE="REFERENCE">North 2009</LINK>). There is no clear evidence that treatment of subclinical hypothyroidism influences the risk of women developing pre-eclampsia. </P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2010-07-05 12:19:09 +0200" MODIFIED_BY="Lelia Duley">
<P>Comment received from RM Alford, February 2004. Reply by L Duley and D Chou, May 2010.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2010-09-21 12:20:44 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-05-28 11:35:17 +0200" MODIFIED_BY="Lynn Hampson" NO="1">
<TITLE MODIFIED="2010-05-28 11:34:30 +0200" MODIFIED_BY="Lynn Hampson">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-28 11:35:17 +0200" MODIFIED_BY="Lynn Hampson">
<P>#1        MeSH descriptor Hypertension, Pregnancy-Induced explode all trees<BR/>#2        hypertens* near pregnan*<BR/>#3        eclamp*<BR/>#4        preeclamp* or pre next eclamp*<BR/>#5        magnesium<BR/>#6        diazepam<BR/>#7        lytic next cocktail<BR/>#8        phenytoin<BR/>#9        chlorpromazine<BR/>#10     meperidine or pethidine<BR/>#11     MeSH descriptor Anticonvulsants explode all trees<BR/>#12     anticonvulsant* or anti next convulsant*<BR/>#13     (#1 OR #2 OR #3 OR #4)<BR/>#14     (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)<BR/>#15     (#13 AND #14)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-09-21 12:20:44 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-06-04 13:07:36 +0200" MODIFIED_BY="Sonja L  Henderson">Methods used in previous version of the review</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-21 12:20:44 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Data collection and analysis</HEADING>
<P>Two reviewers independently assessed for eligibility. Two reviewers independently extracted and double entered data. Discrepancies were resolved by discussion. If the two reviewers could not agree, the third reviewer was consulted. There was no blinding of authorship or results. Whenever possible, we sought unpublished data from investigators. We assigned a quality score for concealment of allocation to each trial, using the following criteria:</P>
<P>(A) adequate concealment of allocation;<BR/>(B) unclear whether adequate concealment of allocation;<BR/>(C) inadequate concealment of allocation.</P>
<P>We excluded quasi-randomised trials, for example those using alternate allocation.</P>
<P>In addition, we assigned to each reported outcome quality scores for completeness of follow-up and blinding of the assessment of outcome using the following criteria:</P>
<P>For completeness of follow-up:</P>
<P>(A) less than 3% of participants excluded;<BR/>(B) 3% to 9.9% of participants excluded;<BR/>(C) 10% to 19.9% of participants excluded.</P>
<P>Excluded: If not possible to enter data based on intention to treat, and/or 20% of participants were excluded from that outcome.</P>
<P>For blinding of assessment of outcome:</P>
<P>(A) Double blind, neither caregiver nor participant knew or were likely to guess the allocated treatment.<BR/>(B) Single blind, either the caregiver or the participant knew the allocation. Or, the trial is described as double blind, but side effects of one or other treatment mean that it is likely that for a substantial proportion of participants (greater than 40%) the allocation could be correctly identified.<BR/>(C) No blinding, both caregiver and participant knew (or were likely to guess) the allocated treatment; or, blinding not mentioned.</P>
<P>Excluded: no blinding, and the outcomes were very subjective.</P>
<P>We performed statistical analyses using the Review Manager software (RevMan 2000), with results presented as risk ratio (RR) and risk difference (RD). From 1/RD the number needed to treat for for an additional beneficial outcome (NNTB) or number need to treat for an additional harmful outcome (NNTH) were calculated. For each measure the 95% confidence intervals are given. The fixed-effects model was used for calculating the risk. If there was clear heterogeneity between the studies in any one outcome, a random effects model was used. Possible factors in the heterogeneity were also explored, including study quality, clinical factors as determined by the prespecified subgroup analyses, and the play of chance.</P>
<P>Subgroup analyses for the main outcomes were planned by severity of pre-eclampsia at trial entry (see above for definition), whether delivered or not, gestation at trial entry (above or below 34 weeks), and whether anticonvulsants had already been given. The main outcomes were maternal death, eclampsia, severe maternal morbidity, total fetal and neonatal deaths, and death or serious morbidity for the baby (such as greater than seven days in a special care baby unit). Subgroups by dose and route of administration for magnesium sulphate were planned for maternal death, eclampsia, baby deaths and side effects.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>